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“The important thing is not to stop questioning.  





Omega-3 fatty acids (ω-3 FA, including eicosapentaenoic acid [EPA] and 
docosahexaenoic acid [DHA]), are essential polyunsaturated fatty acids which are 
correlated with lower incidence of chronic diseases. DHA and EPA can be 
enzymatically converted to resolvins, protectins and maresins, which play important 
roles in resolution of inflammation. Additionally, ω-3 FA can also directly activate 
surface receptors, namely the long-chain free fatty acid receptors GPR40 and 
GPR120, two GPCRs with poorly investigated biology.  
Using real-time PCR analysis, GPR40 transcript in human neutrophils was 
detected; the protein expression was also confirmed by flow cytometry and image 
stream analysis. Expression of GPR40 protein was up-regulated after stimulation with 
platelet-activating factor (PAF, 10nM) or leukotriene B4 (LTB4, 10nM) for 10 minutes. 
I utilised the selective agonist GW9508 to investigate the biology of GPR40. Tested 
on human neutrophils, GW9508 elevated intracellular calcium when applied within 
the 0.1-10µM range. The up-regulation of GPR40 expression by pro-inflammatory 
stimuli suggested to us potential regulatory roles for this receptor during inflammation. 
I then showed that 1 and 10µM GW9508 increased neutrophil chemotaxis in response 
to the cytokine IL-8 (30ng/ml). In addition, GPR40 activation by GW9508 enhanced 
phagocytosis of E. coli by human neutrophils by approximately 50% when tested at 
0.1 and 1µM. Moreover, GW9508-neutrophil stimulation augmented microvesicle 
release and delayed apoptosis after stimulation.  
Finally, I demonstrated that GPR40 is expressed in inflammatory cells isolated 
from murine arthritic joints, such as neutrophils, macrophages and inflammatory 
monocytes. KBN-serum induced arthritic mice developed a more severe disease 
when treated prophylactically with GW9508 (10mg/kg, i.p. treated from day 0, daily), 




vehicle control mice. Therapeutic intervention with GW9508 at the peak of the disease 
(day 5) delayed the resolution of arthritis. 
In summary, the data suggest that activation of GPR40 by GW9508 enhances 
neutrophil activation, up regulating the pro-inflammatory properties of this cell type, 
and therefore, exacerbating experimental inflammatory arthritis. 
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1.1. THE INFLAMMATORY RESPONSE 
 
1.1.1. General aspects of the inflammatory response 
Inflammation is a fundamental process that has been essential to humans 
since our origins. The cardinal signs of inflammation – rubor (redness), calor (heat), 
tumor (swelling) and dolor (pain) – were described in the 1st century AD by the Roman 
medical writer Aulus Cornelius Celsus. In addition, the fifth cardinal sign, loss of 
function, was described in the 19th century. Ever since, our knowledge of the 
inflammatory response has increased, but even after almost 20 centuries, we still do 
not have a full understanding of the multitude of molecular and cellular events that 
characterise this life-saving response of the host.  
In the simplest definition, inflammation is an adaptive response that can be 
triggered by a variety of noxious stimuli, including infection and injury, that aims to 
restore homeostasis of the affected structures, and therefore has a crucial role in the 
physiology of mammalian organisms (Medzhitov, 2008). Inflammatory responses are 
highly heterogeneous in terms of cell types and molecular mediators involved. 
Inflammation also comes in different modalities that can be classified as acute versus 
chronic and local versus systemic. Despite this complexity, all inflammatory 
responses can be broken down into four common components that align in a universal 
configuration of the inflammatory pathway: inflammatory inducers, sensors, 







Figure 1: Examples of common components of the inflammatory response. The inflammatory 
response consists of inductors, sensors, mediators and effectors. Inducers initiate the response and are 
detected by the sensors. The sensors (receptors like Toll-like receptors) are expressed in specialized 
sentinel cells as tissue-resident macrophages, dendritic cells and mast cells. They induce the production 
of mediators, including cytokines, chemokines, vasoactive amines, lipid mediators and products of 
proteolytic cascades. These inflammatory mediators act on various target tissues to elicit changes in 
their functional states, favoring the migration of leukocytes from the blood to produce effector molecules 
(such as reactive radicals and proteases), thus facilitating the adaptation to deleterious condition in 
accordance with the inducer (tissue injury or infection) that elicited the inflammatory response 
(Medzhitov, 2010). 
 
Inflammatory inducers can be exogenous signals (e.g. pathogens and toxins) 
or endogenous signals (e.g. ATP and urate crystals) that report on tissue stress, 
injury, or malfunction. Sensor cells, such as tissue-resident macrophages, dendritic 
cells and mast cells, detect inducers with specific receptors and respond by producing 
inflammatory mediators. Depending on the nature of the inducers, sensor cells 
produce different combinations and amounts of mediators (including cytokines, 
chemokines, vasoactive amines, lipid mediators and proteolytic cascades products), 
creating unique mediator signatures. Inflammatory mediators, in turn, act on target 
tissues triggering changes in the functional state thereof, favouring the migration of 
leukocytes from the blood and production of effector molecules (such as reactive 
radicals and proteases) (Okin and Medzhitov, 2012). 
The development of an appropriate inflammatory response is essential for the 
host. Indeed, the activation and recruitment of leukocytes are required for the 
processing and presentation of antigens by leukocytes, and effector function of any 
immune response (Teixeira et al., 2001). However, inflammatory processes have the 
potential to cause damage to host tissues. Indeed, the effector molecules produced 
in this process do not discriminate if their targets are pathogens or structures of the 
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host, so the tissue damage is a potential side effect associated with any inflammatory 
response (Nathan, 2006, Medzhitov, 2008, Wink et al., 2011). Thus, this adaptive 
response is beneficial only if retained for a short duration. Indeed, chronic responses 
may lead to significant physiological changes. There is a wide list of human diseases 
associated with an inappropriate or uncontrolled inflammatory response that are 
triggered by known or unknown stimuli origin, this include rheumatoid arthritis, 
asthma, multiple sclerosis, chronic obstructive pulmonary disease and 
atherosclerosis (Libby, 2002, Weiner and Selkoe, 2002, Vilcek and Feldmann, 2004). 
Under these conditions, it is clear that tissue inflammation is deleterious. Therefore, 
an adequate control of inflammation is of fundamental importance for the restoration 
of the physiological conditions of the organism. 
For years, it was believed that termination of acute inflammation was due to 
passive dilution of pro-inflammatory signals and effectors (Levy, 2010), in a process 
as simple as turning off the lights. Nowadays it is known that the resolution of 
inflammation is a tightly orchestrated and multifaceted host response. Indeed, the key 
steps in resolution of inflammation include 1) clearance of the inciting stimuli; 2) 
decrease of neutrophil and increase of monocyte recruitment; 3) apoptosis of 
recruited inflammatory cells; 4) efferocytosis of apoptotic cells by tissue and 
monocyte-derived macrophages; 5) switching from pro-inflammatory cell phenotypes 
and mediators to pro-resolution cell phenotypes and mediators; 6) either 
incorporation of myeloid cells into the local population or their recirculation via lymph 
or blood (Alessandri et al., 2013, Norling and Perretti, 2013, Buckley et al., 2014). 
Therefore, for resolution to occur an active and coordinated series of events must 
take place, likely involving multiple proresolving mediators and cellular processes.   
Further, the understanding of the process of the resolution of inflammation 
gives hope for the treatment of a wide list of human diseases that are associated with 
chronic inflammatory responses. Diseases that are traditionally treated with anti-




inflammatory mediators and/or inhibit the recruitment of leukocytes and their 
activation. Therapies including non-steroidal anti-inflammatory drugs (NSAID), 
glucocorticoids (GC) receptors agonists (synthetic GCs) and antibodies or inhibitors 
targeting specific pro-inflammatory cytokines, such as TNF-α and IL-1, have proven 
beneficial and have revolutionised the treatment of various diseases, yet a number of 
patients fail to respond to these therapies, or are subjected to side effects (Alessandri 
et al., 2013). For example, steroids can cause osteoporosis and impair wound 
healing, whereas novel selective inducible cyclooxygenase (COX)-2 inhibitors might 
reduce protective vascular prostacyclin synthesis, leading to an increase risk of 
thrombosis. Indeed, experience with TNF-α-neutralizing therapy has also revealed 
several complications (Lee, 2012). Therefore, pro-resolution-based strategies 
emerge as a new potential solution for the treatment of multiple inflammatory 
conditions. 
Taking in mind the overview of the inflammatory response described above, a 
simplistic way of demonstrating the course of inflammation is shown in Figure 2. With 
inducers stimulating the initiation of acute inflammation, over time the inflammatory 
response reaches its peak, and after resolution steps have taken place, homeostasis 
is restored (blue line). However, when there is an exacerbated inflammatory response 
and a defective resolution, the inflammatory response persists, which could result in 
a range of chronic diseases (red line). In contrast, intervention with external pro-
resolution mediators or drugs depicted on their structure or mimicking their biology 





Figure 2: Time-course of the inflammatory response. 
The inductors are detected by sensor cells, inducing the release of a number of different pro-
inflammatory mediators, initiating the inflammatory response. Once effector cells are able to control or 
clear the inducers, cells with a pro-resolving profile start to produce mediators that control the 
inflammatory response. In a well-orchestrated response, the inflammatory process has its end (blue 
line). An excess of the initial inflammatory response results, in most cases, in a host's inability to control 
inflammation, leading to a chronic state (red line). However, the use of therapies that promote resolution 
of inflammation are believed to be a new intervention strategy capable of restoring tissue homeostasis 
(blue dashed line) Adapted from Perretti et al. (2015). 
 
1.1.2. Mediators of inflammation 
Mediators are substances released from injured or activated cells that co-
ordinate the development of the inflammatory response. The Brazilian 
pharmacologist Rocha e Silva, 1978, defined that a chemical mediator should (i) be 
found in tissues in concentrations that can explain the observed symptoms or effects, 
(ii) be released by endogenous triggers which produces the response, (iii) have the 
same action in all species where the phenomenon occurs, (iv) be destroyed locally or 
systemically to avoid undue accumulation, and (v) be blocked (directly or indirectly) 
by inhibitors of inflammation (Rocha e Silva, 1978). Nowadays, inflammatory 
mediators are classified into several groups according to their biochemical properties, 
such as vasoactive amines, vasoactive peptides, fragments of complement 




Vasoactive amines (histamine and serotonin) are produced mainly by mast 
cells and platelets and are release after degranulation. They can cause an increase 
in vascular permeability and vasodilation, or vasoconstriction, depending on the 
context. Vasoactive peptides can also cause vasodilation and increased vascular 
permeability, however, they are usually stored in an active form in secretory vesicles 
or are generated by proteolytic processes of inactive precursors in the extracellular 
fluid. Another class of mediators, complement components, like C3a, C4a and C5a, 
are produced by several pathways of complement activation. They can promote 
granulocyte and monocyte recruitment, induce mast-cell degranulation and cell-killing 
membrane attack complex activation. Lipid mediators are derived from phospholipids, 
such as phosphatidylcholine, that are present in the inner leaflet of cellular 
membranes. They activate several processes that occur during the inflammatory 
response, including recruitment of leukocytes, vasodilation and vasoconstriction, 
increased vascular permeability and platelet activation. Recently, lipid mediators were 
also shown to be involved in the resolution phase of the inflammatory response 
(Serhan, 2014). Inflammatory cytokines are produced by many cell types, most 
importantly by macrophages and mast cells. They have several roles in the 
inflammatory response, including activation of the endothelium and leukocytes and 
induction of the acute-phase response. Chemokines are produced by many cell types 
in response to inducers of inflammation. They control leukocyte extravasation and 
chemotaxis towards the affected tissue. Finally, proteolytic enzymes are involved in 
many processes, including host defence, tissue remodelling and leukocyte migration 
(reviewed on (Medzhitov, 2008)). 
As Rocha e Silva said, “it would be very unfortunate if any of the above 
mentioned mediators might constitute the final answer to the problem, because that 
would mean to shut our laboratories, or do something else!”. Indeed, although much 




mediators, and identification of new mediators (Serhan, 2014) shows us that much 
remains to be discovered.  
 
1.1.2.1. Inflammatory mediators generated from polyunsaturated fatty acids 
One of the most important classes of lipid mediators, eicosanoids (from the 
Greek eicosa = twenty; for twenty carbon fatty acid derivatives), was discovered after 
the observation that exclusion of fat from the diet were prejudicial in rats. Eicosanoids 
are generated from 20-carbon polyunsaturated fatty acids (PUFAs), and because 
inflammatory cells typically contain a high proportion of the omega-6 PUFA 
arachidonic acid (AA) and low proportions of other 20-carbon PUFAs, AA is usually 
the major substrate for eicosanoid synthesis. Eicosanoids, which include 2-series 
prostaglandins (PG), thromboxanes, 4-series leukotrienes (LTs), and other oxidized 
derivatives, are generated from AA (Calder, 2006) (Figure 3).  
Eicosanoids are a large group of lipid mediators involved in modulating 
intensity and duration of the inflammatory response. They are produced from different 
cell sources upon application of several stimuli. Prostaglandins are formed by most 
cells in our bodies and act as autocrine and paracrine lipid mediators; they are 
synthesised de novo from membrane-released AA which is produced upon cell 
activation, with the second step involving COXs isozymes. It is important to mention 
that prostaglandin generation can be inhibited by NSAIDs, as discovered by John 
Vane and colleagues in 1971 (Vane, 1971). In contrast, leukotrienes are made 
predominantly by inflammatory cells like polymorphonuclear leukocytes, 
macrophages, and mast cells after stimulation by an inducer of the inflammatory 
response. In the case of leukotriene generation, one of the most important enzyme 
involved is 5-lipoxygenase (5-LO).  
 Functionally, eicosanoids frequently have opposing effects. Thus, the overall 
physiologic (or pathophysiologic) outcome will depend on the cells (plus hence 




concentrations of different eicosanoids generated, and the sensitivity of the target 
cells and tissues to the eicosanoid generated. For example, leukotrienes increase 
vascular permeability, enhance local blood flow, are chemotactic agents for 
leukocytes, induce release of lysosomal enzymes and ROS by granulocytes, and 
increase production of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 
(Hammarstrom, 1983). Prostaglandins, such as PGE2, are known to induce fever, 
increase vascular permeability and vasodilatation, cause pain, and increase 
production of IL-6 (Evans et al., 2015). Eicosanoids are also generated from PUFAs, 
such as EPA leading to the formation of 3-series PGs and 5-series LTs, for instance 
PGE3 and LTB5. The same enzymes are involved in the generation of eicosanoids 
from AA or EPA, resulting in a competition of the substrate. However, revealing the 
complexity and specificity of the inflammatory reaction, these autocrine mediators 
may exert anti-inflammatory effects, as shown by the effects of PGE3 in inhibiting 
production of TNF and IL-1 (Miles et al., 2002) (Figure 3).  
 
Figure 3: Generalized pathway for the conversion of AA and EPA to eicosanoids. 
COX, cyclooxygenase; CYP450 cytochrome P450 enzymes, LOX, lipoxygenase. Adapted from Norling 
and Perretti (2013). 
 
In addition to the production of mediators involved in the initialization of the 
inflammatory response, omega-3 and omega-6 PUFAs can also generate mediators 
involved in the resolution phase of inflammation. Firstly, it is important to define that 




as a blocker of specific pathways or enzymes involved in the initiation of an anti-
inflammatory response. Indeed, a pro-resolution mediator stimulates and activates 
endogenous pathways to regulate cellular trafficking, modulate myeloid cell lifespan 
and phenotype, and enhance tissue restoration to accelerate resolution (Norling and 
Perretti, 2013). These pro-resolving mediators include canonical mediators such as 
cortisol and adenosine as well as more recently identified lipid, protein and peptide 
agonists such as the lipoxins (LXs), resolvins (Rvs), annexin A1 (AnxA1) and 
melanocortins (MCs), amongst several others. 
Even simplistically, the generalised description of the roles of lipid mediators 
shows the importance of fatty acids in the inflammatory response.  
 
1.1.3. Major steps of the inflammatory response 
The main and most immediate effect of the mediators produced by sensor 
cells is to elicit an inflammatory exudate locally: plasma proteins and leukocytes that 
are normally restricted to the blood vessels now gain access, through the 
postcapillary venules, to the extravascular tissues at the site of infection or injury.  
 
1.1.3.1. The leukocyte recruitment cascade to the site of inflammation 
The recruitment of leukocytes to the site of inflammation is a tightly regulated 
process characterized by the following stages: capture of leukocytes by the activated 
endothelium, rolling of leukocytes on the endothelium, activation of leukocytes by 
chemokines and other mediators, firm adhesion of leukocytes to the endothelium, 
crawling and transendothelial migration or diapedesis (Figure 4). There are several 
families of molecular regulators involved in the control of this process, which includes 
the selectins (glycoprotein adhesion molecules), integrins, chemokines, and 





Figure 4: Leukocyte recruitment cascade. 
All known steps for leukocytes recruitment are shown, including capture, which is mediated by selectins; 
activation which is mediated by chemokines; and adhesion which is mediated by integrins. Key 
molecules involved in each step are shown in boxes. ESAM: endothelial cell selective adhesion 
molecule; ICAM1: intracellular adhesion molecule 1; JAM: junctional adhesion molecule; LFA1: 
lymphocyte function-associated antigen 1 (also known as L 2 integrin); MAC1: macrophage 1 antigen; 
MADCAM1: Mucosal vascular addressin cell adhesion molecule-1; PSGL1: P-Selectin glycoprotein 
ligand 1; PECAM1: Platelet endothelial cell adhesion molecule-1; PI3K: phosphoinositol 3 kinase; 
VCAM1: vascular cell adhesion molecule 1; VLA4: very late antigen 4; VAV: vav guanine nucleotide 
exchange factor. Modified from Ley et al. (2007). 
 
During the inflammatory response, selectins present on the surface of 
leukocytes interact with their respective receptors on endothelial cells in a transient 
and reversible interaction, promoting the first step of leukocyte recruitment, known as 
capture. Neutrophils (the first cells to arrive to the site of the infection) express L-
selectin, while endothelial cells express P- and E-selectin (Bevilacqua, 1993). P-
selectin is also expressed by activated platelets. A common ligand for all 3 selectins 
is P-selectin glycoprotein ligand-1 (PSGL-1). Although PSGL-1 is expressed in almost 
all leukocytes, it is only functional when properly glycosylated. The captured 
leukocytes then start to roll on the surface of the endothelial cells, which permits them 
to sense chemoattractant factors, including complement factor 5a (C5a), IL-8 
(CXCL8), PAF, eotaxin/CCL11 and LTB4, which reside on the luminal surface of the 
endothelium. The activation of relevant chemoattractant receptors on the rolling 
leukocytes provokes an increase in affinity (conformational changes) of integrins, 
promoting the arrest of leukocytes. This firm adhesion of leukocytes to endothelial 




Mac-1 (αMβ2) and LFA-1 (αLβ2) and their endothelial receptors of the superfamily of 
immunoglobulins, such as intercellular adhesion molecule (ICAM) and vascular cell 
adhesion molecule 1 (VCAM-1). While VCAM-1 interacts with VLA-4, β2 integrins 
(including LFA-1 and Mac-1) bind to ICAM1-5. ICAM-1 and ICAM-2 are extensively 
studied as binds to β2 integrin ligands on the endothelium. Other integrins includes 
ICAM-3, ICAM-4 and ICAM-5 that are expressed in white blood cells, red blood cells 
and brain neurons, respectively (Ley et al., 2007, Chavakis et al., 2009) 
Following firm adherence, leukocytes move slowly on the surface of 
endothelial cells using their Mac-1 and LFA-1 integrin, in a process called crawling, 
to find an appropriate area for transmigration. The endothelial transmigration (also 
designated diapedesis) can happen on intercellular junctions, i.e., a paracellular way, 
or through the body of the endothelial cell, or a transcellular way. The preference of 
a track relative to another is not well understood and may depend on the levels of 
activation of endothelial cells (Chavakis et al., 2009). Migration into tissue relies on 
integrins and other cell adhesion molecules, including platelet endothelial cell 
adhesion molecule 1 (PECAM-1), and junctional adhesion molecules (JAMs) present 
in intercellular junctions (reviewed by Ley et al. (2007)). 
Leukocyte recruitment to inflamed tissue forms the basis for any type of local 
immune response. Targeting this process remains an attractive possibility to either 
enhance immune defence or to suppress inflammation-induced tissue destruction. A 
wide range of pro-resolution mediators that decrease the recruitment of granulocytes 
have been discovered in the last few years. Including adenosine (Hasko et al., 2008), 
AnxA1 and N-terminal peptide Ac2-26 (Perretti and D'Acquisto, 2009), 
docosahexaenoyl ethanolamide (DHEA) metabolites (Shinohara et al., 2012), PGE2 
(Levy et al., 2001), lipoxin (LX)A4 (Fierro et al., 2003), maresin (MaR)1 (Hong, Gronert 
et al. 2003; Serhan, Yang et al. 2009), melanocyte-stimulating hormone (α-MSH and 
γ-MSH) (Leoni, Patel et al. 2008), protectin D1 (PD1) (Hong, Gronert et al. 2003), 




mediators can act directly at endothelial cells or on leukocytes. For instance, 
activation of adenosine A2a receptors can inhibit the expression of E-selectin and 
VCAM-1 on endothelial cells (Hassanian et al., 2014). 
 
1.1.3.2. Clearance of the inflammatory stimulus by phagocytosis 
Once in the tissue, leukocytes can be further activated and become an 
important source of a range of substances, which include colony stimulating factors, 
cytokines, lipid mediators and reactive oxygen species (ROS) (Alessandri et al., 
2013). In addition, neutrophils and macrophages, predominantly, will perform the 
phagocytosis of microorganisms in the site of infection, thereby promoting the 
elimination of injurious stimuli. 
Three primary mechanisms are necessary in neutrophils when eliminating an 
invading pathogen: receptor-mediated uptake of the pathogen into a vacuole within 
the cell; production of highly toxic ROS in the pathogen-containing vacuole; and 
fusion of neutrophil granules, containing various antimicrobial mediators, to the 
vacuole. These steps may also contribute in the pathogenesis of sterile inflammation, 
as in autoimmune diseases, in which ligands are deposited on tissue components.  
Phagocytosis of an opsonized inducer depends on engagement of opsonic 
receptors, such as FcγRs and C-type lectin receptors, which enclose the pathogen 
within a defined vacuole referred to as the phagosome. Uptake is followed by fusion 
of the phagocytic vacuole with preformed granules within the cell to form the 
phagosome, in a process referred to as phagosomal maturation. These granules 
contain hydrolytic enzymes and NAPDH oxidase subunits that initiate killing 
mechanisms. Phagocytosis in neutrophils differs from that in other professional 
phagocytes such as macrophages, in which both particle uptake and phagosome 
maturation are much slower (Vieira et al., 2002). Additionally, the fully mature 
neutrophil phagosome has a neutral pH, whereas in macrophages the phagosome is 




oxidative burst, which is massive in neutrophils compared with macrophages, on 
vacuolar pH. Efficient phagosomal maturation in neutrophils also depends on 
cytosolic calcium, whereas in macrophages, fusion between lysosomes and the 
phagosome is calcium independent (reviewed in Mayadas et al. (2014)). 
Recently, endogenous pro-resolving mediators were found to enhance 
phagocytosis by neutrophils and macrophages, including chemerin-derived peptides 
(Cash et al., 2010), LXA4 (Maderna et al., 2005), MaR1 (Serhan et al., 2009), MSH 
(Montero-Melendez et al., 2011), and RvD and RvE series (Schwab et al., 2007, 
Norling et al., 2012). 
The speed with which the neutrophil can engage, engulf, and kill pathogens 
is an obvious advantage in terms of host defence. However, phagocytosis and 
phagosomal maturation are not perfect processes, as granules may fuse with the 
phagosome before it is completely sealed. This leads to the release of cytolytic 
contents and oxidative products outside the neutrophil, where damage to other cells 
may occur. Neutrophil phagocytic receptors may also be engaged by immune 
complexes or complement deposited along large surfaces, such as the vascular 
endothelium, which the neutrophil cannot completely engulf. This so-called frustrated 
phagocytosis leads to the release of granule contents and oxidative products, causing 
extensive tissue injury (reviewed in (Mayadas et al., 2014). The importance of this 
process will be discussed further in the rheumatoid arthritis section (1.2.1). 
 
1.1.3.3. Apoptosis of neutrophils 
When the inflammatory response is effective and the initiator stimulus is 
cleared, the inflammatory process is switched off. As mentioned before, the ending 
of this process is complex and it involves a series of steps. One of these steps is the 
induction of neutrophil apoptosis.  
Apoptosis is a process of programmed cell death in vertebrates, which was 




that time, it was believed that neutrophils died by the classical mode of cell death, 
necrosis. Necrotic neutrophils present disruption of the plasma membrane, with 
consequence release of intracellular contents to the microenvironment in an 
irreversible mode. The release of intracellular contents of neutrophils in the tissue is 
associated with further damage and recruitment of more inflammatory cells into the 
damaged tissue. On the other hand, neutrophils undergoing apoptosis preserve their 
cytoplasmic granules intact, display a vacuolated cytoplasm and have a densely 
condensed nucleus (Savill et al., 1989). DNA fragmentation and loss of plasma 
membrane asymmetry, with accumulation of phosphatidylserine (PS) on the 
extracellular leaflet, are additional endpoints that can be used to quantify apoptosis 
kinetics. 
Mature neutrophils are terminally differentiated cells and are recognized as 
one of the leukocytes with the shortest lifespan (8-20 hours) in the circulation (Tak et 
al., 2013). However, pro-survival signals, including granulocyte macrophage colony 
stimulating factor (GM-CSF) (Colotta et al., 1992), LTB4 (Lee et al., 1999), C5a (Lee 
et al., 1993) as well as bacterial constituents lipopolysaccharides  (LPS) (Lee et al., 
1993, Colotta et al., 1992) and bacterial DNA (Jozsef et al., 2004) can increase the 
lifespan of neutrophils, which in some occasions, can reach up to 5.4 days (Pillay et 
al., 2010). A balance between survival and intracellular death pathways regulates 
neutrophils apoptosis. In the absence of extracellular stimuli, neutrophils undergo 
spontaneous apoptosis, however, under most conditions, neutrophils receive both 
pro-survival and pro-apoptosis cues, and the net effect is likely determined by the 
balance of these signals.  
Three main apoptotic pathways have been described: an extrinsic pathway, 
that is activated by ligation of surface death receptors that bind Fas ligand, TNF-α or 
TRAIL; an intrinsic pathway, that is regulated at the level of mitochondria and is 
initiated by disruption of the outer mitochondrial membrane; and the phagocytosis-




overview, the extrinsic pathway is initiated by ligation and clustering of plasma 
membrane death receptors leading to activation of caspase-8, which mediates 
activation of the executioner caspase-3 to evoke many of the defining biochemical 
and biophysical changes that occur during apoptosis. The intrinsic apoptotic pathway 
is initiated when the relative abundance of the pro-apoptotic B-cell lymphoma 2 (Bcl-
2) family members [Bcl-2-associated X protein (Bax) and Bcl-2 homologous 
antagonist/killer (Bak)] exceeds that of their anti-apoptotic counterparts [protein 
myeloid cell leukemia-1 (Mcl-1) and A1], which allows Bax and Bak to oligomerize 
and form pores in the outer mitochondrial membrane. This provokes the release of 
cytochrome C from the mitochondria into the cytosol, an essential signal for activation 
of caspase-9 upstream of caspase-3. On the other hand, the PICD pathway is driven 
by particle uptake and NADPH oxidase-derived ROS. Leakage of cathepsins from 
damaged azurophilic granules leads to death receptor-independent activation of 
caspase-8. In addition, cathepsin-driven activation of Bcl-2 homology-3 (BH-3)-
interacting domain death agonist (Bid) and degradation of Mcl-1 favour mitochondrial 
disruption and intrinsic pathway activation [reviewed in McCracken and Allen (2014)]. 
Further, neutrophil apoptosis can be induced by AnxA1 (Perretti and Solito, 2004), 
LXA4 (Weinberger et al., 2008) and RvE1 (El Kebir et al., 2012) either directly or 
against an anti-apoptotic stimulus.  
 
1.1.3.4. Clearance of apoptotic of neutrophils 
In normal physiological conditions, apoptotic cells are rarely detected, and the 
presence of un-cleared apoptotic cells has been linked to several different diseases 
that involve infection, inflammation, autoimmunity and cancer. As such, efficient 
efferocytosis is essential for the resolution of inflammation; this process is a dynamic 
and rapid phenomenon to avoid secondary necrosis of the apoptotic neutrophil and 




Although efferocytosis resembles phagocytosis, it is a distinct process, highly 
regulated and mediated by specific receptors, bridging molecules, and downstream 
signalling pathways. Furthermore, at variance from phagocytosis, efferocytosis is a 
sort of silent process that inactivates the engulfing cell, instead of activating it. Work 
of Rossi and his team showed a lack of cytokine production from macrophages 
engulfing an apoptotic neutrophil as compared to cell phagocytosing bacteria (Liu et 
al., 1999).  When an infected cell undergoes apoptosis during an inflammatory 
process, the inducer and its antigens are presumably packaged along with other 
intracellular contents into apoptotic bodies which have intact cellular membranes. 
During apoptosis, the dying cell produces “find me” signals, such as chemokines that 
recruit macrophages and other phagocytic cells to the site of the dying cell, along with 
the accumulation of PS on the exofacial leaflet of the cytoplasmic membrane (as 
mentioned in the previous sub-section). In the “catch me” phase, recruited 
macrophages express specific receptors and bridge molecules that bind to PS or 
other distinct ligands on the apoptotic cell. Binding between the apoptotic cell and the 
scavenger macrophages activates Ras-related C3 botulinum toxin substrate (Rac1), 
leading to actin reorganization and production of projections that surround the 
infected apoptotic cell, ultimately surrounding and engulfing the apoptotic cell in the 
efferosome. The efferosome undergoes step-wise maturation that includes fusion 
with lysosomes and endosomes, leading to rapid degradation of both the apoptotic 
cell and the intracellular pathogen [reviewed in (Martin et al., 2014)].  
The following mediators have been shown to augment efferocytosis in 
macrophages: α-MSH (Montero-Melendez et al., 2011, Leoni et al., 2008), AnxA1 and 
N-terminal peptide Ac2-26 (Maderna et al., 2005, Koroskenyi et al., 2011), chemerin-
derived peptides (Cash et al., 2010), cortisol (Liu et al., 1999), DHEA metabolites 
(Shinohara et al., 2012), LXA4 (Godson et al., 2000), MaR1 (Serhan et al., 2012), PD1 





1.1.3.5. Switch of cell phenotype 
Phagocytosis of apoptotic bodies is not only important for the clearance, but 
also promotes a switch from a pro-inflammatory to a pro-resolution phenotype of the 
macrophage (and possibly other local resident cells) ultimately extinguishing the 
inflammatory response. This helps to contribute to a non-phlogistic environment that 
paves the way towards successful restoration of tissue function and physiology, 
hence homeostasis.  
Macrophages presenting a pro-inflammatory phenotype are long known as 
M1 macrophages, while macrophages presenting a pro-resolution phenotype are 
known as M2 macrophages. This classification was proposed when a few markers 
were considered to establish differences and similarities in macrophage responses to 
stimuli. However, updated knowledge of cytokine signalling, the role of cytokines in 
the development of the hematopoietic system and in disease models with genetically 
modified mice and transcriptomic and proteomic analysis revealed a far more 
complex picture. Nowadays, the phenotypes of the macrophage are named according 
to the stimuli used (Murray et al., 2014).  
The M1 stimuli are grouped according to their ability to induce pro-
inflammatory responses and markers, but their source, role, receptors, and signalling 
pathways differ substantially. The main stimulus used to induce the pro-inflammatory 
M1 phenotype is interferon (IFN)-γ. When IFN-γ activates its receptors IFNGR-1 and 
IFNGR-2, Janus kinase (Jak)1 and Jak2 adaptors are recruited, activating STAT1 
(signal transducers and activators of transcription 1) and interferon regulatory factors 
(IRF), such as IRF-1 and IRF-8. IFN-γ controls specific gene expression programs 
involving cytokine receptors (CSF2RB, IL15 receptor alpha [RA], IL2RA, and IL6R), 
cell activation markers (CD36, CD38, CD69, and CD97), and a number of cell 
adhesion molecules ICAM1, integrin alpha L [ITGAL], ITGA4, ITGbeta-7 [B7], mucin 
1 [MUC1], and ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 [SIAT1]). The 




cytokine inducible SH2-containing protein (CISH), N-myc-interactor (NMI), protein 
tyrosine phosphatase receptor (PTPR) type -O and type -C, and suppressor of 
cytokine signalling 1 (SOCS1) are also under the control of the cytokine. Generally, 
IFN-γ stimulation is used in combination with LPS, to enhance the pro-inflammatory 
phenotype of the macrophages [reviewed in (Martinez and Gordon, 2014)]. 
The M2 group of stimuli arose from the initial IL-4 observations, and they are 
grouped mainly due to their ability to antagonize pro-inflammatory responses and 
markers. IL-4 is produced by Th2 cells, eosinophils, basophils, or macrophages 
themselves and is recognized by two different receptor pairs (IL-4Rα1 can pair with 
the common gamma chain (γc), and with the IL13Rα1 chain). Receptor binding of IL-
4 activates JAK1 and JAK3, leading to activation STAT6. Other transcription factors 
involved include c-Myc and IRF4. IL-4 induces macrophage fusion and decreases 
phagocytosis. The IL-4 multispecies transcriptome includes transglutaminase 2 
(TGM2), mannose receptor (MRC1), cholesterol hydroxylase (CH25H), and the 
prostaglandin-endoperoxide synthase PTGS1 (prostaglandin G/H synthase 1), the 
transcription factors IRF4, Krüppel-like factor 4 (KLF4), and the signalling modulators 
CISH and SOCS1 macrophages [reviewed in (Martinez and Gordon, 2014)]. 
It is important to mention that the pro-inflammatory or pro-resolution properties 
of M1 and M2 like macrophages can change between the type of the disease. For 
instance, in breast cancer, M2 like macrophages are immunosuppressive, contribute 
to the matrix-remodelling, and hence favour tumour growth (Mantovani et al., 2002). 
But as for most of the diseases the skewing from M1 to M2 results in protection, the 
use of adenosine and RvD1, that are known to promote such switching, could become 
an alternative for therapy (Titos et al., 2011). 
 
1.1.3.6. Ending of the inflammatory response 
Finally, the exudate tissue leukocytes that did not undergo apoptosis and 




lymphatics or systemic re-circulation, restoring the homeostasis of the tissue. LXA4, 
RvE1 and PD1 have been shown to enhance the traffic of leukocytes out of the 
inflamed – but resolving - tissue (Schwab et al., 2007). 
Sometimes the damaged caused by the inflammatory response is irreversible 
after tissue leukocytes exudation. However, newly discovered mediators might play 
a role in tissue regeneration. Maresins (macrophage mediators 
in resolving inflammation) by definition are formed via 14-lipoxygenation of 
docosahexaenoic acid and promote resolution of acute inflammation and tissue 
regeneration (Dalli et al., 2014). Recently, a series of work by Serhan’s group 
discovered new bioactive peptide-lipid conjugated mediators that are produced during 
the later stages of self-resolving infections (Dalli et al., 2014) that are also present in 
human sepsis patients (Dalli et al., 2015), named maresin conjugates in tissue 
regeneration (MCTR) because they regulate mechanisms in inflammation-resolution 
as well as tissue regeneration establishing links between local inflammatory exudates 
and tissue regeneration via novel chemical signals (Serhan, 2014). Specifically, Dalli 
and colleagues have very recently showed that three synthetic MCTR dose-















1.2. RHEUMATOID ARTHRITIS 
 
1.2.1. Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects 
approximately 0.5-1% of the worldwide population, characterized by autoimmune 
reactivity and persistent active inflammation with concurrent tissue destruction. RA 
manifests as swelling, pain, functional impairment, and morning stiffness, severely 
affecting the quality of life of those suffering from this disease. Most commonly 
affected joints are within the feet, knees and hands, but any peripheral joint could be 
affected. If not appropriately treated, this can result in significantly higher incidence 
of cardiovascular diseases, and, consequently, enhanced mortality (Kollias et al., 
2011, Klareskog et al., 2009, McInnes and Schett, 2007, Maradit-Kremers et al., 
2005).  
It is widely accepted that RA is a systemic autoimmune disease with a variety 
of etio-pathogenic determinants acting in concert to contribute to disease initiation, 
progression and chronicity. These factors include genetic susceptibility, 
environmental stimuli, physical stress and defective immune responses. While T and 
B cell-dependent pathways have been traditionally implicated in the development of 
RA, innate immune perturbations mediated mainly by neutrophils, macrophages and 
synovial fibroblasts have also gained momentum as major orchestrators of the 
unbalanced associated immune response. As a result of the molecular complexity 
that stems from the multifactorial nature of the disease, the clinical picture is highly 
heterogeneous with several different subsets of RA being manifested in patients 
(Kollias et al., 2011, Klareskog et al., 2009, McInnes and Schett, 2007). This 
complexity in the pathogenesis of human RA can also be visualized in mice, as 
nowadays a variety of experimental models have been created, reproducing different 
stages of the disease. 




NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs). NSAIDs only 
interfere with a small segment of the inflammatory cascade, mainly prostaglandin 
generation by inhibition of COXs (Smolen and Steiner, 2003).  By contrast, DMARDs 
like methotrexate control disease activity, reduce joint erosions and improve quality 
of life as well as reduce cardiovascular morbidity associated with RA such as ischemic 
heart disease (van Halm et al., 2006). However, still a great number of patients do 
not response to the therapy, and those that respond, have to make use of this therapy 
life-long.  
In the next subchapters, a general overview of the etiology, pathogenesis and 
known roles of the cells involved in the progression of arthritis will be given. 
 
1.2.2. Aetiology of RA 
The specific aetiological agent of RA has yet to be identified: it is accepted 
that RA is a systemic disease resulting from breach of tolerance leading to self-attack 
to several tissues (e.g. the joints) together with a clear systemic inflammatory 
component. In addition, the genetics of RA have been a focus of investigation for 
nearly 40 years, and genetic predisposition to the disease has now been refined to 
the level of individual amino acids. Previous studies have indicated that genetic 
factors contribute to approximately 60% of the variation in the liability of the disease. 
In addition, it is believed that, at least, five specific amino acids located in different 
HLA are associated with an increased risk of acquiring RA. However, genetic 
predisposition for RA is not only due to HLA genes. Actually, there are more than 30 
loci outside of the MHC that are associated with an increased risk of developing RA, 
but some of these associations are not universal, being relevant in certain populations 
or ethnic groups (Okada et al., 2014).  
Although RA clearly has a considerable genetic component, some 
environmental risks factors are also associated with the initiation of the disease, such 




environmental factors remain largely unknown and their contribution to RA aetiology 
is likely to be considerable. 
Another factor that intrigues scientist is associated with the observed sex-bias 
(3:1 female to male ratio) in the incidence of RA. A wide range of hypotheses including 
potential roles for sex hormones is proposed by investigators as one of the reasons 
behind this gender bias (van Vollenhoven, 2009).  
 
1.2.3. Pathogenesis of RA 
The synovial joint is composed of two adjacent bony ends each covered with 
a layer of cartilage, separated by a joint space and surrounded by the synovial 
membrane and joint capsule. Only a few, if any, mononuclear cells are interspersed 
in the sublining connective tissue layer, which has considerable vascularity in a 
healthy individual. In contrast, RA is initially characterized by an inflammatory 
response of the synovial membrane (‘synovitis’) that is conveyed by a 
transendothelial influx and/or local activation of a variety of mononuclear cells, as well 
as by new blood vessel formation. The lining layer becomes hyperplastic and the 
synovial membrane expands and forms villi (Smolen and Steiner, 2003). 
The inflammatory response of RA is characterized by infiltration of neutrophils, 
B and T lymphocytes and monocyte-derived macrophages in the arthritic joints. But 
the exact role of each cell type during RA pathogenesis is not completely understood. 
Neutrophils are the first immune cell to arrive at the site of inflammation. Within the 
synovial fluid, neutrophils phagocytose immune complexes and release powerful 
proteases and inflammatory mediators, which in turn recruit monocytes, T and B cells 
to the synovium. These cells then form discrete lymphoid aggregates, sometimes with 
ectopic germinal centers (Pitzalis et al., 2013), while macrophage-like and fibroblast-
like synoviocytes accumulate in the intima causing hyperplasia and secreting 
degradative enzymes. Among the proteases and inflammatory mediators produced 




of chemotactic factors, while reactive oxygen species are associated with tissue 
damage [reviewed in Cascao et al. (2010)]. 
In association with the increased infiltration of inflammatory cells to the joints, 
patients with arthritis have increased levels of adhesion molecules including E-
selectin, VCAM-1, and ICAM-1, in the synovial endothelium and macrophage synovial 
tissue (Adams and Shaw, 1994, Bevilacqua et al., 1994). As the disease develops, 
the cells of the synovial lining proliferate, forming an invasive pannus. Together these 
processes can ultimately result in loss of cartilage, bone destruction and dramatic 
joint deformation with loss of function if uncontrolled. High concentrations of different 
cytokines and chemokines, including IL-1β, IL-6, IL-8, and TNF-α are found in 
synovial biopsies from patients with RA, which have been implicated in the 
development of the disease (Feldmann and Maini, 1999). In addition, PGE2, LTB4, 5-
hydroxyeicosatretraenic acid and PAF are also found in the synovial fluid of patients 
with active RA (Sperling, 1995) 
Large numbers of activated neutrophils are found within both RA synovial fluid 
and pannus (Wittkowski et al., 2007), and are associated with increased damage 
within RA joints. Indeed, a vast range of cytokines and chemokines are secreted by 
RA synovial fluid neutrophils, which are implicated in the activation of other cells. In 
addition, conditions within the synovial joint, such as hypoxia (Cross et al., 2006) and 
the presence of anti-apoptotic cytokines (Lally et al., 2005, Parsonage et al., 2008) 
increase neutrophil survival for up to several days (Raza et al., 2006, Weinmann et 
al., 2007).  
However, neutrophils are not only responsible for the pathogenesis of the RA, 
but may also be important for protection. Recently we found that neutrophil-derived 
microvesicles (MVs) were increased in concentration in synovial fluid from RA 
patients compared to paired plasma (Headland et al., 2015). Interestingly, the 
synovial MVs overexpressed the pro-resolving protein AnxA1. In vitro, exogenous 




chondrocytes via FPR2, leading to extracellular matrix accumulation and cartilage 
protection through the reduction in stress-adaptive homeostatic mediators IL-8 and 
PGE2. In vivo, intra-articular injection of AnxA1-positive MV lessened cartilage 
degradation caused by inflammatory arthritis (Headland et al., 2015). These findings 
are of extreme importance, as it could be used as a new therapeutic for RA.  
Further, neutrophils are not the only subtype of cells with potential opposite 
roles in the development of the inflammation in RA. Indeed, many groups have shown 
that different subsets and/or polarized phenotypes of monocytes and macrophages 
may play distinct roles during the development and resolution of inflammation. 
Misharin and colleagues (2014) demonstrated in a murine model of RA that non-
classical Ly6C− monocytes are required for the initiation and progression of sterile 
joint inflammation. Moreover, non-classical Ly6C− monocytes differentiate into 
inflammatory macrophages (M1), which drive disease pathogenesis and display 
plasticity during the resolution phase. But during the development of arthritis, these 
cells polarize toward an alternatively activated phenotype (M2), promoting – at this 
stage - the resolution of joint inflammation (Misharin et al., 2014). 
 
1.2.4. Experimental models of Arthritis 
Use of animal models have significantly increased our understanding of the 
pathogenesis of RA, despite the inherent limitations, contributing to several major 
advances in treatment. The most used model of arthritis is the collagen-induced 
arthritis (CIA) model, which shares many similarities with human RA. It was first 
described in rats, but quickly mouse models become available, with the use of type II 
heterologous collagen in complete Freund’s adjuvant. Importantly, susceptibility in 
mice is linked to strains that have MHC Class II I-Aq haplotypes (Wooley et al., 1985, 
Brunsberg et al., 1994). CIA has also been used in non-human primates, a powerful 




For induction of arthritis with CIA, DBA/1 mice are the most widely used strain. 
Clinical signs of disease typically develop 21–25 days after the initial inoculation, 
which presents as a polyarthritis, which is most prominent in the limbs and 
characterized by synovial inflammatory infiltration, cartilage and bone erosion and 
synovial hyperplasia similar to human RA. The development of CIA is associated with 
both B- and T-lymphocyte responses with the production of anti-collagen type II 
antibodies and collagen-specific T cells. The auto-antibody response in CIA is 
predominated by the IgG2 subclass with high levels of both IgG2a and IgG2b present 
at the peak of arthritis. Disease severity is expected to peak at approximately day 35, 
after which DBA/1 mice enter remission, marked by increased concentrations of 
serum IL-10 and a subsequent decrease in pro-inflammatory Th1 cytokines (Mauri et 
al., 1996). 
One disadvantage of this model is the challenge to use it for genetic 
modifications or targeted gene deletion, as most transgenic mice are on the C57BL/6 
background, which is generally considered resistant to CIA. However, changes in the 
way CIA is induced (immunisation with chicken type II collagen), have recently 
allowed the use of CIA in C57BL/6 background (Inglis et al., 2007). The C57BL/6 
strain develops arthritis ∼4–7 days later compared with DBA/1 mice, eventually 
reaching severity at a level comparable to arthritis in DBA/1 mice (Inglis et al., 2007). 
The arthritis was associated with sustained levels of serum anti-collagen antibody 
titters, higher levels of T-cell proliferation and IFN-γ secretion in the late stage of 
disease. However, there are differences in the onset and progression of disease 
between the DBA/1 and C57BL/6, which may cause discrepancies when comparing 
studies between these two strains. The severity in the B6 strain is sustained, but 
incidence of disease is markedly lower than DBA/1 mice and more variable across 
different substrains of B6 mice. Therefore, while both strains of mice may be useful 




C57BL/6 model requires further characterization in different B6 substrains (Asquith et 
al., 2009). 
 Recently another model of inflammatory arthritis has been developed. In this 
model, transgenic mice expressing the KRN receptor in T cells and the A(g7) MHC 
class II, once bred with the NOD mouse colony (often used for experiments on 
diabetes), spontaneously develop severe inflammatory arthritis. Sera are collected 
from 10-week old mice by cardiac puncture. Importantly, the serum from these 
animals induces arthritis when injected into recipient mice, a response mounted in a 
large number of mouse strains (Kouskoff et al., 1996, Matsumoto et al., 2002, Kyburz 
and Corr, 2003). In this model, the deposition of glucose-6-phosphate isomerase 
antibodies from the arthritogenic serum onto the surface of the cartilage initiates an 
innate immune response mainly mediated by complement and LTB4 recruiting 
neutrophils (Kyburz and Corr, 2003, Chen et al., 2006). K/BxN serum transfer arthritis 
is an acute, aggressive polyarthritis with high disease penetrance, which can resolve 
over 28 days, depending on the volume of serum injected and the frequency of these 
injections.  
Other models of arthritis include collagen-antibody-induced arthritis, 
zymosan-induced arthritis, and the methylated BSA model, and the genetically 
manipulated or spontaneous arthritis models such as the TNF-α-transgenic mouse, 
and the Skg mouse. Table 1 report comparative characteristics of the models 







   
Table 1: Main characteristics of some models of arthritis 












Polyarthritis, only inducible in 
susceptible strains, antibody and T-cell 
response. Low incidence and variability 
of disease severity in C57BL/6 mice. 
Inoculation with homologous collagen 
induces relapsing/remitting arthritis but 
otherwise is self-limiting. 
Symmetric joint 
involvement, peripheral 
joints affected, synovitis, 
cartilage and bone 
erosions, inflammatory cell 
infiltrate, pannus formation, 
erythema, oedema, 
genetically regulated by 
MHC and non MHC genes 
Formation of antibodies to 
collagen, greater incidence in 
males, periostitis, poor 
responses to NSAIDs, not 
characterized by 




Mouse Self-limiting polyarthritis in 100% 
animals, onset within 48 h, macrophage 
and polymorphonuclear cell 
involvement, no T- and B-cell 
involvement. Can be induced in most 
strains of mice 
 
Macrophage and PMN 
inflammatory cell infiltrate 





Mouse, rat Monoarthritis, develops 3 days after 
inoculation and subsides by day 7, but 
has shown to relapse after day 25. 
Needs a high degree of technical ability 
to perform intra-articular injection in 
mice. TLR 2 dependent and can be 
induced in multiple strains of mice 
 
Proliferative inflammatory 
arthritis with mononuclear 
cell infiltration, synovial 







Mouse, rat Inoculation with antigen by intra-
articular injection requires a high degree 
of technical ability and precludes 





cell infiltrate, cartilage 
degradation, synovial 
hyperplasia, genetic 
linkage, T cell dependence 
Damage to cartilage less 
severe than in RA, bone 
destruction more prominent; 
no rheumatoid factor 
produced, gastrointestinal 






Mouse Generated by crossing the TCR transgenic 
KRN line with mice expressing the MHC 
class II molecule Ag7. K/BN mice develop 
severe and destructive inflammatory 
arthritis 
Symmetrically affects small 
peripheral joints 
Distal interphalangeal joints 
often affected, no systemic 
manifestations, no production 




Mouse Chronic inflammatory erosive polyarthritis Synovial hyperplasia, 
presence of an 
inflammatory cell infiltrate, 
pannus formation, cartilage 
destruction, and bone 
resorption 
No production of rheumatoid 
factor 
Reviewed in Bevaart et al. (2010) Asquith et al. (2009). 
   




Previously I discussed the effects and importance of some lipid mediators in 
the initiation and resolution phases of inflammation. However, there has been 
particular interest in free fatty acid (FFA) sensing and its association with the mode 
of signalling of a number of recently de-orphanised G protein-coupled receptors 
(GPCRs) as many of FFA can directly activate GPCRs. In addition, an epidemic 
increase of obesity and other chronic conditions has been visualised in western 
populations. The increased incidence of such conditions is associated with increased 
intake of high fat- and high sugar content foods (Thorburn et al., 2014). In the next 
subsection, it will describe some of the FFA and their receptors Next, it will be 
described some of these FFA and their receptors, and their association with 
inflammatory processes. In the next subchapters, an overview of free fatty acid and 
free fatty acid receptors will be given, focussing in the know literature for GPR40 and 
GPR120. The importance of fatty acids in rheumatoid arthritis will also be discussed. 
 
1.3.2. Overview of FFAs and FFARs 
A FFA is a carboxylic acid with a long aliphatic chain, which is either saturated 
(no double bonds between carbons atoms) or unsaturated (Figure 5). Unsaturated 
FFA can be further classified as monounsaturated fat acids, which have only one 
double bond between carbons atoms, or as polyunsaturated FFAs when more than 
two double bonds are present. In addition, unsaturated FFA can be classified as cis 
(when the two hydrogen atoms adjacent to the double bound stick out on the same 
side of the chain) or trans (when adjacent two hydrogen atoms lie on opposite sides 





Figure 5: Types of fatty acids. 
 
FA are also widely classified based on the length of their carbon chains and 
grouped into short chain fatty acids (2-6 carbon atoms long) such as butanoic acid; 
medium chain fatty acids (7-12 carbon atoms long) such as lauric acid; and long chain 
fatty acids (more than 12 carbon atoms long) such as palmitic acid (Alvarez-Curto 
and Milligan, 2016). Essential fatty acids, such as linoleic acid (18:2, n-6) or alpha-
linolenic acid (18:3, n-3), which humans cannot synthesise directly, and other long 
and medium chain fatty acids, are generally obtained through the diet. Some other 
FFAs are obtained through the breakdown of fats (triglycerides) in adipose tissue and 
the liver. By contrast the vast majority of short chain fatty acids, including acetate and 
propionate are derived from the fermentation of fibres and breakdown of dietary 
carbohydrates by the bacteria present in the gut (Krishnan et al., 2015, Macfarlane et 
al., 2011).  
As mentioned before, an important family of FFA are the omega-3 fatty acids, 
which are essential polyunsaturated fatty acids with a double bond between the third 
and fourth carbon atoms from the methyl end of the fatty acid carbon chain. 
Nutritionally important omega-3 fatty acids include α-linolenic acid (ALA), EPA and 
DHA. Although the health benefits of long-chain omega-3 fatty acids were discovered 
in the 1970s by researchers studying the Greenland Inuits, much more is now known 
of these benefits (O'Keefe and Harris, 2000). The Greenland Inuit people consumed 
large amounts of fat from seafood but experience lower incidences of cardiovascular 
diseases (Yates, Calder et al. 2014). Today omega-3 fatty acids are prescribed for 




Evidently, omega-3 fatty acids reduce blood triglyceride levels and regular intake may 
reduce the risk of a secondary or primary heart (He et al., 2004). However, PUFA can 
influence inflammatory cell function by the following mechanisms (Yates et al., 2014):  
• PUFA intake can influence complex lipid, lipoprotein, metabolite and hormone 
concentrations that in turn influence inflammation;  
• PUFAs can be oxidized and the oxidized derivatives can act directly on 
inflammatory cells via surface or intracellular receptors;  
• PUFAs can be incorporated into the phospholipids of inflammatory cell 
membranes, which can influence the membrane order (fluidity) and lipid raft 
formation. The composition of the membrane phospholipids can also interfere 
in cell signalling pathways (composition of second messengers);  
• Non-esterified PUFAs can act directly on inflammatory cells via surface or 
intracellular fatty acid receptors.  
 The last mechanism involves the activation of free fatty acid receptors, as 
detailed in the next section.   
 
1.3.3. A family of GPCRs for Free Fatty Acids  
G-Protein-coupled receptors constitute the most prosperous protein families 
for drug discovery, with 30–50% of all approved drugs acting by targeting GPCRs. 
The complexity of GPCRs is determined by the diversity of external stimuli they can 
respond to (including lipids, amino acids, proteins, hormones, nucleotides, 
neurotransmitters, light, etc.) and the variety of intracellular pathways they can 
engage, which depends in part by which particular Gα, Gβ, or Gγ proteins they are 
coupled to. GPCRs are characterized by 7 transmembrane segments, which based 
on sequence similarity, can be clustered into 5 families: the rhodopsin family (701 




the glutamate family (15 members), and the secretin family (15 members) 
(Rosenbaum et al., 2009).  
FFARs are members of the ‘rhodopsin-like’ GPCR family and currently four 
receptors have been classified and named as FFAR1 (GPR40), FFAR2 (GPR43), 
FFAR3 (GPR41) and FFAR4 (GPR120). GPR40, GPR43 and GPR41 are closely 
related in terms of sequence and are co-located on chromosome 19q13.12 in 
humans (Sawzdargo et al., 1997). Recently, a gene sequence between the coding 
regions for GPR41 and GPR40, which was initially considered a pseudogene, seems 
to be active in some individuals, and has been named GPR42 (Puhl et al., 2015). On 
the other hand, GPR120 is located on chromosome 10 (10q23.33) in humans and 
displays little overall homology with the other FFARs. GPR41 and GPR43 can be 
activated by short chain fatty acids, and display various potencies for the different 
ligands (Nilsson et al., 2003, Brown et al., 2003). In contrast both GPR40 and 
GPR120 are activated selectively by long chain fatty acids, as described below. 
 
1.3.3.1. Free Fatty Acid Receptor 1 (GPR40)  
 GPR40, also known as the FFAR1, was originally isolated from a human DNA 
fragment (Sawzdargo et al., 1997). Three independent groups demonstrated that 
GPR40 functions as a receptor for medium- and long-chain saturated and 
unsaturated FFAs (Briscoe et al., 2003, Itoh et al., 2003, Nilsson et al., 2003). 
Arachidonic acid and the omega-3 PUFAs EPA and DHA can activate GPR40 
(Briscoe et al., 2003), but it is not known if activation of this receptor by different 
ligands would result in different responses. In CHO cells with a stable expression of 
GPR40, FFAs induced an increase in intracellular calcium levels and activation of 
extracellular signal-regulated kinase (ERK) 1/2 (Itoh et al., 2003). A large rise in the 
intracellular calcium was also observed in pancreatic β-cells (Shapiro et al., 2005, 
Hara et al., 2009) and in primary pancreatic islet cells (Fujiwara et al., 2005). 




changes were detected with respect to cAMP production, it seemed that GPR40 did 
not couple with Gs or Gi/Go in pancreatic β-cells (Briscoe et al., 2003, Welters et al., 
2006). In human embryonic kidney 293 (HEK293) cells overexpressing GPR40, 
linoleic acid evoked activation of phospholipase C (PLC) through the Gq protein 
(Salehi et al., 2005). This identifies linoleic acid as an endogenous ligand for GPR40. 
The hydrolysis of inositol lipids by GPR40 activation has not been studied directly in 
β-cells, however the FFA-induced intracellular calcium rise in β-cells is consistent with 
the involvement of PLC. Through the use of reverse-transcription polymerase chain 
reaction, immunohistochemistry, and in situ hybridization, GPR40 was shown to be 
expressed in insulin-producing pancreatic islet cells (Itoh et al., 2003). The expression 
level of GPR40 in pancreatic islets was from two-fold to 100-fold higher than in whole 
pancreas (Briscoe et al., 2003) indicating a selective or restricted expression pattern 
for this receptor. However, GPR40 expression has also been detected in monocytes, 
brain and cell lines of breast cancer (Briscoe et al., 2003, Hardy et al., 2005).  Many 
compounds showing either agonistic or antagonistic activity have been identified and 
their physiological and pharmacological effects have been examined using various 
experimental systems (Bharate et al., 2009). The first report identifying a series of 
novel GPR40 agonists based on 3-(4-[(N-alkyl) amino]phenyl) propanoic acid was 
from Garrido and colleagues (Garrido et al., 2006). These compounds showed a 100-
fold increase in potency, and structure-activity relationships have been investigated 
for some of them. Furthermore, synthetic GPR40 antagonists have been identified 
and their antagonistic activities were examined via both in vitro and in vivo studies 
(Briscoe et al., 2003) (Humphries et al., 2009, Zhang et al., 2010). In particular, the 
physiological and pharmacological properties of GW9508 have been studied in detail 
because it has the potential as an agonist for not only GPR40, but also GPR120. 
However, GW9508 is approximately 100-fold more selective for GPR40 over 
GPR120. In addition, the small-molecule GW1100 inhibited (1µM) the intracellular 




mediated via GPR120, demonstrating that GW1100 was a selective antagonist of the 
GPR40 receptor (Briscoe et al., 2006). Besides the ability to increase the release of 
insulin only when glucose levels are elevated (Briscoe et al., 2003, Alquier et al., 
2009), GPR40 is also involved in the suppression of CCL5, CCL17 and CXCL10 
induced by TNF-α stimulation (Fujita et al., 2011), protection of bone loss by inhibiting 
osteoclast differentiation (Wauquier et al., 2013), inhibition of NLRP3 activation in 
macrophages (Yan et al., 2013), and in the suppression of inflammatory chronic pain 
(Nakamoto et al., 2013). Furthermore and in contrast to the succinctly described anti-
inflammatory properties, a recent study showed that the long-chain FFAs palmitic acid 
and linoleic acid induce secretion of pro-inflammatory cytokine/chemokines, such as 
IL-6, IL-8 and MCP-1, in RA synovial fibroblasts (RASF) and production of IL-6 in 
palmitic acid, linoleic acid and oleic acid induced human chondrocytes, showing that 
FFA may also directly contribute to inflammation and joint degradation in inflammatory 
joint diseases (Frommer et al., 2015). 
 
1.3.3.2. Free Fatty Acid Receptor 4 (GPR120)  
 GPR120 shares only 10% sequence homology with FFAR1, and is optimally 
activated by saturated FAs of chain length 14-18 and unsaturated FAs of chain length 
16-22 carbons. GPR120 is expressed in adipose tissue, macrophages, the 
gastrointestinal tract, lung and pituitary. Long-chain FFAs induce a rise in cytosolic 
free calcium in HEK293 overexpressing GPR120, but they do not promote cAMP 
production. This suggested that GPR120 is coupled with Gq protein, as GPR40, but 
not with the Gs or Gi/o families (Hirasawa et al., 2005, Bharate et al., 2009). GPR120 
can also induce the activation of ERK1/2 under certain conditions, and the activation 
of phosphoinositide (PI)-3-kinase and the serine/threonine protein kinase Akt in 
GPR120-expressing cells (Katsuma et al., 2005) but is unclear whether this response 
derives from the rise in intracellular calcium or whether an independent coupling 




3 fatty acids DHA and EPA, and stimulation of macrophages with these omega-3 
FFAs caused broad anti-inflammatory effects, all abrogated by siRNA against 
GPR120 (Oh et al., 2010). Stimulation of GPR120 specifically inhibited TGF-β-
activated kinase 1 (TAK1) phosphorylation and activation of both toll like receptor 
(TLR) and TNF-α signalling. 
 
1.3.4. Fatty acids in Rheumatoid Arthritis 
Numerous randomized, placebo-controlled, double-blinded studies using 
omega-3 polyunsaturated fatty acids in RA are reported. Almost all of these trials 
showed some benefit of fish oil, a source of these fatty acids. Such benefits include 
reduced duration of morning stiffness, reduced number of tender or swollen joints, 
decreased pain and time to fatigue, increased grip strength, and decreased use of 
non-steroidal anti-inflammatory drugs (reviewed in Calder (2008), and (Miles and 
Calder, 2012)). The dose range of omega-3 polyunsaturated fatty acids reported in 
these trials varied from 1.6 to 7.1 g/day and averaged 3.5 g/day (Calder, 2008, Miles 
and Calder, 2012). Thus, evidence-based reports implicate fish oil supplementation 
as an useful complementary therapy for RA. Alongside some of these studies, the 
authors also investigated inflammatory parameters that are modulated following 
omega-3 treatment, which include decreased LTB4 production by neutrophils (Cleland 
et al., 1988, Kremer et al., 1987, Kremer et al., 1990, Sperling et al., 1987), reduced 
IL-1β production by macrophages (Kremer et al., 1990), and lower plasma levels of 
IL-11β (Espersen et al., 1992, Kremer et al., 1990). Thus, the mechanisms by which 
omega-3 PUFAs exert their beneficial effects are of mounting interest. These actions 
can be mediated, directly or indirectly, by EPA and DHA, the most prevalent omega-
3 PUFAs found in fish oil.  
One of the traditional hypothesis is that omega-3 PUFAs compete with the 
canonical omega-6 substrate AA to generate eicosanoids such as prostaglandins of 




inflammatory than their AA-derived counterparts (reviewed by Calder (2015)). More 
recently, Serhan discovered that both EPA and DHA could be enzymatically 
converted in vivo to novel bioactive lipid mediators, termed resolvins, protectins and 
maresins (termed specialized pro-resolving mediators) that stimulate the resolution 
of inflammation and have proven to be log-orders more potent than their lipid 
precursors (reviewed in Serhan (2014)). Biosynthetic generation of these mediators 
may represent a potential molecular mechanism to explain the beneficial use of 























1.4. SCOPE OF THE THESIS 
 
1.4.1. Hypothesis  
Free Fatty Acids are newly described as extracellular signalling molecules, 
besides their nutritional and metabolic properties. Given the widespread expression 
of FFAR and the attributed health benefits of the PUFA omega 3 fatty acids in 
prevention of various diseases, it is hypothesized that GPR40 and GPR120, receptors 
for medium- and long-chain fatty acids, could have protective roles in inflammation 
and possibly in RA. Thus, the objective of this work consists of investigating functions 
and expression of GPR40 in cell types found within the joints in RA such as synovial 
fibroblasts, macrophages, monocytes, neutrophils, endothelial cells, lymphocytes, 
and chondrocytes. And then determine if GPR40 activation in human leukocytes 
could modulate the inflammatory response.  
 
1.4.1.1. Aims 
This hypothesis will be challenged by addressing the following specific aims:  
• Evaluate the expression and modulation of GPR40:  
o Genomic expression will be evaluated in human cells, including 
leukocytes, endothelial cells and chondrocytes by polymerase chain 
reaction (PCR); 
o Protein expression will be verified by flow cytometry.  
o GPR40 modulation will be assessed after stimulation with pro-
inflammatory mediators.  
• Evaluate the functionality of GPR40 in leukocytes by using the agonist 
GW9508 to modulate:  
o Intracellular calcium flux;  




o Neutrophil-endothelial interactions under flow; 
o Neutrophil chemotaxis; 
o The phagocytic ability of neutrophils and macrophages; 
o Release of microvesicle in neutrophils; 
o Apoptosis of neutrophils; 
o The polarization of M1/M2 macrophages.  
• To determine the expression and functional roles of GPR40 in vivo and ex 
vivo:  
o Evaluate if GPR40 is expressed in immune cells from arthritic joints by 
flow cytometry; 
o Assess whether prophylactic treatment with GW9508 modulates the 
initiation and progression of inflammatory arthritis by evaluating 
arthritic parameters, inflammatory mediators and leukocytes 
infiltration; 
o Assess whether therapeutic treatment with GW9508 modulates the 
resolution of inflammation in arthritic mice.






























2.1. Cell Culture 
Dulbecco’s phosphate buffered saline (DPBS) with calcium and magnesium and 
DPBS without calcium and magnesium, foetal bovine serum (FBS), Hank’s Balanced 
Salt Solution (HBSS), human serum, Medium 199 with Earle’s Salts with L-glutamine 
(M199), penicillin/streptomycin (100U/100mg/ml) and Roswell Park Memorial Institute 
medium 1640 (RPMI), acetic acid, crystal violet, dextran (molecular weight 450,000-
650,000), gelatine type B from bovine skin, HBSS 10X, Histopaque 1077, phosphate 
buffered saline (PBS), sodium citrate, LPS, ionomycin, IL-8, Escherichia coli strain 
K12 and human recombinant tumour necrosis factor- (hrTNF-) were purchased 
from Sigma-Aldrich, Poole, Uk. Insulin transferrin selenium (ITS) supplement, non-
heat inactivated FBS, Fungizone and trypsin/EDTA (0.25%/0.01%), Dulbecco's 
Modified Eagle Medium (DMEM), DMEM/Nutrient Mixture F-12 (DMEM/F12) 
(containing phenol red or phenol red free), RPMI and macrophage serum-free 
medium (SFM, 1X) were purchased from Gibco, Invitrogen, Paisley, UK. Type II 
collagenase was purchased from Worthington Biochemical Corporation, Lakewood, 
USA. Accutase was purchased from Millipore, Watford, UK. Macrophage colony-
stimulating factor (M-CSF) and IL-4 were purchased from Peprotech, NJ, USA. IFN-
γ was purchased from eBioscience, Hatfield, UK. BodyP 576/589 dye, Fura-2AM and 
pluronic acid were purchased from Life technologies, Eugene, OR, USA.  
 
2.2. Flow Cytometry 
Annexin V-FITC apoptosis detection kit was purchased from BD Pharmingen, Oxford, 
UK. Human Fc block was purchased from BD Bioscience, Abingdon, UK. Intracellular 
fixation and permeabilisation buffers were purchased from eBioscience, Hatfield, UK. 
Bovine serum albumin (BSA), paraformaldehyde (PFA), collagenase D, DNase and 
sodium chloride were purchased from Sigma-Aldrich, Poole, Uk. Zombie NIR was 
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purchased from BioLegend, San Diego, CA, USA. All antibody suppliers, clones and 
concentrations are listed below. 
 
























eBioscience PECy5 IgG1 100ng/ml 
F4/80 
(Mouse) 






Abcam - IgG 0.181g/ml 
Isotype 
CD11b 
Mouse eBioscience APC IgG1 100ng/ml 
Isotype 
CD62L 





eBioscience PerCP-Cy5.5 IgG2c 200ng/ml 
Ly6G 
(Mouse) 
1A8, Rat BD Pharmigen APC IgG2a 10g/ml 
Ly6G 
(Mouse) 















































BioLegend Pacific Blue IgG1 200ng/ml 
Isotype 
GPR40 
EPR25A Abcam - IgG 0.181g/ml 
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2.3. Molecular biology reagents 
GelRed DNA dye was purchased from Biotium, Cambridge, UK. A 1-kilobase 
molecular weight DNA ladder buffer, deoxyribonucleiotide triphosphate (dNTP) and 
oligo(DT)15 were purchased from Promega, Southampton, UK. Quantitec™ primers 
(listed in Table 3) and Qiagen mini-kit were purchased from Qiagen, Manchester, UK. 
Chloroform, 2-Propanolol, -mercaptoethanol, RNAlater and molecular biology grade 
ethanol were purchased from Sigma-Aldrich, Poole, UK. ReddyMix PCR master-mix 
was purchased from Thermo-Scientific, St-Leon Rot, Germany. Power SYBRgreen 
mastermix, dithiothreitol (DTT) and TURBO DNA-free kit were purchased from 
Applied Biosystems Inc., CA, USA. Trizol, agarose, RNase out, first strand buffer 
and SuperScript III were purchased from Invitrogen, Paisley, UK.  
 
Table 3: Quantitec™ Primers used for analysis of mRNA expression  
 
 
2.4. Other reagents and materials 
Isoflurane inhalable gas anaesthetic was purchased from Baxter, Norfolk, UK. 
Haematoxylin, DPX slide mountant and methanol were purchased from Sigma-
Aldrich, Poole, UK. Eosin was purchased from VWR, Leicestershire, UK. Polystyrene 
Gene code Catalogue number Detected transcript 
Hs_GAPDH QT01192646 NM_002046 (1401 bp) 
Hs_RPL32 QT01668198 NM_000994 (1668 bp) 
Hs_FFAR1_1_S QT00211449 NM_005303 (923 bp) 
Mm_Nos2_1_SG QT00100275 NM_010927 (3990 bp) 
Mm_Tnf_1_SG QT00104006 
NM_013693 (1653 bp) 
NM_001278601 (1605 bp) 
Mm_Rpl13a_1_SG QT00267197 
NM_009438 (1039 bp) 
XR_105101 (1039 bp) 
XR_105102 (1039 bp) 
XR_107897 (1039 bp) 
Mm_Il1b_2_SG QT01048355 
NM_008361 (1328 bp) 
XM_006498795 (2137 bp) 
Mm_Il4_1_SG QT00160678 NM_021283 (605 bp) 
Mm_Il6_1_SG QT00098875 NM_031168 (1087 bp) 
Mm_Il10_1_SG QT00106169 NM_010548 (1306 bp) 
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ultracentrifuge tubes were purchased from Beckman Coulter, High Wycombe, UK. 
Neubauer Chamber was purchased from Celeromics, Valencia, Spain. Histoclear 
was purchased from Fisher Scientific, Loughborough, Leistershire, UK. Neuroprobe 
ChemoTxTM 96-well plate, Receptor Technologies Ltd, U.K. Six channel μ-slides VI0.4 
was purchased from ibidi, Martinsried, Germany. Tabasco sauce was purchased 
from McIlhenny Company, Louisiana, USA. Maldon sea salt was purchased from 
Maldon Crystal Salt Company Ltd, Essex, UK. Evian natural mineral water was 
purchased from Danone Waters, Evian, France. Precellys tubes were purchased from 
Peqlab, Germany. Syringes and needles were purchased from Terumo, Heverlee, 
Belgium. Glass microscope slides were purchased from Thermo Scientific, 
Leicestershire, UK. All cell culture flaks, plates and plastics not stated before were 
purchased from Corning Amsterdam, NL. 
 
2.5. Software and equipment 
Software packages utilised during this project were IDEAS and INSPIRE software, 
Amnis Corporation, Seattle, WA, USA; FLOWJO Software, FlowJo, Stanford, CA, 
USA; Lucia Imaging Software, Lucia Laboratory Imaging, Prague, CZ; ND 1000 
software, NanoDrop Technologies, Wilmington, DE; ImageJ software, NIH, Bethesda, 
MD, USA; ImagePlus. 
Analytical hardware included ImagestreamX mk. II, Amnis corporation, Seattle, WA, 
USA; ABI Prism 7900 real-time PCR system, Applied Biosystems Inc., CA, USA; BD 
LSR Fortessa and BD FACSCalibur, BD Bioscience, Abingdon, UK; Leica tissue 
processor and Leica microtome, Leica Microsystems, Milton Keynes, UK; NanoDrop 
Spectrophotometer, NanoDrop Technologies, Wilmington, DE; Nikon DXM1200 
digital camera, Nikon, Melville, NY, USA; Olympus BH-2 light microscope, Olympus, 
Tokyo, Japan; FluorChem E digital darkroom, Protein Simple, Santa Clara, CA, USA; 
NOVOSTAR, BMG Labtech, Germany; and Abgene Thermal Cycler, 
ThermoScientific, Leicestershire, UK. 





 IN VITRO METHODS 
2.6. Isolation and culture of primary human umbilical vein endothelial cells 
(HUVEC) 
All cell culture flasks/dishes were coated in 0.5% gelatin type B from bovine 
skin in DPBS without calcium and magnesium (DPBS -/-) for 20 minutes prior to use. 
Following this coating procedure, gelatin was aspirated before seeding cells. 
Umbilical cords were kindly supplied by the midwifery staff of the Maternity 
Unit, Royal London Hospital (Ethicals Approval REC Reference Number: 
06/Q0605/40). Cords were placed in cord buffer [HBSS containing 
penicillin/streptomycin (100U/100mg/ml) and fungizone (2.5μM/ml)] and stored at 4oC 
until endothelial isolation. Endothelial cells were isolated from umbilical cords by 
collagenase digestion of the interior of the umbilical vein (Jaffe et al., 1973). Briefly, 
a 21-gauge butterfly needle was introduced into the vein of the umbilical cord and 
clamped. The vein was perfused with approximately 30ml of DPBS -/- using a sterile 
syringe to wash out the residual blood. The other end of the cord was then clamped 
and approximately 20ml of 0.1% collagenase type II in serum free M199 containing 
penicillin/streptomycin (100U/100mg/ml) and fungizone (2.5μM/ml) was added. The 
cord was incubated in a humidified chamber in 5% CO2 at 37°C for 15 minutes. 
Following incubation, the collagenase solution was collected into a 50ml centrifuge 
tube and the vein was flushed with 30ml of DPBS -/-, and once with air to remove 
endothelial cells. The cells were centrifuged at 300g for 5 minutes, supernatant 
removed, and the pellet was re-suspended in 12ml of complete medium [M199 
containing penicillin/streptomycin (100U/100mg/ml), fungizone (2.5μM/ml) and 20% 
human serum] and transferred to a T75 flask (75cm2). The cells were incubated in a 
humidified chamber in 5% CO2 at 37°C, medium was replaced after 24h and changed 
every 48h thereafter.  
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Once the confluence of 95% was reached, cells were subcultured at a ratio of 
1:3 in T75 flasks. Flasks were rinsed with DPBS -/- to remove any serum, and cells 
were detached with warm trypsin/EDTA (0.25%/0.01%). Once cells had rounded and 
detached, the trypsin was deactivated by the addition of complete medium. Cells were 
divided between T75 flasks kept in culture and used in subsequent experiments 
between passages 1-3. 
 
2.7. Human blood leukocyte isolation 
Human leukocytes were isolated from the peripheral blood of healthy 
volunteers (Ethicals Approval REC Reference Number: QMREC2014.61) using the 
dextran sedimentation method. Blood was collected from healthy volunteers with a 
21-gauge butterfly needle into a 60ml syringe and transferred to a 50ml centrifuge 
tube containing 1/10 volume of 3.2% sodium citrate, to prevent clotting. The blood 
was centrifuged at 130g for 20 minutes at room temperature to sediment the cells. 
The upper layer (platelet rich plasma) was removed then 10ml DPBS -/- and 8ml 
dextran 6% (in DPBS -/-, molecular weight 450000-650000) was gently added on top. 
The tubes were inverted gently to mix the cell suspension with DPBS and dextran. 
Dextran causes red cells to form aggregates, which sink to the bottom of the tube, 
leaving a layer of DPBS/dextran enriched in blood leukocytes that is largely depleted 
of red blood cells. This process takes around 20 minutes. Following the incubation, 
the leukocyte rich layer was carefully collected without generating bubbles and 
layered over 10ml Histopaque® (10771 density) in a new 50ml centrifuge tube. The 
sample was centrifuged at 450g for 30 minutes at room temperature. This step allows 
the separation of peripheral blood mononuclear cells (PBMC) and polymorphonuclear 
cells (PMN) as shown in Figure 6 below: 
 




Figure 6: Human blood leukocyte isolation. 
 
2.7.1. Preparation of human monocyte derived macrophages 
PBMC were collected by using a Pasteur pipette and transferred into a new 
centrifuge tube. Cells were washed by adding up to 50ml of DPBS -/-, and centrifuged 
at 300g for 10 minutes at room temperature. Following the centrifugation, half of the 
supernatant was aspirated off, and up to 50ml of DPBS -/- was added for a second 
wash and centrifuged at 150g for 10 minutes at room temperature. This improves the 
number of the cells that are isolated as any Histopaque® in the solution could prevent 
the PBMC to reach the bottom of the tube; and also allows a better separation of the 
platelets. The supernatant was discarded and the cells were gently re-suspended in 
2ml of DPBS -/- for counting by using Pasteur pipette. To count, 10l of the cell 
suspension was added to 990l Turk’s stain (98ml distilled water, 2ml acetic acid and 
2g crystal violet) in a 1.5ml microcentrifuge tube, then vortexed briefly to obtain a 
homogenous cell suspension with no clumps. Cells in Turk’s dye were applied to a 
Neubauer counting chamber with coverslip. The cells were visualised with an 
Olympus BH-2 standard light microscope with X40 objective. Cells in the 4 larger 
outer squares were counted (marked in red in Figure 7), and divided by 4 to obtain 








PMN and Erythrocytes 
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Figure 7: Illustration of grid counting in a Neubauer haemocytometer. Cells were counted in the 
four outer squares marked in red and the average was calculated dividing the total value by four, and 
using the equation indicated. 
 
Once counted, cells were re-suspended in incomplete media and left at 37oC 
for 1h to allow monocytes to adhere. Non-adherent cells were washed off and 
monocyte-derived macrophages were obtained by incubating the cells for seven days 
at 37oC in RPMI supplemented with 10% FBS and 50ng/ml M-CSF. 
 
2.7.2. Isolation of peripheral blood neutrophils 
After removal of PBMC, the remaining layers were removed leaving only the 
layer containing PMN and erythrocytes. The erythrocytes were lysed through 
hypotonic shock with 9ml ice-cold ultrapure distilled water. Isotonicity was quickly 
restored (after less than 20 seconds) by drawing up the cell/water suspension and 
transferring it to a new centrifuge tube containing 1ml 10X HBSS. New tubes were 
used for isotonicity restoration to prevent any mononuclear cells adherent to the 
plastic of the tube being washed into the granulocyte suspension. Cells were washed 
by adding up to 50ml of DPBS -/-, and centrifuged at 300g for 10 minutes at room 
temperature. The supernatant was discarded and pellet (containing the cells) were 
gently re-suspended using a Pasteur pipette in 2ml of DPBS -/- for counting. Cells 
were counted as described above for PBMC. 
 
 
Average cell count per square x dilution factor x 
104 = Cell count per ml. 
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2.8. Collection of Exudated Human PMN 
Activation of Transient Receptor Potential Cation Channel subfamily V 
member 1 (TRPV1) receptors expressed at dorsal root ganglion by capsaicin can lead 
to neurogenic inflammation. Activation of those receptors results in the release of 
calcitonin-related gene product (CGRP) and substance P, neuropeptides that act on 
the local vasculature to promote inflammation (Helme and McKernan, 1985). 
Tabasco Sauce contains high levels of capsaicin (0.33.g capsaicinoids/ml) as 
determined by high pressure chromatography (Gonzalez et al., 1998) and thus 
induces this effect when administered orally. 
The local research committee approved experiments with healthy volunteers 
and informed consent was provided according to the declaration of Helsinki (Ethicals 
Approval REC Reference Number: QMREC2010/17). Volunteers were asked to rinse 
the buccal cavity three times with 20ml of 0.9% saline (prepared with Maldon sea salt 
as it contains low levels of impurities compared to other table salts and Evian still 
water) for 30 seconds and then a 10% Tabasco solution in Evian water (20ml for 30 
seconds). These were discarded and the volunteers were asked not to eat or drink 
anything for the following two hours. The volunteers were then asked to rinse the 
buccal cavity again three times with 20ml of 0.9% saline. The samples were collected 
and passed through a 70m strainer and centrifuged at 300g for 10 minutes at room 
temperature to pellet the cells. The cells were resuspended with 50ml of DPBS-/- and 
passed through a 40m strainer to separate epithelial cells and centrifuged at 300g 
for 10 minutes at room temperature to pellet the cells. The supernatant was discarded 
and the cells were gently re-suspended using a Pasteur pipette in 2ml of DPBS -/- for 
counting. Cells were counted as described above.  
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2.9. In vitro culture of chondrocytes 
2.9.1. Culture of C28/I2 chondrocyte cell line 
The C28/I2 cell line was used in this project for production of micromass 
culture. These cells express collagen type II, one of the most labile features of 
cultured (primary and immortalised) chondrocytes, and produce matrix that reacts 
with antibodies against collagen type II, large proteoglycan and sulphated 
glycosaminoglycans. They also exhibit decreased expression of collagen type II and 
increased expression of matrix metalloproteinases (MMPs) in response to IL-1 
stimulation (Goldring et al., 1994), reminiscent of the true chondrocytic phenotype. 
Cells were cultured DMEM/F12 complete medium [supplemented with 10% 
non-heat inactivated FBS, penicillin/streptomycin (100U/100mg/ml)] during 
monolayer culture. C28/I2 cells were cultured to confluence before subculture. Flasks 
were rinsed with DPBS to remove any serum, and cells were detached with warm 
trypsin/EDTA (0.25%/0.01%). Once cells had rounded shape and detached, the 
trypsin was deactivated by the addition of complete medium. Cells were re-
suspended in 30ml complete medium and transferred to fresh flasks (10ml per flask) 
to achieve a 1:3 subculture. Cells were used between passage 3 and 20 for 
micromass culture.  
 
2.9.2. Generation of C28/I2 chondrocyte micromass cultures 
C28/I2 can be differentiated into matrix-producing chondrocytes when 
cultured in high density and serum free conditions (Greco et al., 2011). Briefly, 
confluent C28/I2 monolayers were rinsed with DPBS to remove any serum, and cells 
were detached with trypsin/EDTA (0.25%/0.01%). Once cells had rounded and 
detached, the trypsin was deactivated by the addition of complete medium, 
transferred to a tube, then centrifuged for 10 minutes at 400g before being re-
suspended in 5ml complete medium for counting (see section 2.7). The cells were re-
suspended to a volume of 2.5 x 107 cells/ml in complete medium. Using a reverse 
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displacement Gilson pipette, 20l of the well-mixed cell suspension was placed into 
each well of a 48-well plate, so that the surface tension allowed a rounded drop to be 
formed on the bottom of the well. The peripheral wells of a 48-well plate were pre-
filled with sterile DPBS to increase relative humidity to prevent evaporation of the 
medium. Plates were carefully transferred to an incubator without disrupting the 
pellets and cells were left to adhere for 3 hours at 37°C in 5% CO2. After the 3 hour 
period, 2ml complete medium was added very slowly to each well, taking care not to 
dislodge the delicate cell pellet. After 24 hours the medium was replaced with 1ml 
chondrocyte differentiation medium [serum free, phenol-red free DMEM/F12 
containing 1% insulin/transferrin/selenium (ITS) supplement]. After 24 hours, cells 
were considered ready to use. 
 
2.10. Modulation of GPR40 expression in neutrophils and macrophages 
Neutrophils and macrophages were isolated and prepared as described in 
section 2.7. To assess their pattern for GPR40 expression and potential function, 
neutrophils and macrophages were stimulated with different pro-inflammatory 
mediators involved in the initiation and progression of RA.  
To assess the genomic modulation of GPR40, I personally decided to 
stimulated neutrophils for 4 and 6 hours, while macrophages were stimulated for 6 
and 18 hours with TNF- (10ng/ml) in 0.1% FBS RPMI. After stimulation, RNA was 
isolated and quantify as described in section 2.11. To assess protein modulation, 
neutrophils were stimulated with TNF-α (10ng/ml), IL-8 (10ng/ml), PAF (10nM) and 
LTB4 (10nM) for 10 minutes in incomplete RPMI at 37oC (Norling et al., 2012, 
Krishnamoorthy et al., 2010). After stimulation, GPR40 expression was determined 
by flow cytometry analysis as described in section 2.12.1. 
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2.11. Gene expression analyses 
In this project, two different types of Ribonucleic acid (RNA) isolation were 
used: a commercially available kit (Qiagen RNeasy® Plus Mini Kit) was used for RNA 
isolation from micromass, HUVEC, monocytes, lymphocytes and macrophages; while 
TRIzol® reagent was used to isolate RNA from neutrophils as it resulted in better 
recovery. Both methods are explained below: 
 
2.11.1. RNA isolation using RNeasy® Plus Mini Kit 
Total RNA was extracted using a commercially available kit (Qiagen RNeasy 
Mini Kit) following manufacturer’s guidelines. Briefly, one million cells of micromass, 
HUVEC, monocytes, lymphocytes and macrophages samples were lysed in 600l 
buffer RLT plus (containing 1:100 -mercaptoethanol) and frozen at -80°C to increase 
RNA yield. The exact composition of Buffer RLT plus is confidential, but it is a lysis 
buffer for lysing cells and tissues before RNA or deoxyribonucleic acid (DNA) 
isolation. It contains a proprietary blend of detergents that allows efficient binding of 
DNA molecules to the gDNA Eliminator column. It also contains a high concentration 
of guanidine isothiocycanate, which supports the binding of RNA to the silica 
membrane. The -mercaptoethanol is added to effectively inactivate RNases in the 
lysate. Samples were defrosted on ice before being homogenised by syringing 5 
times through a 23-gauge needle. One volume of 70% molecular biology grade 
ethanol was added and samples were mixed well by pipetting before transferring the 
entire volume to the RNeasy kit columns. The ethanol creates conditions that promote 
selective binding of RNA to the RNeasy membrane. Samples were centrifuged at 
10,000g for 15 seconds and flow-through discarded. Contaminants were washed by 
adding 700l RW1 buffer to the columns and centrifuged at 10,000g for 15 seconds. 
The exact composition of Buffer RW1 is confidential, but it contains a guanidine salt, 
as well as ethanol, and is used as a stringent washing buffer that efficiently removes 
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biomolecules such as carbohydrates, proteins and fatty acids, that are non-
specifically bound to the silica membrane. At the same time, RNA molecules larger 
than 200 bases remain bound to the column. Flow through was discarded before the 
addition of 500l RPE and a further centrifugation step. The exact composition of 
Buffer RPE is confidential, but it is a mild washing buffer that removes traces of salts, 
which are still on the column due to buffers used earlier in the protocol. A second 
wash with 500l RPE followed, and samples were centrifuged a further time at 
10,000g, this time for 2 minutes. The collection tube was discarded and replaced with 
a new collection tube followed by a centrifugation at 12,000g for 1 minute to dry the 
membrane. Columns were placed into new collection microcentrifuge tube and 30l 
RNase-free water was added directly to the membrane for RNA elution. Total RNA 
concentrations and purity was measured as described in section 2.11.3. The samples 
were stored at -80oC until further use. 
 
2.11.2. RNA isolation using TRIzol® reagent 
To access specific messenger RNA (mRNA) levels, total cellular RNA was 
isolated using TRIzol® reagent (a solution of phenol and guanidine isothiocyanate). 
Neutrophils were lysed directly by adding 1ml of reagent to 5-10x106 cell pellet, and 
frozen at -80oC to increase RNA yield. Samples were defrosted on ice before being 
homogenized by passing the lysate at least 5 times through a 23-gauge needle fitted 
to a RNase-free syringe to improve the homogenization. The homogenised samples 
were incubated for 15 minutes at room temperature to allow complete dissociation of 
nucleoprotein complexes, before addition of 200l of chloroform (per ml of TRIzol®). 
Tubes were shaken vigorously by hand for 15 seconds, left at room temperature for 
5 minutes before centrifuging at 12000g for 15 minutes at 4oC. This procedure 
separates the solution into a colourless aqueous phase containing the RNA, an 
interphase and a lower organic phase (Figure 8). The aqueous phase was transferred 
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to new tube and the RNA was precipitated with 0.5ml of 2-propanol (per ml of 
TRIzol®). Samples were incubated for 10 minutes at room temperature, centrifuged 
at 12000g for 10 minutes at 4oC to pellet the RNA, supernatants were carefully 
aspirated off, and the pellet was washed with 1ml of 75% ethanol (per ml of TRIzol®). 
Samples were vortexed, centrifuged at 7500g for 5 minutes at 4oC, supernatants 
carefully aspirated and pellets briefly air-dried at 50oC, and the RNA was dissolved in 
30μl of RNase-free water. Total RNA concentrations and purity were measured as 
described below. The samples were stored at -80oC until further use. 
Figure 8: Phases of RNA extraction by TRIzol. 
 
2.11.3. RNA quantification 
RNA was quantified using a Nanodrop ND-1000 Spectrophotometer. With the 
sampling arm open, 1l of RNase-free water was pipetted onto the lower 
measurement pedestal (to setup the machine), the sampling arm was closed and 
spectral measurement made using the ND 1000 software (NanoDrop Technologies); 
for RNA quantification, the nucleic acid option was selected. When the measurement 
was complete, the sampling arm was opened and wiped gently from both upper and 
lower pedestals using a soft tissue. All the samples were then measured by repeating 
this procedure. The concentration of RNA was measured in ng/µl from the 
absorbance at 260nm. The purity of RNA was considered satisfactory when the ratio 
of absorbance at 260 and 280nm was greater than 1.6. 
 
Aqueous phase: RNA 
Interphase: DNA 
Organic phase: proteins  
               and lipids. 
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2.11.4. cDNA Synthesis 
Following RNA extraction, complementary DNA (cDNA) was obtained via 
reverse transcription of 0.5μg of the total RNA samples, using Superscript III reverse 
transcriptase system. Firstly, a mastermix A solution was created containing 1μl 
Oligo(dT)15 primer, 1μl dNTP Mix and 4μl RNase free distilled water per sample. 
Oligo(dT) is a short single-stranded sequence of deoxythymine (dT) used for priming 
reactions catalysed by reverse transcriptase. The Oligo(dT) primer is first annealed 
to the poly(A) sequences universally present at the 3’ end of nearly every mRNA by 
T:A base-pairing. The reverse transcriptase then extends from the annealed 
Oligo(dT) primer along the mRNA template, copying the mRNA sequence into the 
cDNA sequence. To a clean microcentrifuge tube, 6μl mastermix A was added and 
0.5μg RNA sample (total 7μl volume) and incubated for 5 minutes at 65oC to denature 
RNA secondary structure, followed by incubation on ice for 4 minutes to allow primers 
to anneal. A mastermix B solution was made by adding 4µl 5X First-Strand buffer, 1l 
1M DTT, 1µl RNaseOUT (a recombinant RNase inhibitor), and 1l of Superscript™ 
III Reverse Transcriptase (200U/µl). Thereafter, 7l of the mastermix B was added to 
the samples. Samples were then placed in the Abgene thermal cycler and incubated 
for 1 hour at 55°C for cDNA extension then heated at 70°C for 15 minutes to 
deactivate the enzyme and stop the reaction. Negative controls were samples run 
without Reverse Transcriptase enzyme to exclude the possibility of human genomic 
DNA contamination. The cDNA samples were stored at -20oC until use. 
 
2.11.5. Standard Polymerase Chain Reaction (PCR) 
The resultant cDNA was analysed using the gene specific primers. The 
conventional PCR reaction was performed by adding 10µl ReddyMix PCR Master 
Mix® (that contains DNase polymerase, dNTPs, magnesium chloride and buffer), 1l 
gene specific primer and 1µl cDNA. PCR tubes were placed in a MWG Biotech Primus 
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96 Plus thermal cycler and the following program was employed: 94oC for 5 minutes, 
then 40 cycles of 94oC for 30 seconds (denaturation), 55oC for 30 seconds 
(annealing), and 72oC for 30 seconds (elongation); and 72oC for 10 minutes. The PCR 
product were loaded in 4% agarose gel with 1:10000 GelRed™ Nucleic Acid Gel Stain 
and migrated at approximately 100 volts for 80 minutes. The products were visualized 
using FluorChem E Digital Darkroom (Protein Simple™). 
 
2.11.6. Real-Time Polymerase Chain Reaction  
Real-Time PCR (qPCR) allows sensitive quantification of mRNA within cells 
by using SYBRgreen dye to visualise amplicon generation from a complimentary-
DNA template. SYBRgreen dye binds to newly synthesised double-stranded DNA 
and emits fluorescent light in direct proportion to the number of amplicons generated 
in the reaction. A threshold of fluorescence detected above background was set in 
the exponential phase of amplification, and the cycle number at which the sample 
reached this level was referred to as the cycle threshold value (Ct), thus reflecting the 
relative abundance of the specific mRNA transcripts. To quantify the relative 
expression of each gene, Ct values were normalized with an endogenous 
housekeeping (reference) gene.  
For the real-time (qPCR), a mastermix C solution was created adding 2µl of 
RNase free distilled water, 5µl of Power SYBR mastermix and 1µl of gene-specific 
primer, enough for each sample and corresponding gene. Primers were commercially 
available and used to probe for target mRNA. Two microliters cDNA was added to 
the appropriate mastermixes. Quantitative PCR was performed using the ABI Prism 
7900 Real-Time PCR system, using the following amplification profile: 2 minutes at 
50°C, 15 minutes at 95° followed by 40 cycles of 94°C for 15 seconds (denaturation), 
55°C for 30 seconds (annealing), and 72°C for 30 seconds (elongation). A 
dissociation step of 95°C for 15 seconds, 60°C for 15 seconds and 95°C for 15 
seconds was added after the PCR reaction to confirm the absence of non-specific 
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PCR products. The comparative Ct method (Pfaffl, 2001) was used to measure gene 
transcription in the samples. mRNA data were normalised relative to housekeeping 
gene mRNA and then used to calculate expression levels. Two housekeeping genes 
were run routinely to check variation in experiments with treatments. Results are 
expressed as 2-ΔΔCT, which gives the relative amount of target gene normalised to the 
endogenous constitutive control. Negative controls were prepared without cDNA 
template. 
 
2.12. Flow cytometry analysis 
Flow cytometry is a well-characterised and useful tool that can simultaneously 
detect multiple parameters such as the size, granularity (internal complexity), surface 
topography and biochemical makeup of a population of cells in suspension. Ideally, 
cells guided in a hydrodynamically focussed stream pass one-by-one through a flow 
cell (any remained doublets were excluded during analysis). Fixed alignment lasers 
transmit light through the flow cell, and as the cell passes through the beam, an optical 
signal is generated. This optical signal reaches a detector, which translates the signal 
to an electronic one. Two types of detector are used in this system, photomultiplier 
tubes (PMT), used to detect weaker signals such as those generated by fluorescent 
labels and the side scatter (a measure of internal cellular complexity), and 
photodiodes, used to detect stronger forward scatter signals (a rough measure of 
cellular size). To allow accurate detection of different fluorescent signals, the signals 
pass though filters and mirrors arrayed around the flow cell. Long pass dichroic filters, 
placed in front of the PMT detectors transmit wavelengths that are longer than a 
specified value, steering shorter wavelengths of light to the next PMT so that 
progressively shorter wavelengths are detected by the last PMT. Band-pass filters 
are used to only transmit a narrow bandwidth of light to the detector. The digital 
signals generated using this system can be used to probe multiple parameters of 
cellular phenotype, and data generated are usually displayed in histograms of one 
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parameter, such as fluorescence intensity, or in 2-parameter scatter plots, such as 
forward/side scatter (showing size and complexity). 
 
2.12.1. Expression of GPR40 on human leukocytes by flow cytometry 
PMN and PBMC were isolated from healthy volunteers using dextran 
sedimentation followed by gradient centrifugation as described in section 2.7. Cells 
were washed twice with DPBS + 0.1% BSA and plated in a 96-well plate. Cells were 
fixed with 100μl of Fixation buffer (containing 1:4 Fixation/Permeabilization 
concentrate) for 20 minutes at room temperature. Following the incubation, 200μl of 
permeabilization buffer was added on top and the cells were left for another 20 
minutes on ice. Cells were washed twice with permeabilization buffer and incubated 
with the GPR40 antibody (clone EP4632, 0.181g/ml) for 30 minutes on ice. Following 
the incubation, cells were washed twice with permeabilization buffer. A 488-
conjugated secondary antibody was added to allow the visualization by flow 
cytometry, as the GPR40 antibody was unconjugated. The secondary antibody (goat 
anti-rabbit, 5g/ml) was incubated for 45 minutes on ice. Following the incubation, the 
cells were washed twice with permeabilization buffer and re-suspended in 200μl of 
DPBS + 0.1% BSA. The cells were transferred to clean microtubes and kept 
refrigerated until use. IgG isotype and unstained controls were also prepared for 
accurate calibration of the flow cytometry machine. GPR40 expression was recorded 
as MFI units in the FL1 channel of a BD FACSCalibur or in the B530/30 channel of a 
BD LSR Fortessa. 
 
2.12.2. Assessment of adhesion molecule expression on PMN by flow cytometry 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described in section 2.7. One million cells were 
incubated in DPBS +/+ with GW9508 (agonist of GPR40, 0.1μM, 1μM or 10μM) or 
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vehicle (0.1% ethanol) for 10 minutes at 37°C. Some of the cells were also stimulated 
with hrTNF-α (10ng/ml). Cells were washed twice with DPBS + 0.1% BSA and plated 
in a 96-well plate. Cells were then incubated with the following purified mouse anti-
human monoclonal antibodies (mAb): CD11b (clone ICRF44, 100ng/ml, fluorochrome 
APC) and CD62L (clone DREG56, 100ng/ml, fluorochrome PE/Cy5) for 30 minutes 
on ice. Antibodies were diluted in DPBS-/- containing Fc block to prevent nonspecific 
binding of antibodies. Following the incubation, the cells were washed twice with 
DPBS-/- containing 0.1% BSA and re-suspended in 0.2ml of 1% paraformaldehyde 
(PFA). The cells were transferred to clean microtubes and kept refrigerated until use. 
Conjugated isotypes and unstained controls were also prepared for accurate 
calibration of the flow cytometry machine. Adhesion molecule expression CD11b and 
CD62L were recorded as MFI units in the R670/14 and YG670/30 channels, 
respectively, of a BD LSR Fortessa. 
 
2.12.3. Leukocyte preparation using whole blood lysing reagents 
Blood was collected from healthy volunteers (Ethicals Approval REC 
Reference Number: QMREC2014.61) with a 21-gauge butterfly needle into a 30ml 
syringe and transferred to a 50ml centrifuge tube containing 1/10 volume of 3.2% 
sodium citrate, to prevent clotting. One-hundred microliters of blood were them 
transferred to 15ml centrifuge tubes. Cells were fixed with 100μl of Fixation buffer 
(containing 1:4 Fixation/Permeabilization concentrate) for 20min at room 
temperature. Following the incubation, 200μl of permeabilization buffer was added on 
top and the cells were left for another 20min on ice. Cells were washed twice with 
permeabilization buffer and incubated with the GPR40 antibody (clone EP4632, 
0.181g/ml) for 30min on ice. Following the incubation, cells were washed twice with 
permeabilization buffer. A 488-conjugated secondary antibody was added to allow 
the visualization by flow cytometry, as the GPR40 antibody was unconjugated. The 
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secondary antibody (goat anti-rabbit, 5g/ml) was incubated for 45min on ice. 
Following the incubation, the cells were washed twice with permeabilization buffer 
and re-suspended in 200μl of DPBS + 0.1% BSA. Cells were then incubated with the 
following purified mouse anti-human monoclonal antibodies (mAb): CD11b (clone 
ICRF44, 100ng/ml, fluorochrome APC) and CD62L (clone DREG56, 100ng/ml, 
fluorochrome PE/Cy5) for 30 minutes on ice. Antibodies were diluted in DPBS -/- 
containing Fc block to prevent nonspecific binding of antibodies. Following the 
incubation, the cells were washed twice with DPBS -/- containing 0.1% BSA. After 
staining, red cells were lysing by adding 1ml of Immune-Lyse working solution to each 
tube and vortex vigorously. Tubes were allowed to sit for no more than 30 seconds, 
and no longer than 2 minutes before adding 250μl of Fixative. Tubes were them 
vortexed vigorously. Cells were washed twice with PBS and centrifuged at 400g for 3 
minutes at room temperature. Supernatant was discarded and cells were re-
suspended in 0.2ml of PBS. The cells were transferred to clean microtubes and kept 
refrigerated until use. GPR40 and adhesion molecules expression were recorded as 
MFI units in the B530/30, R670/14 and YG670/30 channels, respectively, of a BD 
LSR Fortessa. 
 
2.12.4. Determination of pro-inflammatory and pro-resolution polarization of 
macrophages by flow cytometry 
PBMC were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation and the monocytes were induced into 
macrophages in culture as described above. On the seventh day, cells were washed 
with DPBS -/- and treated for 24h in macrophages SFM media with GW9508 (0.1 µM, 
1 µM, 10µM) at 37oC. Without washing, cells were then stimulated with IFN-γ 
(10ng/ml) and LPS (50ng/ml) to induce into pro-inflammatory macrophages or 
stimulated with IL-4 (10ng/ml) to induce into pro-resolution macrophages for 24 hours 
at 37oC. Concentrations of INF-γ, LPS and IL-4 used to induce polarization of 
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macrophages were chosen in accordance with personal experience by other 
members of the group in Biochemical Pharmacology. Un-stimulated macrophages 
were also used to measure basal levels of specific markers. Following incubation, 
cells were de-attached using accutase/EDTA (0.01%/0.5mM) and washed twice with 
DPBS + 0.1% BSA and plated in a 96-well plate. Cells were incubated with the 
following purified mouse anti-human monoclonal antibodies (mAb): CD14 (clone 
HCD14, 100μg/ml, fluorochrome PE/Cy7), CD86 (clone IT2.2, 100μg/ml, 
fluorochrome PE), CD206 (clone 15-2, 100μg/ml, fluorochrome APC), and HLA-DR 
(MHC-II, clone T39, 100μg/ml, fluorochrome FITC) pre-diluted in Fc block to prevent 
nonspecific binding of antibodies for 30 minutes on ice. Following the incubation, the 
cells were washed twice with DPBS + 0.1% BSA and re-suspended in 0.2ml of 1% 
PFA. The cells were transferred to clean microtubes and kept refrigerated until use. 
Conjugated isotypes and unstained controls were also prepared for accurate 
calibration of the flow cytometry machine. The specific markers CD14, CD86, CD206 
and HLA-DR expression were recorded as MFI units in YG780/60, YG582/15, 
R670/14 and B530/30 channels, respectively, using a BD LSR Fortessa. 
 
2.13. Imaging flow cytometry 
Amnis ImagestreamX mk. II (ISX), an imaging flow cytometry, uses charge-
coupled devices instead of PMTs and captures up to 12 images of each event as it 
passes through the flow cell. The machine was designed to allow the co-localisation 
of subcellular particles within cells and is equipped with a X60 objective in order to do 
this. Acquisition parameters can be determined by a large variety of physical 
parameters rather than just size, complexity and fluorescence intensity, as in the 
standard flow cytometry. Each event recorded is paired with a bank of images 
generated for each single event. Dot plots and image galleries are therefore 
searchable and can be used to corroborate event identity. Furthermore, multicolour 
staining can be used for accurate identification of various subpopulations. 




2.13.1. GPR40 expression by imaging flow cytometry 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described in section 2.7. Cells were tripled 
stained for GPR40, CD11b and CD62L using the same protocol used in the standard 
flow cytometry. Following staining, the cells were transferred to a clean 1.5ml tube for 
acquisition. 
The INSPIRE instrument and software were configured as follows: channel 01 
(brightfield), channel 02 (Alexa 488), channel 05 (PE-Cy5) and channel 12 (APC) 
were activated in addition to any other fluorescence channels required. Sixty times 
magnification, providing a pixel size of 0.3μm2 was chosen, and flow rate was set to 
low speed/high sensitivity and alignment stream was always adjusted as necessary. 
A minimum of 10000 events were acquired, which were subsequently analysed for 
the expression of the labelled antibodies by gating the population of PMN using the 
area and intensity profiles. 
 
2.13.2. Assessment of microvesicle release by imaging flow cytometry 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described as described in section 2.7. After 
counting, cells were re-suspended to 5x106 cells/ml in incomplete RPMI (phenol red 
free). Five million cells were stimulated with GW9508 (10μM) for 15 minutes at 37°C. 
A positive control was prepared by stimulating the cells with hrTNF-α (10ng/ml) for 15 
minutes at 37°C. Vehicle control (0.01% ethanol) was also used to measure basal 
levels of microvesicle release. After stimulation, cells were centrifuged at 4400g for 
15 minutes at 4°C to pellet cells. Following centrifugation, supernatant was collected 
in new microcentrifuge tubes and centrifuged at 13000g for 2 minutes at 4°C to pellet 
platelets. Following centrifugation, supernatant was transferred to new high speed 
microtubes and centrifuged for a last time at 20000g for 30 minutes at 4°C to pellet 
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microvesicle. The supernatant was discarded, and the microvesicle were re-
suspended in 50l of DPBS containing 1:100 BODIPY. Following staining, 
microvesicle were kept at 4°C until acquisition. 
The INSPIRE instrument and software were configured as follows: channels 
01 and 09 (brightfield), channel 02 (FITC) were activated in addition to any other 
fluorescence channels required. Sixty times magnification, providing a pixel size of 
0.3μm2 was chosen, and flow rate was set to low speed/high sensitivity and alignment 
stream was always adjusted as necessary. A minimum of 10000 events was acquired, 
which were subsequently analysed for the presence of microvesicle labelled with the 
dye by gating the specific population using the intensity profiles as described by 
Headland (2014). 
 
2.14. Intracellular Calcium measurement 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described in section 2.7. One million cells were 
added per well in a 96 black-well plate. The cells were washed twice with DPBS -/- 
and 100μL of loading buffer (containing 2μM Fura-2AM and 1μM pluronic acid in 
DPBS -/-) was added per well. The cells were incubated for 1 hour in a humidified 
chamber in 5% CO2 at 37°C. Subsequently, the cells were washed twice with DPBS 
-/- and 50μL HBSS was added per well. Mobilization of intracellular calcium was 
measured by recording the ratio of fluorescence emission at 510nm after sequential 
excitation at 340nm and 380nm. Fluorescence was determined using a plate reader. 
The results were compared to ionomycin (1μM) used as a positive control. The results 
are expressed as percentage of the positive control or as delta of time “zero”. 
 
2.15. PMN chemotaxis assay 
The commercially available Neuroprobe ChemoTxTM 96-well plate with 
polycarbonate membrane filters and 3µm membrane pores was utilised as described 
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previously (Frevert et al., 1998) to assess the chemotaxis of PMN. PMN were 
stimulated with GW9508 (0.1μM, 1μM or 10μM,) or vehicle for 10 minutes at 37°C in 
RPMI medium containing 0.1% FBS. The chemotaxis assay was performed using 
interleukin-8 (IL-8 or CXCL8; 30ng/ml) as the chemotactic stimulus (concentration 
chosen from preliminary studies, in order to obtain around 80% to 90% of the maximal 
response). IL-8 or medium was added to the bottom wells (28µl), the filter was placed 
on top and 25µl of the PMN cell suspension (previously diluted to 4x106 cells/ml) were 
placed above the membrane (Figure 9). Plates were incubated for 60 minutes in a 
humidified incubator at 37°C with 5% CO2. Cells remaining on top of the filter were 
absorbed off using cotton buds and the surface was washed with 25µl of RPMI per 
well and absorbed off again using cotton buds.  
 
Figure 9: Chemotaxis assay. 
(A) Cross-section of one well of the 96-well chemotaxis chamber. (B) Experimental setup of the 
chemotaxis assay. 
 
The plate was centrifuged at 312g for 1 minute, and then the filter was 
removed and the pelleted cells re-suspended.  An aliquot of 20µl was transferred and 
mixed with 30µl of PrestoBlue® (pre-diluted 1:6 in DPBS) in a 96-well plate and 
incubated at 37°C with 5%CO2 for 4 hours.  PrestoBlue® is a ready to use cell 
permeable resazurin-based solution that functions as a cell viability indicator by using 
the reducing power of living cells to quantitatively measure cell metabolism. When 
added to cells, the PrestoBlue® reagent is modified by the reducing environment of 
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the viable cell and turns red in colour, becoming highly fluorescent. A standard curve 
was constructed using 0-4x106 PMN, and adding known cell numbers in 20µl to the 
wells, then transferring them to the 96-well plate for PrestoBlue addition, as above. 
Plates were then read at 530-560nm excitation wavelength and 590nm emission 
wavelength for fluorescence values. Fluorescence was determined using a plate 
reader. All stimulations were performed in quadruplicate. Unknown values were 
interpolated using the standard curve constructed with known PMN numbers. 
Average of each group was subtracted by the average of negative control group to 
give the total number of cells chemotactic to IL-8. 
 
2.16. Flow chamber assay 
To assess the interactions between neutrophils and endothelial cells, flow 
chamber assay was used, as described before (Norling et al., 2012). Briefly, HUVEC 
were plated on μ-slides VI0.4 and confluent monolayers were stimulated with hrTNF-
α (10ng/ml) for 4 hours to up-regulate adhesion molecules such as CD62E, ICAM-1 
and VCAM-1. PMN were isolated from healthy volunteers using dextran 
sedimentation followed by gradient centrifugation as in section 2.7. Immediately prior 
to flow over HUVEC, PMN were suspended at 1x106/ml in DPBS supplemented with 
calcium and magnesium (DPBS +/+) containing 0.1% BSA (as integrins on the PMN 
require these divalent cations for their adhesive function), and stimulated with 
GW9508 (1μM or 10μM) for 10 min at 37°C. In a second set of experiments, 
neutrophils were pre-stimulated with LTB4 (10nM) for 10 minutes, followed by 10min 
stimulation with 1μM GW9508. PMN were perfused over the HUVEC monolayer at 1 
dyne/cm2 using a programmable syringe pump (Stoelting, Germany) for 8 minutes, 
then 100 sequences of six fields per treatment were randomly capture, for 10 seconds 
each. The number of PMN interacting with the HUVEC monolayer was measured as 
captured and also classified as adherent or rolling (if stationary for the period of 10 
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seconds), the transmigrated motility cells were characterized by the appearance of a 
dark phase and motility under the HUVEC monolayer (Figure 10). 
 
Figure 10: Flow Chamber Assay. Diagram represents a flow chamber slide, showing the way the 
photos were taken, and the direction of the PMN flow. The top image shows the first photo of the 
sequence of photos taken to analyse the movement of PMN, while the bottom image is the last photo 
taken in the same sequence from the same frame. PMN (white circle cells) is counted as adherent if in 
the last photo of the sequence the same cell from frame 1 is inside the red circle. On the other hand, if 
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2.17. Phagocytosis Assay 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described in section 2.7. One million PMN were 
stimulated with GW9508 (0.1μM, 1μM or 10μM) for 10 minutes at 37°C in medium 
RPMI containing 0.1% FBS. After the treatments, E. coli (final concentration 1mg/ml) 
labelled with BODIPY 576/589 (final concentration 1μM) was added. The cells were 
incubated at 37°C, 5% CO2 for 30 minutes to allow the phagocytosis of the bacteria 
by the neutrophils. After 30 minutes, the cells were washed three times with cold 
DPBS to stop the process. The rate of the phagocytosis was determined using a 
fluorescence plate reader. The results are expressed in intensity of fluorescence or 
as the percentage of the positive control. 
Monocyte-derived macrophages were obtained from healthy volunteers using 
dextran sedimentation followed by gradient centrifugation as described in section 2.7. 
Half million macrophages were stimulated with GW9508 (0.1μM, 1μM or 10μM) for 
18 hours at 37°C in macrophage serum-free medium. After the treatments, E. coli 
(final concentration 1mg/ml) labelled with BODIPY 576/589 (final concentration 1μM) 
was added. The cells were incubated at 37°C, 5% CO2 for 1 hour to allow the 
phagocytosis of the bacteria by the macrophages. Following incubation, cells were 
washed three times with cold DPBS to stop the process. The rate of phagocytosis 
was determined using a fluorescence plate reader. The results are expressed in 
intensity of fluorescence or as percentage of the positive control. 
  
2.18. Measurement of apoptosis in neutrophils 
2.18.1. By Morphology in Light Microscopy 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described in section 2.7. PMN were plated at 
4x106 cells/ml in a 6-well plate in RPMI 0.1%FBS. The cells were stimulated with 
GW9508 (10μM) and vehicle and incubated at 37oC in a 5% CO2 incubator for 24 
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hours. After 2, 8, 18 and 24 hours of incubation, 100μl of aged neutrophils suspension 
were loaded in cytospin chambers. Cells were cytocentrifuged at 300g for 3 minutes. 
Cells were then left to air-dry for 5 minutes. Once dried, cells were fixed in methanol 
for 1 minute and stained with eosin (1 minute) and haematoxylin (1 minute). Cells 
were rinsed with water to wash off the excess dye. The slides were left to dry 
overnight. Using a light microscope, 200 cells per slide were counted with x100 
objective. Viable neutrophils (arrowhead, Figure 11) can be readily differentiated from 
apoptotic neutrophils (black arrow, Figure 11) by their characteristic condensation of 
nuclear material, prominent nucleoli, and frequent vacuolization of the cytoplasm. 
 
Figure 11: Cytospin of neutrophils following overnight culture.  
Apoptotic neutrophils are indicated by arrows, whereas a viable neutrophil is indicated by the arrowhead. 
x100 magnification.  
 
2.18.2. Annexin V apoptosis detection 
For quantification of apoptotic neutrophils, FITC Annexin V Apoptosis 
Detection Kit was used. FITC Annexin V is used to quantitatively determine the 
percentage of cells within a population that are actively undergoing apoptosis. It relies 
on the property of cells to lose membrane asymmetry in the early phases of apoptosis. 
In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner leaflet of the plasma membrane to the outer leaflet, 
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thereby exposing PS to the external environment. Annexin V is a calcium-dependent 
phospholipid-binding protein that has a high affinity for PS, and is useful for identifying 
apoptotic cells with exposed PS. Propidium Iodide (PI) is a standard flow cytometric 
viability probe and is used to distinguish viable from nonviable cells. Viable cells with 
intact membranes exclude PI, whereas the membranes of dead and damaged cells 
are permeable to PI. Cells that stain positive for FITC Annexin V and negative for PI 
are undergoing apoptosis. Cells that stain positive for both FITC Annexin V and PI 
are either in the end stage of apoptosis, are undergoing necrosis, or are already dead. 
Cells that stain negative for both FITC Annexin V and PI are alive and not undergoing 
measurable apoptosis (Figure 12).  
 
Figure 12: Measurement of apoptotic neutrophils by Annexin V staining. Healthy PMN have 
polymorphonuclear aspect, while apoptotic neutrophil presents a round nuclei, and superficial exposition 
of phosphatidylserine (PS) that bind to annexin V. In addition to PS exposition, necrotic PMN present 
damage in the cytoplasmic membrane, which allows the penetration of propidium iodide into the 
cytoplasm. 
 
PMN were isolated from healthy volunteers using dextran sedimentation 
followed by gradient centrifugation as described in section 2.7. PMN were plated at 
4x106 cells/ml in a 6-well plate in RPMI 0.1%FBS. The cells were stimulated with 
GW9508 (10μM) and vehicle and incubated at 37oC in a 5% CO2 incubator for 18 
hours. After incubation, cells were washed twice with cold DPBS and then re-suspend 
CHAPTER 2: MATERIAL AND METHODS 
90 
 
in 1X Binding Buffer at a concentration of 1x106 cells/ml. A hundred microliters of the 
solution (1x105 cells) were transferred to a 96-well plate. Ten microliters of staining 
solution containing 5μl FITC Annexin V and 5μl PI was added per sample. The cells 
were gently vortexed and incubated for 15 minutes at room temperature in the dark. 
After incubation, cells were transferred to 3ml tubes containing 400μl of 1X Binding 
Buffer to each tube. The cells were analysed by flow cytometry within 1 hour. FITC 
Annexin V and PI expression were recorded as MFI units in B530/30 and YG610/20 
channels respectively, using a BD LSR Fortessa. 
 
2.18.3. Efferocytosis assay 
To quantify the clearance of apoptotic neutrophils by macrophages in vitro, a 
plate-based myeloperoxidase (MPO) assay was performed as previously described 
(Taylor et al., 2000). To perform this experiment, peritoneal macrophages were 
recruited by injecting 1ml 2% polyacrylamide beads (in sterile PBS) in C57Bl/6 (ip). 
After 4 days, the peritoneum was washed twice with 4ml EDTA (30µM in PBS). Cells 
were washed twice by centrifugation for 10 min at 300g and filtered through a 70µM 
cell strainer to remove biogel beads. Macrophages were counted as described before 
(section 2.7.1) and plated at a density of 0.5 ×106 cells per well in 24-well plate in 
SFM medium. Meanwhile, human neutrophils were isolated as described before 
(section 2.7.2) and left to apoptose for 18 hours in RPMI serum free medium. Two set 
of experiments were performed. First neutrophils were stimulated with vehicle (0.01% 
ethanol) or GW9508 (0.1, 1 and 10µM) for 18 hours in RPMI serum free medium. In 
a second set of experiments, macrophages were stimulated with vehicle (0.01% 
ethanol) or GW9508 (0.1, 1 and 10µM) for 18 hours in SFM medium. In both cases, 
after stimulation, cells were washed twice. Apoptotic neutrophils were counted and 
added at a ratio of 1:2 (macrophage:neutrophil). After 1 hour incubation, cells were 
washed with cold PBS and were fixed for 30 minutes in 2.5% glutaraldehyde. Cells 
were then rinsed with PBS, and the MPO assay was performed by adding 0.1 mg/mL 
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of dimethoxybenzidine and 0.03% (v/v) hydrogen peroxide. Cells were washed with 
PBS 1 hour later and were analysed by light microscopy, with four random fields being 
acquired per well (n = 2 wells per treatment). More than 400 cells were counted per 
treatment point. 
 
IN VIVO METHODS 
2.19. Mice 
All experiments were approved and performed under the guidelines of the 
Ethical Committee for the Use of Animals, Barts and The London School of Medicine 
and Home Office regulations (Scientific Procedures Act, 1986). All experiments 
strictly followed UK Home Office regulations (Guidance on the Operation of Animals, 
Scientific Procedures Act, 1986). C57BL/6 mice were purchased from Charles River 
(London, United Kingdom). In all experiments age and sex-matched controls were 
used. Mice were fed standard laboratory chow and water ad libitum and were 
maintained on a 12-hour light-dark cycle under specific pathogen-free conditions.  
 
2.20. K/BxN Serum Transfer Arthritis 
Ten to twelve-week old male C57BL/6 mice were injected intraperitoneally (ip) 
with 100l arthritogenic serum (generated in-house by crossing KRN TCR transgenic 
mice and NOD mice, and diluted 1:2 in PBS) on day 0 and day 2. Arthritic parameters 
were recorded everyday including clinical score, where any digits, wrists, ankles or 
pads on each limb were swollen, for a total score out of a possible twelve (Figure 13); 
weight loss (cachexia) and water displacement plethysmometry was performed to 
determine paw volume. The incidence of arthritis was also monitored. 





2.20.1. Treatment of K/BxN arthritic mice with GW9508 
Ten to twelve-week old male C57Bl6 mice were administered 100μl K/BxN 
serum intraperitoneally day 0 and day 2. To assess the effects of GW0805 in the 
progression and pathogenesis of inflammatory arthritis, two protocols of treatments 
were used. First, arthritic mice received vehicle (0,1% ethanol, 100μl) and GW9508 
(100μl, 10mg/kg) intraperitoneally from day 0 to day 6 to assess the effects of 
GW9508 during the initiation and progression of the inflammatory response. In a 
second set of experiments, arthritic mice received vehicle (0,1% ethanol, 100μl) and 
Figure 13: Arthritis scoring procedure.  
A scoring system was used to monitor the 
progression of the disease throughout the 
experiment as follows: each limb was inspected 
for signs of swelling and given a score based on 
the part of the paw which was swollen. Each paw 
can receive a total score of three, giving a 
maximum of 12 for each mouse. 0, No signal of 
arthritis. 1, Just one sign of swelling (digit, wrist, 
ankle or pad). 2, Combination of two swollen 
areas (more than one digit count as 1). 3, 
Swollen wrist or ankle AND pad AND any digit 
(Patel et al., 2012). 
 
Normal Swollen 
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GW9508 (100μl, 10mg/kg) intraperitoneally from day 5 to day 10 to assess the effects 
of this agonist in the resolution phase of the inflammatory response. 
 
EX VIVO METHODS 
2.21. Isolation of cells of the paws for flow cytometry analysis 
C57Bl/6 mice received K/BxN serum for induction of arthritis as described in 
section 2.20. On day 8, cells from arthritic paws were isolated by collagenase 
digestion. Briefly, joints were collected by dissecting the paws of skin and cutting 
between digits, taking care to not break the bones. The paws were then transferred 
to an Erlenmeyer flask containing 15ml of digestion solution [collagenase D (0.5ng/ml) 
and DNAse (40ng/ml) in serum free RPMI]. The paws were incubated at 37oC for 30 
min whilst mixing at a medium speed on a magnetic stirrer. Following incubation, the 
digestion solution was collected into a 50ml centrifuge tube by passing the solution 
through a 70μm strainer, and kept on ice. Another 15ml of the digestion solution was 
added to the paws and incubated in a shaking chamber at 37oC for 30 min on medium 
speed for a second time. The digest solution was collected by passing the solution 
through a 70μm strainer. The cells were centrifuged at 450g for 10 min at room 
temperature. Following centrifugation, the supernatant was discarded, and the cells 
were re-suspended in DPBS-/- for counting. The cells were stained for flow cytometry 
analysis. 
 
2.22. GPR40 expression in cells from arthritic joints  
C57Bl/6 mice received K/BxN serum for induction of arthritis as described in 
section 2.20. On day 6, cells from arthritic paws were isolated by collagenase 
digestion as described above. After counting, cells were transferred to a 96-well plate. 
Cells were then incubated with Zombie NIRTM dye diluted 1:1000 in DPBS-/- for 20 
minutes on ice and protected from the light. Zombie dye allows the separation 
between live and dead cells. Following incubation, cells were washed twice with flow 
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buffer (DPBS-/- containing 0.1% BSA) and anti-mouse Fc block diluted 1:5 in DPBS 
+ 0.1% BSA was added to prevent nonspecific binding of antibodies. Following 
incubation, cells were washed twice with flow buffer. The following purified anti-mouse 
mAb were added to the cells for staining: CD45 (clone 30-F11, 2μg/ml, fluorochrome 
V450), CD11b (clone M1/70, 200ng/ml, fluorochrome Pe-Cy7), Ly6G (clone 1A8, 
10μg/ml, fluorochrome APC), F4/80 (clone BM8, 250ng/ml, fluorochrome PE) and 
Ly6C (clone HK1.4, 200ng/ml, fluorochrome PerCP-Cy5.5) for 30 minutes on ice. 
Following the incubation, the cells were washed twice with DPBS + 0.1% BSA and 
re-suspended in 0.2ml of 1% PFA. Cells were transferred to clean microtubes and 
kept refrigerated until use. IgG isotype and unstained controls were also prepared for 
accurate calibration of the flow cytometry machine. Expression of CD45, CD11b, 
Ly6G, F4/80 and Ly6C were recorded as MFI units in the V450/50, YG780/60, 
R670/14, YG582/15 and B695/40 channels, respectively, of a BD LSR Fortessa. The 
same protocol described for GPR40 intracellular staining (section 2.12.1) was then 
followed to access the expression of GPR40 in the specific populations. 
 
2.23. Gene expression in cells isolated from arthritic joints 
C57Bl/6 mice received K/BxN serum for induction of arthritis as described in 
section 2.20 and treated with GW9508 as described previously. On the 6th day after 
the first injection, front paws were collected by dissecting the paws of skin and cutting 
between digits and stored in RNAlater for RNA stabilization and protection and 
RNase inactivation and stored at -80oC until use. About 30-50mg of the tissue was 
used for RNA extraction.  Weighed tissue was transferred for 2ml Precellys tubes 
containing 600l buffer RLT plus (containing 1:100 -mercaptoethanol). Tissue was 
homogenised with a Precellys 24 machine (Bertin technologies) at 6500rpm for 30 
seconds and left on ice for 5 minutes. This process was repeated 3 times. The lysate 
was then centrifuged for 3 minutes at 10000g. The supernatant was collected and 
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transferred for a gDNA Eliminator column. The protocol for RNA isolation described 
in section 2.11.1 was used. To eliminate any residue of DNA, purified RNA was 
treated with TURBO DNA-free kit. Thirty microliters of purified RNA were transferred 
to a clean 0.5ml microtube. To each sample, 3l of 10X TURBO DNAse buffer and 
2l of TURBO DNase were added, which were then gently mixed. Samples were 
incubated at 37oC for 20 minutes. After incubation, 7l of DNase Inactivation Reagent 
was added to the sample, and mixed. Samples were incubated at room temperature 
for 2 minutes, mixing the samples every 30 seconds. Samples were centrifuged at 
10000g for 90 seconds and transferred to a new tube. RNA was quantified as 
described in section 2.11.3. After RNA isolation, cDNA and qPCR were performed as 
in sections 2.11.4 and 2.11.6. 
mRNA expression was analysed using the gene specific primers (Qiagen 
Quantitec Primer Assay®) for the following human genes: IL-1β, IL-4, IL-6, IL-10, 
NOS2 and TNF-α. The comparative Ct method (Pfaffl, 2001) was used to measure 
gene transcription in the samples. mRNA data were normalised relative to 
housekeeping gene mRNA (RPL13a) and then used to calculate expression levels. 
Results are expressed as 2-ΔΔCT, which gives the relative amount of target gene 
normalised to the endogenous constitutive control. Negative controls were PCR 
without cDNA template 
 
2.24. Histological staining and analysis 
C57Bl/6 mice received K/BxN serum for induction of arthritis as described in 
section 2.20. On the 6th day after the first injection, joints were collected. The entire 
hind limbs with skin removed were fixed for 48 hours in neutral buffered formalin (40X 
the volume of the limb, around 50ml each; 10% neutral buffered formalin containing 
0.4% sodium phosphate monobase and 0.65% sodium phosphate dibasic) before 
decalcification in 10% formic acid for 24 hours. To determine full decalcification, a fine 
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needle was used to test the softness of the bones. Once decalcification was complete, 
tissue was dissected into knee tissues and paw tissues and placed in labelled tissue 
cassettes for embedding separately. Cassettes were placed in running tap water for 
one hour, then left in tap water overnight to help remove the formic acid. Samples 
were then placed in 70% ethanol and processed for wax infusion in a Leica Tissue 
Processor. Finally, knee samples were embedded in molten paraffin wax using small 
molds. Knees were embedded coronally, so that the knee joint faced the front of the 
block with the femur and tibia perpendicular to each other. Embedded sample blocks 
were left to harden on a cold plate (-4oC) before being removed from their molds. 
Blocks were taken kept at -20oC degrees to harden for cutting. Sections (7m) were 
cut using a Leica microtome, and placed on lukewarm water to remove wrinkles. 
Sections were transferred to charged glass microscope slides and left to dry. 
Before staining, dried slides were placed in a 65oC oven to soften the wax, 
which was removed by two 5 minutes incubations of Histoclear (xylene 
replacement). Sections were rehydrated by moving from 100% ethanol from 5 
minutes to 95% ethanol for 5 minutes followed by distilled water for 2 minutes before 
proceeding to staining. 
  
2.24.1. Toluidine Blue Staining and cartilage quantification 
Rehydrated slides were placed in 1% toluidine blue dye for 10 minutes before 
being washed with tap water for 5 minutes (or until the water was clear). Slides were 
air dried before mounting in DPX slide mountant and left to harden for 24 hours.  
Percentage toluidine blue positive area was measured using ImageJ imaging 
software. Six-representative images per joint were obtained using an Olympus BH-2 
light microscope with Nikon DXM1200 digital camera attached. Colour images were 
split into their individual red/green/blue channels and the channel which best 
represented the positive and negative staining was used for quantification (Figure 14). 




Figure 14: Split channels for cartilage damage evaluation by Image J. 
 
The cartilage area was selected with the free hand tool.  A positive threshold 
was applied by eye using positive and negative controls from the experiment and 
checked against the original colour image. With a free hand tool, the entire cartilage 
area was traced. The threshold mask was then measured over the selected area 
(Figure 15).  




Figure 15: Cartilage selection area for quantification in Image J as indicated by yellow line. 
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2.24.2. Haematoxylin and Eosin (H&E) Staining and damage quantification 
De-waxed and rehydrated slides were incubated in haematoxylin for 2 minutes 
then rinsed in tap water for 5 minutes to remove excess stain but also to blue the 
nuclei by introducing a more alkali pH. Slides were then stained for 1 minute in eosin 
before another wash in tap water. Slides were then dehydrated with 5 minutes each 
in graded ethanol (70%, 90% and 100% ethanol) followed by clearing twice in 
Histoclear for 5 minutes. Slides were left to dry completely before mounting in DPX 
slide mounting solution and left to harden for 24 hours. Images were captures using 
an Olympus BH-2 microscope (Tokyo, Japan) and NIKON DXM1200 digital camera 
(New York, USA). 
H&E sections were analysed and scored by two blinded scorers: 0 = normal, 
non-arthritic joint; 1 = moderate arthritis, minimal synovitis without cartilage/bone 
erosions; 2 = moderate arthritis, synovitis and erosions but joint architecture 
maintained; 3 = severe arthritis, erosions and loss of joint integrity. Results are 
expressed as the average from both scorers to each animal. 
 
2.25. Statistical analyses  
Statistical significance was assessed using GraphPad Prism 5 software. Data 
are expressed as mean ± standard error of the mean (SEM) of n experiments. Data 
were analysed using either 2-tailed paired or unpaired Student’s t test, 1-way or 2-
way ANOVA with appropriate post hoc analysis, Mann-Whitney t test, or 2-way 
ANOVA with repeated measures where appropriate. In all cases, p <0.05 was 
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EXPRESSION AND MODULATION OF GPR40  
 
3.1. Genomic expression of GPR40 
The initial aim of my thesis was to evaluate the expression of GPR40 in cell 
types relevant to the inflamed joint, such as monocytes, macrophages, neutrophils, 
endothelial cells, lymphocytes and chondrocytes. I first assessed the basal 
expression of GPR40 in human primary immune cells isolated from blood, 
endothelium obtained from human umbilical cords and from the chondrocyte C28/I2 
cell line grown in a 3D micromass (that augments the chondrocyte-like features) by 
using PCR. First, RNA integrity was checked by running 200ng of total RNA in a 0.8% 
agarose gel. A representative extraction from two different neutrophil samples is 
shown (Figure 16A). Only two bands were visualized in the gel, representing the 18s 
and 28s RNA, meaning that the RNA was intact (Figure 16A). After confirming the 
quality of RNA, conventional PCR was performed in all RNA isolates. As shown 
below, GPR40 mRNA was expressed in all the cell types tested (Figure 16B), 
including neutrophils and macrophages. There was some variation in levels of 
expression of the receptor in the different preparations of cells that may reflect the 
activation status of the cell. The expression of GPR40 in monocytes, macrophages, 
lymphocytes, HUVEC and chondrocytes was shown previously (Briscoe et al., 2003, 
Wauquier et al., 2013), but this is the first time that expression of GPR40 is reported 










Figure 16: Expression of GPR40 mRNA in different cell types.  
RNA was extracted from 1x106 cells using Trizol (PMN) or RNeasy mini kit, and GPR40 and GAPDH 
assessed using gene specific primers. (A) RNA integrity for neutrophil samples. (B) mRNA expression 
in neutrophils, monocytes, macrophages, HUVEC, lymphocytes and chondrocytes. NC, negative control 
was made by adding water in place of cDNA. bp, base pare. GAPDH, Glyceraldehyde 3-phosphate 
dehydrogenase. 
 
3.2. Expression of GPR40 in human neutrophils  
The next step was to demonstrate the protein expression of GPR40. Here, I 
focused on the first line of host defence, the neutrophils, that play important roles in 
inflammation and resolution. To do this, flow cytometry analysis was used to titrate a 
mouse IgG isotype control and anti-GPR40 antibodies. After serial dilutions of the 
antibody, a concentration of 0.181ng/ml was selected for the subsequent 
experiments, as this gave the biggest difference between the isotype and specific 
stain of GPR40, corresponding to a 1:100 dilution. (Figure 17A). The expression of 
GPR40 in neutrophils was also visualized by imaging flow cytometry (Figure 17B). 
The activation status of neutrophils was assessed by the levels of adhesion molecules 
L-selectin and CD11b. As expected, non-activated neutrophils present low CD11b 












Figure 17: Expression of GPR40 in human neutrophils.  
GPR40 levels in neutrophils isolated from healthy volunteers. (A) Titration of GPR40 antibody by flow 
cytometry. Each bar represents the mean ± SEM of 4 different experiments. (B) Expression of GPR40 
and adhesion molecules in neutrophils by imaging flow cytometry (60x). ul, unlabeled cells. iso, IgG 











































CHAPTER 3: RESULTS 
104 
 
After demonstrating the expression of GPR40 in neutrophils, it was important 
to determine whether GPR40 gene expression was modulated or whether GPR40 is 
rapidly mobilized from granular stores after a short stimulation with inflamogens or 
trafficking to the inflammatory site. I therefore used a key cytokine involved in the 
pathogenesis of rheumatoid arthritis to test whether this receptor was transcriptionally 
controlled. Firstly, neutrophils were stimulated with TNF-α (10ng/ml, 4 and 6 hours), 
and the mRNA levels of GPR40 were assessed by real-time PCR. The amplification 
plot (Figure 18A and Figure 18C) and dissociation curve (Figure 18B and Figure 18D) 
for gapdh and gpr40 are shown, respectively. As expected, the first cycle threshold 
for gapdh (Figure 18A) appears before the first cycle threshold for gpr40 (Figure 18C). 
This is because GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) is an enzyme 
involved in the glycolysis process, breaking down glucose for energy and carbon 
molecules. So, GAPDH is produced and highly expressed in all live cells at all times. 
The dissociation curves for gapdh (Figure 18B) and for gpr40 (Figure 18D) are also 
shown, and illustrate, in both cases, the unique pattern of the melting curve for each 
reaction, in other words, all PCR products for the same primer pair has the same 
melting temperature, indicating that there is no contamination, mispriming (PCR 
products made due to annealing of the primers to complementary, or partially 
complementary sequences on non-target DNAs), primer-dimer artifacts (primers can 
sometimes anneal to themselves and create small templates for PCR amplification) 
or some other problem in the reaction. However, as shown on Figure 18E, the 
expression of GPR40 mRNA levels was not modulated by TNF-α (10ng/ml) in the 
chosen time-points 




Figure 18: Modulation of GPR40 mRNA expression in neutrophils. Amplification plot and 
dissociation curve for gapdh (A and B, respectively) and gpr40 (C and D, respectively). E, Levels of 
GPR40 mRNA expression in neutrophils after stimulation with TNF-α (10ng/ml) for 4 or 6 hours in 0.1% 
FBS RPMI. The relative expression of each gene, cycle threshold values, were normalized to a 
housekeeping gene (GAPDH) and expression quantified using 2-CT with control unstimulated cells set 
as 1. Each bar represents the mean ± SEM of three different donors. 
 
In another set of experiments, neutrophils were stimulated with TNF-α, IL-8 (a 
chemokine involved in the process of in vivo trafficking), PAF (a chemotactic agent 
capable of inducing enzyme release in neutrophils) and LTB4 (a powerful chemotactic 
agent, which also induces the formation of reactive oxygen species and the release 
of enzymes in neutrophils). Protein expression of GPR40 was then analysed by flow 
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cytometry. To confirm the expression of GPR40 expression, some samples were not 
labelled with the antibody (UL). Rabbit IgG isotype control was also used to 
distinguish false positive staining (ISO). As shown below, the expression of GPR40 
was not significantly modulated by TNF-α (10ng/ml) or IL-8 (10ng/ml) after 10 minutes 
(Figure 19A) when compared to vehicle (0.1% ethanol) stimulated cells (CT). On the 
other hand, PAF (10nM) and LTB4 (10nM) stimulation increased the protein levels of 
GPR40 in neutrophils at the same time point. Figure 19B is an exemplification of the 
histogram overlay for GPR40 expression by flow cytometry, showing that after the 
stimulation with the selected mediators, intensity of fluorescence is shifted to the right. 
 
Figure 19: Modulation of GPR40 protein levels expression in human neutrophils.  
Neutrophils isolated from healthy volunteers. (A) Levels of GPR40 protein expression after 10 minutes 
stimulation with TNF-α (10ng/ml), IL-8 (10ng/ml), PAF (10nM) and LTB4 (10nM) at 37oC. (B) Histogram 
overlay of the expression of GPR40 protein analysed by flow cytometry (Grey, isotype; blue control; 
green TNF-α; red IL-8; aqua, LTB4 and pink, PAF). Each bar represents the mean ± SEM of three 
different donors. UL, unlabeled. ISO, isotype control, CT, control. MFI, mean fluorescence intensity. * 
p<0.05, ** p<0.01 and *** p <0.001 compared to control. 1-way ANOVA, followed by Dunnett’s post-test. 
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It is well known that neutrophil recruitment to the site of inflammation results 
in an activation of those cells. The sensing of chemokines, and the physical contact 
with endothelial cells promotes a change in neutrophil profile, with substantial 
alterations in cellular composition, due to degranulation of a number of vesicles. To 
evaluate if this important step of the inflammatory response (the recruitment of cells) 
could modulate the expression of GPR40, human exudate neutrophils were isolated 
from the buccal cavity using a tabasco mouth wash in healthy volunteers (as 
described in section 2.8). Cells from whole blood were isolated as described in section 
2.12.3. After isolation, cells were stained with antibodies to allow visualization by flow 
cytometry. Neutrophils were selected by size (FSC-A) and granularity (SSC-A) as 
represented in Figure 20A (whole blood sample) and Figure 20C (mouth wash 
sample) followed by selection of single cells (Figure 20B and D, representing samples 
from whole blood and mouth wash respectively). The activation level of neutrophils 
was assessed by measuring the levels of the adhesion molecules CD11b and L-
selectin. As expected, neutrophils isolated from whole blood (red population Figure 
20E) had a basal expression of CD11b, however, during the process to getting to the 
site of inflammation, in this case, promoted by tabasco mouth wash (blue population 
Figure 20F), a rapid increase in the expression of CD11b is seen in exudate 
neutrophils (Figure 20G). On the other hand, inactivated neutrophils showed high 
levels of L-selectin in the whole blood, expression that is lost during recruitment 
(Figure 20E and G). In addition, exudate neutrophils had a higher expression of 
GPR40 when compared to neutrophils isolated from peripheral blood in the same 
individual (Figure 20H and I). 




Figure 20: Expression of GPR40 in exudate neutrophils.  
Blood was collected from healthy individuals and diluted to 1/10 volume of 3.2% sodium citrate. Red 
blood cells were lysed using a commercial kit. Neutrophils from the buccal cavity were isolated after 
mouth wash with Tabasco™ (MW). After antibody staining, PMN population from whole blood (A) and 
mouth wash (C) was selected by size (FSC-H) and granularity (SSC-H), followed by single cells selection 
(B and D, whole blood and mouth wash respectively) in flow cytometry. (E) Representative samples from 
whole blood (red population) and mouth wash (blue population) showing double staining of CD11b and 
L-selectin. (F) Expression of CD11b and (G) expression of L-selectin. (H) Representative histogram with 
expression of GPR40. (I) Expression of GPR40. Results are mean ± SEM, n=4. * p<0.05, **p,0.01 
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3.3. Expression of GPR40 in macrophages 
After showing expression and modulation of GPR40 in human neutrophils, I 
then decided to evaluate the expression of this receptor in macrophages, which are 
essential for clearance of cellular debris and the return of tissue homeostasis during 
the inflammatory process. 
Expression of GPR40 in macrophages was previously demonstrated, 
however, most of those results used the THP-1 cell line or bone-marrow-derived 
macrophages (BMDMs) (Yan et al., 2013). I therefore evaluated the expression of 
GPR40 in primary human macrophages derived from blood monocytes with M-CSF 
(50ng/ml) for seven days (section 2.7.1). The protein expression of GPR40 in 
macrophages was determined by flow cytometry using the same concentration of the 
antibody used during assessment of the expression of this receptor in neutrophils. 
Positive expression of GPR40 was determined when compared to use of IgG isotype 
control (Figure 21).  
 
Figure 21: GPR40 expression in macrophages. 
Monocytes were isolated from peripheral blood of healthy volunteers. Monocytes were separated from 
other PBMC by 1h adherence at 37oC in RPMI medium without serum followed by seven days at 37oC 
in RPMI supplemented with 10% FBS and 50ng/ml M-CSF. (A) Histogram overlay of the expression of 
GPR40 protein analysed by flow cytometry (Grey, isotype; blue GPR40). (B) MFI expression of GPR40. 
Each bar represents the mean ± SEM of four different donors. UL, unlabeled. Iso, isotype control. MFI, 









 Levels of mRNA for GPR40 were also assessed in macrophages stimulated 
with TNF-α (10ng/ml). As macrophages are longer lived cells compared to 
neutrophils, later time-points (6 and 18h stimulation) were chosen. The amplification 
plot (Figure 22A and Figure 22C) and dissociation curve (Figure 22B and Figure 22D) 
for gapdh and gpr40 are shown, respectively. Again, expression of gapdh (Figure 
22A) appears before the expression of gpr40 (Figure 22C) at the amplification plots. 
Three samples showed lower levels of gapdh expression that could be due the quality 
of the RNA isolation or a human error during the preparation of real-time PCR assay. 
On the other hand, the dissociation curves for both primers tested were considered 
acceptable (Figure 22B and D). Figure 22E shows the expression of mRNA of GPR40 
in the different times-points, but as can be visualised, TNF-α did not modulate the 
expression of this receptor after 6 or 18 hours of stimulation. Interestingly, CT values 
comparing neutrophils and macrophages indicated lower level of expression in 
macrophages, which corresponds to levels of mRNA expression by PCR (Figure 16) 
and protein expression by flow cytometry (Figure 21). 




Figure 22: Modulation of mRNA GPR40 expression in human macrophages. 
Amplification plot and dissociation curve for gapdh (A and B, respectively) and gpr40 (C and D, 
respectively). E, Levels of GPR40 mRNA expression in macrophages after stimulation with TNF-α 
(10ng/ml) for 6 or 18 hours in 0.1% FBS RPMI. The relative expression of each gene, cycle threshold 
values, were normalized to a housekeeping gene (GAPDH) and expression quantified using 2-CT with 




CHAPTER 3: RESULTS 
112 
 
FUNCTIONALITIES OF GPR40 IN HUMAN 
LEUKOCYTES  
 
3.4. GPR40-induced intracellular calcium mobilization in neutrophils 
GPR40 is coupled to the α subunit of the Gq family of G proteins, and its 
activation in pancreatic islets is known to induce the activity of PLC, followed by 
hydrolysis of inositol lipids and an increase of intracellular calcium levels (Figure 23A) 
(Salehi et al., 2005). Because I demonstrated for the first time GPR40 expression in 
neutrophils, the next step was therefore to evaluate whether GW9508, a GPR40 
selective agonist (Briscoe et al., 2006), was able to mobilise intracellular calcium in 
this cell type. As shown below, the concentrations of 0.1μM, 1μM and 10μM GW9508 
promoted an intracellular calcium flux in neutrophils when compared to the vehicle 
control (Figure 23B). The time profiles for the changes in intracellular calcium levels 
at 0.1μM, 1μM and 10μM concentrations of GW9508 are also shown (Figure 23C). 
 
Figure 23: Intracellular mobilization of calcium by GW9508 in human neutrophils. 
Neutrophils isolated from healthy volunteers were treated with Fura 2-AM and incubated with vehicle or 
GW9508 (0.1, 1 and 10μM final concentration). The intracellular calcium levels were recorded in a 
spectrophotometer. (A) Schematic of the cascade following activation of GPR40 by GW9508 resulting 
in intracellular calcium mobilization. (B) Intracellular calcium flux of GW9508 in neutrophils expressed 
as a percentage of the maximal response induced by the ionomycin positive control. (C) GW9508-
induced calcium flux in neutrophils over time. Results are expressed as mean ± SEM from four 
independent experiments. ** p <0.01 and *** p <0.001 compared to vehicle (0.1% Ethanol); 1-way 
ANOVA, followed by Bonferroni post-test. 




3.5. Modulation of PMN adhesion molecules by GW9508  
Neutrophils are among the first cells to be recruited to the site of inflammation. 
Through a well-regulated cascade of events, neutrophils are capable of interacting 
with endothelial cells to migrate to the site of inflammation. One of the characteristics 
of this process is the change in adhesion molecule expression on both leukocytes 
and endothelial cells. Therefore, I assessed whether GPR40 activation leads to the 
modulation of adhesion molecules expression on neutrophils. L-selectin is involved in 
neutrophil tethering, the first step of recruitment, and it is expressed in higher levels 
in non-activated neutrophils. GW9508 did not modulate the expression of L-selectin 
with the concentrations chosen (Figure 24A). CD11b, is an integrin that is important 
during the adhesion step of recruitment. Expression of CD11b was also not 
modulated by treatment with GW9508 (Figure 24B). A tendency for an increase of 
CD11b expression could be visualised, but it did not reach statistical significance. In 
another set of experiments, neutrophils were pre-incubated with GW9508 followed by 
stimulation with TNF-α (a key cytokine involved in the pathogenesis of RA). TNF-α 
stimulation, as expected, promoted L-selectin shedding (Figure 24C). Whereas pre-
incubation of neutrophils with GW9508 did not alter the modulation caused by TNF-α 
stimulation in neutrophils (Figure 24C). Also as expected, CD11b expression was 
increased after 10 minutes TNF-α stimulation. However, GW9508 pre-incubation did 
not alter the upregulation of CD11b induced by the cytokine TNF-α (Figure 24D).  




Figure 24: Modulation of adhesion molecules by GW9508 in neutrophils.  
PMN isolated from the peripheral blood of healthy volunteers were treated GW9508 (0.1μM, 1μM and 
10μM) for 10min at 37oC. Expression of L-selectin and CD-11b in neutrophils without (A and C, respectly) 
or with TNF-α stimulation (10ng/ml) (B and D, respectly). Results are expressed as mean ± SEM from 
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3.6. Effect of GW9508 on neutrophil-endothelial interactions under flow 
The next step was to investigate the effect of GW9508 on neutrophil 
recruitment onto the endothelium under flow conditions. HUVEC were used in these 
assays due to the availability of the umbilical cords, ease of isolation and the essential 
advantage of using of primary endothelial cells. HUVEC express low levels of 
adhesion molecules, such as E-selectin, required to promote neutrophil rolling on the 
endothelium. Thus, monolayers of HUVEC were stimulated with the cytokine TNF-α 
for 4h to increase the levels of expression of ICAM-1, E-selectin and VCAM-1 
(Mackay et al., 1993). As expected, the activation of monolayers of HUVEC caused 
a modest capture of the neutrophils, a prerequisite for further interactions, and hence 
both rolling and adherent neutrophils were visualised. However, GW9508 (1µM and 
10µM) stimulation did not alter the number of neutrophils captured (Figure 25A), 
rolling (Figure 25B), adherent (Figure 25C) or transmigrated (Figure 25D) when 
compared to the vehicle control group. Nevertheless, the absence of induction of 
recruitment induced by GW9508 is in agreement with the lack of effect of GW9508 
stimulation in modulating adhesion molecules on neutrophils (Figure 24). 
 




Figure 25: Effects of GW9508 on neutrophils-endothelial interactions under flow. 
Neutrophils isolated from healthy volunteers were incubated with GW9508 for 10min at 37oC. Number 
of neutrophils captured (A), rolling (B), adherent (C) and transmigrated (D) under flow. HUVEC were pre-
incubated for 4h with TNF-α stimulation (10ng/ml), prior to the perfusion of neutrophils at 1dyne/cm2. 
Interactions were quantified form 6 random fields/treatment. Results are expressed as max and min from 
eight independent experiments. + represents mean. TEM, trans-endothelial migrated. 1-way ANOVA 
followed by Bonferroni post-test. Veh, vehicle (0.1% ethanol). 
 
It was then hypothesized that the level of GPR40 were not high enough to 
generate a modulation of the interaction of neutrophils-endothelial cells under flow. 
To test this hypothesis, neutrophils were pre-stimulated with LTB4 (10nM) in DPBS+/+ 
prior to stimulation with GW9508, as I demonstrated previously that this pro-
inflammatory mediator can upregulate GPR40 in neutrophils (Figure 19A). The 
concentration of 1μM GW9508, which induced calcium flux in neutrophils (Figure 
23C), was chosen for this assay. In agreement with results shown in Figure 25, 
GW9508 (1µM, 10 minutes) stimulation did not modulate capture (Figure 26A), rolling 
(Figure 26B), adherence (C) or transmigration (Figure 26C) of neutrophils under flow. 
Whereas LTB4 stimulation promoted a decrease in the number of neutrophils rolling, 
and a tendency to increase adhesion and transmigration. Similarly, pre-stimulation 
with LTB4 followed by GW9508 stimulation also decreased the number of neutrophils 
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rolling (Figure 26B), however, no modulation was observed in capture (Figure 26A), 
adherence (Figure 26C) or transmigration (Figure 26D). In general, these results 
show that treatment of neutrophils with GW9508 had little effect on their recruitment. 
 
Figure 26: Effect of GW9508 on neutrophil-endothelial interactions after LTB4 stimulation under 
flow.  
Neutrophils isolated from healthy volunteers were pre-treated with LTB4 (10nM) followed by treatment 
with GW9508 (1µM) for 10min at 37oC. HUVEC were pre-incubated for 4h with TNF-α stimulation 
(10ng/ml), prior to the perfusion of neutrophils at 1dyne/cm2. Number of neutrophils captured (A), rolling 
(B), adherent (C) and transmigrated (D) under flow. Interactions were quantified form 6 random 
fields/treatment. Results are expressed as max and min from four independent experiments. + 
represents mean. TEM, trans-endothelial migrated. * p<0.05 and **p<0.01 when compared to Veh. 1-
way ANOVA followed by Bonferroni post-test. Veh, vehicle (0.1% ethanol). 
 
3.7. Effect of GW9508 on neutrophil chemotaxis 
Chemokines play a key role in the process of leukocyte recruitment; their chief 
function is to direct cell migration. Thus, I next investigated the effects of GW9508 on 
neutrophil chemotaxis in response to the chemokine IL-8. Isolated human neutrophils 
were incubated with vehicle (0.1% ethanol) or pre-incubated with different 
concentrations of GW9508 (0.1, 1 and 10µM) in RPMI 0.1% FBS for 10 minutes, and 
the response to IL-8 tested. As shown below (Figure 27), incubation of neutrophils 
with GW9508 promoted a higher chemotactic response compared with vehicle alone. 
This effect was concentration-dependent, with the highest concentration of 10µM 
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evoking a cellular response over 80% higher than that quantified after application of 
IL-8 alone. 
 
Figure 27: Effect of GW9508 treatment on the chemotaxis of neutrophils.  
Neutrophils isolated from healthy volunteers were treated with GW9508 (0.1-10μM) or vehicle (0.1% 
ethanol) for 10min at 37oC. Chemotactic response to IL-8 (30ng/ml) was assessed after 1 hour. Results 
are expressed as mean ± SEM from four independent experiments. 1-way ANOVA, followed by 
Bonferroni post-test. Veh, vehicle.  
 
3.8. Effects of GPR40 agonist GW9508 on phagocytosis of E. coli 
Different stimuli can trigger the inflammatory response, and bacterial infection 
is a very frequent cause of inflammation. Even in sterile inflammation, the 
phagocytosis of a variety of irritant particles, including crystals, minerals, and protein 
aggregates can damage the inflamed tissue. Phagocytic clearance of bacteria or 
cellular debris is one of the key steps for the resolution of inflammation. So, next I 
investigated whether GW9508 could alter the phagocytic ability of neutrophils and 
macrophages, key phagocytic cells. Phagocytosis was determined after incubation 
with labelled Escherichia coli. Figure 28A shows representative images of pre-
stimulated human neutrophils with GW9508 (0.1-10μM) or vehicle (ethanol 0.1%) 
after 30min incubation with E. coli. Vehicle-stimulated neutrophils perform 
phagocytosis of E. coli. When neutrophils were stimulated with GW9508 the capacity 
of phagocytosis performance was increased, which was confirmed by the amount of 
intracellular E. coli. Indeed, 0.1μM GW9508 increased the phagocytosis by about 
50% when compared to vehicle.  The optimal concentration of GW9508 was 1μM, 
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leading to enhanced phagocytosis of 60% over vehicle stimulation. GW9508 was also 
effective at 10μM yet to a lesser extent when compared to lower concentrations 
(Figure 28B).  
 
Figure 28: Enhanced E. coli phagocytosis by GW9508 in human neutrophils.  
PMN isolated from the peripheral blood of healthy volunteers were stimulated with GW9508, 0.1μM, 1μM 
and 10μM) for 10min at 37oC. Followed by incubation with BODYPI-labelled E. coli at 37°C for 30 
minutes. After washing, the phagocytic level was recorded in a spectrophotometer. (A) Shows 
representative images of labelled E. coli in human neutrophils following treatment with GW9508. (B) 
Quantification of phagocytosis at 594 excitation spectra. Results are expressed as mean ± SEM from 
five independent experiments. 1-way ANOVA, followed by Bonferroni post-test. Veh, vehicle (0.1% 
ethanol). 
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  In addition, phagocytic levels were also evaluated in human monocyte derived-
macrophages after GW9508 stimulation. In this case, macrophages were incubated 
with E. coli for 1 hour. However, no modulation of the phagocytic response was 
visualised in any of the three concentrations of GW9508 tested (Figure 29). 
 
Figure 29: No effect of GW9508 on E. coli phagocytosis by human monocyte derived-
macrophages. 
PBMC were isolated from peripheral blood of healthy volunteers. Monocytes were induced into 
macrophages by culturing for 7 days in 10% FBS RPMI containing 50ng/ml M-CSF. Monocyte derived-
macrophages were stimulated with GW9508 (0.1μM, 1μM and 10μM) for 18h at 37oC. Followed by 
incubation with BODYPI-labelled E. coli at 37°C for 1 hour. After washing, the phagocytic level was 
recorded in a spectrophotometer at 594 excitation. Results are expressed as mean ± SEM from three 
independent experiments. 1-way ANOVA, followed by Bonferroni post-test. Veh, vehicle (0.1% ethanol). 
 
3.9. Release of microvesicles induced by GW9508 in neutrophils 
Cells can communicate between each other by sending small packages of 
information; these are called microvesicles that contain a wide range of protein and 
genomic information. Microvesicles are generated from the plasma membrane of 
many cell types, with leukocytes being particularly efficient in producing these blebs, 
though platelets are also highly active in this respect. Thus, it was tested if GW9508 
stimulation in neutrophils could modulate the release of microvesicles; following cell 
incubation, microvesicles were purified from cell suspensions by a series of 
centrifugations. After staining, microvesicles were acquired using INSPIRE 
Instrument, a flow cytometer with a microscope attached allowing direct visualization 
(Figure 30A). Selection of the microvesicle population was made by plotting samples 
in intensity of BODIPY (FITC) against intensity of brightfield (Figure 30B). A more 
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refined selection of microvesicle was made by changing the scale on axis X and Y for 
10 and 100, respectively, to reflect the small size of these microstructures (Figure 
30C). Stimulation of neutrophils with GW9508 (10M) in serum-free RPMI induced 
an increase in the microvesicle release (Figure 30D), similar to that observed with the 
positive control, TNF-α, a known stimulant for microvesicle release from human 
neutrophils (Headland et al., 2015).  
 
Figure 30: Neutrophil-microvesicle release induced by GW9508. 
PMN isolated from the peripheral blood of healthy volunteers were stimulated with GW9508 (10μM) for 
15min at 37oC. After serial centrifugations, microvesicle were isolated. Microvesicle were stained with 
BODIPY and assessed by intensity in channel 2 of the INSPIRE Instrument. (A) Representative images 
of microvesicle. (B) Selection of microvesicle population. (C) Refined selection of microvesicle 
population. (D) Number of microvesicle released normalized to TNF-stimulated neutrophils. *<p 0.05. T-
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3.10. Effects of GW9508 induction on neutrophil apoptosis. 
An important phase of the resolution of inflammation is neutrophil apoptosis, 
a process necessary for disposing these cells after they have killed pathogens and 
cleared debris. Otherwise, the continual release of mediators from the activated 
neutrophil into the tissue could lead to self-induced damage. The mode by which the 
neutrophil dies is also important: two main mechanisms can occur during neutrophil 
death, necrosis and apoptosis. Necrosis can cause tissue damage, by release of a 
range of mediators that are in the cytoplasm of neutrophils into the tissue by rupture 
of the cytoplasmic membrane. On the other hand, apoptosis preserves the membrane 
so those mediators will not be released into the tissue.  As shown below, stimulation 
with GW8508 resulted in a delay of the natural apoptotic process when compared to 
vehicle (ethanol 0.1%) (Figure 31A). At later times points (8 and 18 hours), the 
difference between groups was reduced, and by 24 hours all cells were considered 
apoptotic (Figure 31A). Figure 31B shows representative images from neutrophils 
stimulated with vehicle (top) or GW9508 (bottom) for 2 hours.  
 
 




Figure 31: GW9508 stimulation delays apoptosis of human neutrophils.  
PMN isolated from the peripheral blood of healthy volunteers were stimulated with GPR40 agonist 
(GW9508, 10μM). A, After 2, 8, 18 and 24 hours stimulation, 100μl of cells were transferred to a slide, 
stained with H&E and counted by light microscopy. Results are expressed as mean ± SEM from three 
independent experiments. **p<0.01 compared to Veh; 2-way ANOVA, followed by Bonferroni post-test. 
B, representative images from neutrophils stimulated for 2 hours with vehicle or GW9508 (x40 
magnification). Stars represent apoptotic cells. 
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A second protocol was used as it has higher sensitivity. This time, neutrophil 
apoptosis was assessed by measuring the level of staining for annexin V and 
propidium iodide(PI). Neutrophils were stimulated with GW9508 (10µM) in RPMI 
0.1% FBS for 18 hours. After stimulation, cells were stained with annexin V and PI. 
During apoptosis there is a loss of membrane asymmetry and PS is exposed on the 
cell surface, onto which annexin V binds. In addition, apoptotic cells can be 
differentiated from necrotic cells by the capacity of PI entry into the cytoplasm. Figure 
32A and Figure 32B show representative images from vehicle-stimulated and 
GW0508-stmulated neutrophils, respectively. Once more, delay of apoptosis was 
visualised in the GW9508 stimulated-group, when compared to vehicle (0.1% 
ethanol) (Figure 32C). Interestingly, stimulation did not result in an increase of 
necrotic cells (Figure 32D), rather GW9508 increased the life-span of neutrophils 
(Figure 32E). 
 
Figure 32: Measurement of neutrophil apoptosis by flow cytometry. 
After 18 hours incubation at 37oC with or without GW9508 (10μM), cells were washed and stained for 
annexin-V and PI and assessed by flow cytometry. (A) and (B) show representative image from vehicle- 
and GW9508-stimulated neutrophils, respectively. Percentage of (C) apoptotic cells, (D), necrotic cells 
and (E) live cells. Results are expressed as mean ± SEM from three independent experiments. *p<0.05 
compared to Veh; T-test. Veh, vehicle. 
 




3.11. M1/M2 polarization of macrophages by GW9508 
Another important step for the resolution of inflammation is the switching from 
pro-inflammatory to pro-resolution cell phenotypes and mediators. When 
macrophages are sampling and encounter a xenobiotic (be it a pathogen or damaged 
tissue), their receptors trigger a decision to fight (kill it) or fix (repair it). The fight profile 
is associated with M1 macrophages and is characterized by production of pro-
inflammatory mediators (Italiani and Boraschi, 2014). While the fix profile is 
associated with M2 macrophages and characterized by production of pro-resolution 
mediators. Therefore, to test if activation of GPR40 could modulate macrophage 
phenotype, monocyte derived-macrophages were pre-treated with GW9508 (10M) 
in macrophage SFM medium for 24 hours and stimulated with IFN-γ/LPS 
(10ng/ml/50ng/ml) for 24 hours, to induce a M1 phenotype, or with IL-4 (10ng/ml) to 
induce a M2 phenotype. Cultures of macrophages were then analysed by flow 
cytometry. As shown below, cells were selected by size (FSC-H) and granularity 
(SSC-H) (Figure 33A) and macrophages selected by expressing low intensity of CD14 
(Figure 33B). The profile of polarization was measured by levels of expression of 
CD86 and MHC-II for M1 macrophages and CD206 for M2 macrophages. Stimulation 
of macrophages with GW0508 did not significantly alter the expression of the M1 
markers CD86 (Figure 33C) or MHC-II (Figure 33D), although the results showed a 
tendency to increase CD86 expression after GW9508 stimulation in IFN-γ/LPS-
stimulated cells. Activation of GPR40 also did not modulate the basal expression of 
the M2 marker CD206 (Figure 33E) nor following IL-4 stimulation. 




Figure 33: GW9508 does not affect M1/M2 polarization of human macrophages.  
PBMC were isolated from peripheral blood by density gradient centrifugation. Monocytes were separated 
from other PBMC by 1h adhesion at 37oC followed by differentiation over 7-day culture in 10% FBS 
RPMI containing 50ng/ml M-CSF. Monocytes derived-macrophages were treated with GW9508 (10μM) 
for 24h at 37oC in MSF media. Without removing compounds, IFN-γ (10ng/ml) and LPS (50ng/ml) or IL-
4 (10ng/ml) was added and incubated at 37°C for 24h. After washing, cells were stained and expression 
was determined by flow cytometry. (A) Selection of cells by size (FSC-H) and granularity (SSC-H). (B) 
Selection of macrophages (CD14Low). Expression of (C) CD86, (D) MHC-II, and (E) CD206. Results are 
expressed as mean ± SEM from three independent experiments. 1-way ANOVA, followed by Bonferroni 




3.12. Effects of GW9508 stimulation in efferocytosis 
As mentioned in the Introduction chapter, efferocytosis is the process where 
apoptotic cells are phagocytosed by macrophages. This process is of fundamental 
importance as it prevents secondary necrosis of the apoptotic neutrophil thus avoiding 
perpetuation of tissue damage. Above, I showed that GW9508 stimulation delayed 
neutrophils apoptosis (Figure 31). At this stage, to evaluate if efferocytosis was also 
modulated by GW9508, two sets of experiments were performed. Firstly, I treated 
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neutrophils with GW9508 and secondly macrophages. In both cases, apoptotic 
human neutrophils and peritoneal mouse macrophages were utilised. Mouse 
macrophages were isolated after injection of 2% Bio-gel polyacrylamide beads in PBS 
(i.p.): Bio-Gel-elicited macrophages are free of intracellular debris because Bio-Gel 
beads cannot be phagocytosed by macrophages, making these cells more suitable 
for the studies pertaining to phagocytosis. Mouse macrophages were chosen for this 
assay as it was more precise to count the mature macrophages than plate human 
monocytes and induce into macrophages, which could result in different numbers 
between repetitions. 
In the first set of experiments, human neutrophils were stimulated for 18 hours 
with vehicle or GW9508 (0.1, 1 and 10µM) in RPMI serum-free overnight. Following 
stimulation, neutrophils were washed twice in DPBS-/- and apoptotic neutrophils were 
added to the macrophages at a ratio of 1:2 (macrophage:neutrophils). Cells were 
incubated for 1h. After incubation, non-ingested neutrophils were removed and MPO 
assay was performed to selectively stain intracellular neutrophils. Macrophages 
containing ingested neutrophils could be differentiated by the presence of brown 
areas, as visualised in Figure 34A. As expected, vehicle-stimulated macrophages 
have the ability to ingest apoptotic neutrophils. Interestingly, the ability to recognise 
and ingest apoptotic neutrophils was impaired after GW9508 stimulation at all three 
concentrations tested (Figure 34B). 




Figure 34: GW9508 impairs efferocytosis of neutrophils. 
Human neutrophils were stimulated with vehicle or GW9508 (0.1-10µM) in FBS- free RPMI for 18 hours. 
Apoptotic neutrophils were then added to Bio-Gel–elicited macrophages (obtained from C57/Bl6 mice) 
at a ratio of 1:2 (macrophage:neutrophils) for 1 hour. Cells were then washed to remove non-ingested 
neutrophils, and the MPO assay was performed to selectively stain intracellular neutrophils. Images were 
acquired by light microscopy assessing more than 400 cells per treatment. (A) Representative images 
of macrophages after the MPO assay was performed. Red stars identify macrophages that have 
internalised an apoptotic neutrophil. (B) Percentage of positive macrophages. Results are expressed as 
mean ± SEM from four independent experiments. p<0.05 compared to vehicle. 1-way ANOVA, followed 
by Bonferroni post-test. Veh, vehicle (0.1% ethanol). 
 
In the second set of experiments, macrophages were stimulated with the 
GPR40 agonist for 18 hours. Meanwhile, human neutrophils were left to die in RPMI 
serum-free overnight. Following stimulation, macrophages were washed twice in 
DPBS-/- and apoptotic neutrophils at ratio of 1:2 (macrophage:neutrophils) were 
added. Cells were incubated for 1h. After incubation, non-ingested neutrophils were 
removed and MPO assay was performed to selectively stain intracellular neutrophils. 
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Macrophages containing ingested neutrophils were counted (Figure 35A). As 
expected, vehicle-stimulated macrophages have the ability to ingest apoptotic 
neutrophils, however GW9508 failed to modulate this cellular response at any of the 
concentrations (Figure 35B).  
 
Figure 35: GW9508 do not modulate efferocytosis in stimulated mouse macrophages. 
Human apoptotic neutrophils were added to Bio-Gel–elicited macrophages (obtained from C57Bl/6 mice) 
previously pretreated with vehicle or GW9508 at a ratio of 1:2 (macrophage/neutrophils) and were 
incubated for 1 hour. Cells were then washed to remove non-ingested neutrophils, and the MPO assay 
was performed to selectively stain intracellular neutrophils. Images were acquired by light microscopy 
assessing more than 400 cells per treatment. (A) Representative images of WT cells after the MPO 
assay was performed. Red Star identify macrophages that have internalised an apoptotic neutrophil. (B) 
Percentage of positive macrophages. Results are expressed as mean ± SEM from three independent 
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ROLES OF GPR40 IN VIVO 
 
3.13. Expression of GPR40 in cells from murine arthritic joints 
After demonstrating expression of GPR40 in human cells, and evaluating the 
potential roles of this receptor by using a selection of cell assays, the next aim was to 
evaluate the expression of this receptor in an experimental model of arthritis, allowing 
a better understanding of the roles of this receptor in a more complex environment.  
My in vitro results suggested that GW9508 activates neutrophils and has few 
or non-effect in monocyte derived macrophages (with the concentrations tested). So, 
a model where neutrophils plays a key role, was essential to text the effects f this 
compound in a more complex environment. K/BxN model of arthritis is initiated by an 
innate immune response mainly mediated by complement and LTB4 recruiting 
neutrophils (Chen et al., 2006). The unique characteristics of this model are ideal for 
analysing the effects of GW9508 in inflammatory arthritis. In my in vitro data, I have 
shown that LTB4 increases the expression of GPR40 in human neutrophils (Figure 
19).  
Arthritis was induced in mice by injecting 100μl K/BxN serum (i.p.) in C57/B6 
mice on days 0 and 2. On day 8, animals were sacrificed and paws were collected. 
Cells were isolated by digestion with collagenase/DNase (0.5ng/ml and 40ng/ml) 
followed by staining with antibodies to allow visualization by flow cytometry. As the 
protocol used for isolation results in some cell death, I first gated the population of 
live cells by labelling with Zombie dye (an amine-reactive fluorescent dye that can 
differentiate dead cells from live cells) (Figure 38A), followed by selection of cells by 
size (FSC-A) and granularity (SSC-A) (Figure 38B). Subsequently, haematopoietic 
cells were selected by expression of high fluorescence of CD45 (Figure 38C). From 
this point onward, cells were subdivided into: 
1. CD11b+/Ly6Ghigh (neutrophils, Figure 38D); 
2. CD11b+/F4/80high (macrophages, Figure 38E); 
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3. CD11b+/Ly6Chigh (inflammatory monocytes, Figure 38F).  
As shown in Figure 38G, all three cells types expressed GPR40 when compared to 
isotype control. 
 
Figure 36: Expression of GPR40 in cells isolated from murine arthritic joints.  
C57/Bl6 animals received 100μl (ip) of K/BxN serum on days 0 and 2. On day 8, the animals were 
sacrificed and their front and hind paws were removed. Cells were isolated by digestion with 
collagenase/DNase and labeled with the following antibodies to allow identification of cell types by flow 
cytometry. Selection of (A) live cells. (B) cells by size (FSC-H) and granularity (SSC-H) (C) hematopoietic 
cells expressing CD45 (D) neutrophils (CD11b+/Ly6Ghigh). (E) macrophages (CD11b+/F4/80high) (F) 
monocytes (CD11b+/Ly6Chigh) and (G) GPR40 expression in selected cell types. Results are expressed 
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3.14. Effects of GW9508 in the initiation and progression of inflammatory 
arthritis 
After showing the expression of GPR40 in immune cells present within arthritic 
joints, the effects of GW9508 treatment was evaluated. Therefore, arthritis was 
induced in mice by injecting 100μl K/BxN serum (i.p.) in C57/Bl6 mice on days 0 and 
2. Animals then received 100μl GW9508 (10mg/kg, i.p.) or vehicle (0.1% ethanol in 
PBS) from day 0 to 6. Arthritic parameters were recorded everyday including clinical 
score (section 2.20), weight loss and water displacement plethysmometry (oedema). 
On day 6, animals were euthanized, and paws collected for subsequent analysis. As 
shown below, both groups presented maximal disease incidence by day two (Figure 
37A). Treatment with GW9508 daily exacerbated the severity of disease, 
characterized by higher clinical score on days 2-6 when compared to mice that 
received vehicle daily (Figure 37B). No statistical differences were visualized when 
comparing hind paw oedema associated with arthritis between vehicle and GW9508-
treated groups (Figure 37C) despite the clear tendency in increased oedema 
GW9508-treated group. In addition, treatment of mice with GW9508 increased weight 
loss on days 4 and 5 when compared to the vehicle control group (Figure 37D). 
 
 




Figure 37: Characterization of arthritis severity following prophylactic treatment with GW9508. 
C57/Bl6 animals received 100μl (i.p) of K/BxN serum on days 0 and 2 and 100μl of GW9508 (100μl, 
10mg/kg, ip) or vehicle (100μl, 0.1% ethanol in PBS) daily. Arthritic parameters were recorded everyday 
including (A) disease incidence, (B) clinical score, (C edema) water displacement plethysmometry, and 
(D) weight loss. Results are expressed as mean ± SEM. n=9. 2-way ANOVA, *p<0.05, **p<0.01, 
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3.14.1. Expression of inflammatory mediators in GW9508-treated arthritic mice  
Cytokines are implicated in each phase of the pathogenesis of rheumatoid 
arthritis, by promoting autoimmunity, by maintaining chronic inflammatory synovitis 
and by driving the destruction of the joint tissue (McInnes and Schett, 2007). Due to 
the importance of the pro-inflammatory cytokines in the pathogenesis of rheumatoid 
arthritis in humans, therapeutic strategies have been developed with the aim to 
neutralize these mediators. TNF-α- and IL-1R- but not IL-6-deficient mice are 
resistant to disease induction by KBxN serum, but TNF receptor-1- and TNF receptor-
2-deficient mice are susceptible. I analysed the expression of these cytokines in the 
tissue from arthritic joints, but did not observe any differences between vehicle and 
GW9508 treated mice for TNF-α (Figure 38A), IL-1β (Figure 38B) or IL-6 (Figure 38C). 
In animal models, the profile of cytokines can vary depending of the model 
used to induce arthritis. For instance, the development of arthritis in the KBN serum 
transfer model is critically dependent on IL-4 (Ohmura et al., 2005). I analysed the 
expression of IL-4 in cells of arthritic joints and my results showed a higher expression 
of IL-4 in mice treated with GW9508 in comparison with control group (Figure 38D). 
A result that could provide one possible explanation of why the disease manifested 
more severely in this animal group. 
It has also been shown that neutrophils from RA patients have increased nitric 
oxide synthase type 2 (NOS2) protein expression and enhanced formation of nitric 
oxide (NO) that correlates with disease activity (St Clair et al., 1996). Accordingly, 
studies in experimental animal models of arthritis have suggested that excessive 
levels of NO can promote tissue injury and contribute to progression of the disease 
(Clancy et al., 1998). I also analysed expression of NOS2 mRNA in cells from arthritic 
joints, showing that in the group of mice treated with GW9508 there was increased 
expression of this protein in comparison to control group (Figure 38E). Additionally, I 
analysed the expression of the anti-inflammatory cytokine IL-10, and showed that 
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mRNA level of this cytokine was significantly decreased in GW9508-treated mice 
when compared to vehicle control group (Figure 38F). 
 
Figure 38: Expression of inflammatory mediators in murine arthritic joints.  
Levels of (A) TNF-α, (B) IL-1β, (C) IL-6, (D) IL-4, (E) NOS2 and (F) IL-10 mRNA expression in arthritic 
joints. Cells were isolated from paws by RNeasy kit Qiagen® on day 6 after induction of arthritis by 
KBxN-serum transfer. The relative expression of each gene, cycle threshold values were normalized to 
a housekeeping gene (Rpl13a) and expression quantified using 2-CT. Results are expressed as mean 
± SEM (n=5). Non parametric unpaired T-Test followed by Mann Whitney post-test, *p<0.05 compared 
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3.14.2. Histological analysis of arthritic knees  
To evaluate the histological characteristics of the joint, knees were collected 
on day 6 decalcified and embedded in paraffin wax. Sections of knees were then 
stained with haematoxylin and eosin. Arthritis severity was scored as described in 
section 2.24.2. In both vehicle- and GW9508-treated arthritic mice pannus formation 
and leukocyte infiltration were visualised, which are characteristic of the inflammatory 
response that occurs during arthritis (Figure 39A). However, a wider pannus 
formation, stronger cellular infiltration and loss of joint architecture was visualized in 
the GW9508 treated mice (Figure 39A). In agreement, after analysis by two blinded 
scorers, GW9508 treated mice showed a higher score in joint damage (Figure 39B), 
when compared to vehicle control group. 








Figure 39: Leukocyte infiltration in GW9508-treated arthritic mice. Twelve-week old male C57Bl6 
mice were administered 100μl K/BxN serum intraperitoneally day 0 and day 2. Five K/BxN mice received 
intraperitoneally saline (100μl) and 5 K/BxN mice received GW9508 (100μl, 10mg/kg) intraperitoneally 
from day 0 to day 6. Knee joints were collected for histology on day 6. Hematoxylin and eosin (H&E) 
sections were analysed and scored by two blinded scorers. (A-B) Panel representing histological 
features joint from arthritic joint in vehicle control group (A) and GW9508 treated mice (B), x4 
magnification. Scale bars: 200 μm. F, femur; T, tibia; m, meniscus; CI, cellular infiltration. (B) Mean 
histological scores were calculated from two sections for each animal. Results are expressed as mean 
± SEM (n=4). T test, *p<0.05 compared to vehicle (0.1% ethanol in PBS).  
Enzymes secreted by neutrophils, synoviocytes and chondrocytes are 
believed to be responsible for cartilage degradation. Previous results suggested an 
increased number of neutrophils present in the arthritic joints of GW9508-treated mice 
when compared to control group. Next I evaluated if this correlated with a higher 
degradation of cartilage in this group. A characteristic of arthritis is cartilage 
degradation. In agreement, knee sections of vehicle- (Figure 40A, left) and GW9508-
treated mice (Figure 40A, right) stained with Toluidine blue confirmed cartilage 
degradation in both groups. However, no significant difference was visualised 
between GW9508 and vehicle treated group, as analysed by percentage of area 















Figure 40: GW9508 treatment does not affect cartilage degradation in arthritic mice. 
Twelve-week old male C57Bl6 mice were administered 100μl K/BxN serum intraperitoneally day 0 and 
day 2. Five K/BxN mice received intraperitoneal saline (100μl) and 5 K/BxN mice received GW9508 
(100μl, 10mg/kg) intraperitoneally from day 0 to day 6. Knee joints were collected for histology on day 
6. Toluidine Blue stained sections were analysed using ImageJ to determine extracellular matrix integrity. 
(A-B) Representative micrographs of Vehicle treated mice (A) and GW9505 treated mice (B). Scale bars: 
200 μm. F, femur; T, tibia; m, meniscus; C, cartilage, 4x magnification. (C) Data shown are percentage 
area of articular cartilage stained positively for Toluidine Blue, quantified from at least six 20X 
magnification micrographs per section of 3 sections from each knee. Results are expressed as mean ± 
SEM (n=4). T-test. 
 
  
3.15. Effects of GW9508 treatment during the resolution phase of 
inflammatory arthritis 
Finally, the effects of GPR40 activation on the resolution of inflammation in 
vivo were addressed by treating arthritic mice with GW9508 at the peak of the disease 
(day 5, Figure 37). Arthritic parameters were assessed daily to evaluate the 
progression of the disease. As expected, all mice developed arthritis by day 2 and no 
differences were visualised between groups before the initiation of treatments (Figure 
41A). Treatment with GW9508 (100μl, 10mg/kg, ip) or vehicle (100μl, 0.1% ethanol 
in PBS) started on day 5 and continued daily until day 10, when mice were 
euthanized. The vehicle control group showed peak of arthritis on day 5, and then 
began to gradually go into remission (Figure 41B, black line), while treatment with 
GW9508 prolonged the arthritis (Figure 41B, blue line). This effect was also reflected 
by the weight loss, as by day 7 the control group started to gain weight (Figure 41C, 
black line) while the GW9508-treated group continued to lose weight (Figure 41C, 
blue line). This trend was also observed for hind paw oedema, where vehicle group 
showed peak oedema on day 7 (Figure 41D, black line), but GW9508-treated still 








Figure 41: Therapeutic administration of GW9508 at the peak of inflammatory arthritis delays 
resolution. 
C57/Bl6 animals received 100μl (i.p.) of K/BxN serum on days 0 and 2. After day 5, mice received 
GW9508 (100μl, 10mg/kg, ip) or vehicle (100μl, 0.1% ethanol in PBS) daily. Arthritic parameters were 
recorded everyday including (A) disease incidence, (B) clinical score, (C edema) water displacement 
plethysmometry, and (D) weight loss. Results are expressed as mean ± SEM. n=4. 2-way ANOVA, 
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For a long time, fatty acids were considered the “bad boys” of our diet, and for 
many years we tried to decrease their consumption, however, it did not make us 
healthier. Nowadays, we know there are essential fatty acids necessary not only for 
development, but also to regulate our immune system. Two main categories of fatty 
acids are the omega-3 and the omega-6 fatty acids. Arachidonic acid (AA), one of the 
most studied omega-6 fatty acids, is known for its ability to induce the inflammatory 
response. In addition, AA can also be metabolized into other mediators, such as 
lipoxins that have anti-inflammatory and pro-resolution responses. On the other hand, 
omega-3 fatty acids are more widely known for their ability to decrease inflammation, 
due to the actions of their derivatives resolvins, maresins and protectins, which were 
identified at the start of the century (Serhan et al., 2002). Taking into account that 
omega-6 fatty acids have opposite effects on the time-course of inflammation, it is 
natural to believe that omega-3 fatty acids can also have contradictory effects 
depending on the pathways that they directly or indirectly activate. Indeed, omega-3 
fatty acids can also be converted to 3-series prostaglandins and 5-series leukotrienes 
that are known to have pro-inflammatory properties, even if in lower magnitude when 
compared to prostaglandins and leukotrienes derived from AA. Therefore, to 
understand the mechanisms involved in the direct activation of long-chain free fatty 
acid receptors in the time-course of the inflammatory response, this work focused to 
evaluate expression and function of downstream activation of GPR40 in immune cells 
and an inflammatory model of arthritis by using GW9508, an agonist of GPR40.  
Initially, this work was directed to the definition of GPR40 expression in 
different cell types involved in the inflammatory process, focusing on neutrophils (first 
cell of host defence). We were able to demonstrate, for the first time, gene and protein 
expression of GPR40 in human neutrophils. Later, we demonstrated expression of 
this receptor in monocytes as well as in human monocyte derived macrophages. 
Concurrently, and for translational purposes, we demonstrated the expression of this 
receptor in neutrophils, inflammatory monocytes and macrophages harvested from 
CHAPTER 4: DISCUSSION AND CONCLUSION 
144 
 
the arthritic joints of mice. This indicates to us potential modulation of GPR40 
expression by pro-inflammatory mediators, which are in inflammatory settings, and 
also a potential biological functions in the context of ongoing joint inflammation. Both 
these aspects have been addressed in subsequent experiments (vide infra).  
 
As the expression of GPR40 had not been demonstrated in human neutrophils 
before, we used a variety of techniques to confirm the expression of GPR40 in this 
cell type. Initially, the expression of GPR40 was assessed by measuring gene 
expression by real-time and standard PCR. Following this, we showed protein 
expression by basic imaging and flow cytometry. Subsequently, we evaluated if 
mediators of the inflammatory response, such as TNFα, IL-8, LTB4 and PAF, could 
modulate GPR40 expression. The focus was on mediators that are important in the 
inflammatory process by promoting the activation of neutrophils, and also induce the 
chemotaxis of neutrophils to the site of inflammation. Here we showed that LTB4 
(10nM) and PAF (10nM) could modulate the expression of GPR40 in neutrophils as 
early as after 10 minutes of stimulation. We also showed that the expression of this 
receptor was increased by approximately 30% after stimulation with TNF-α and IL-8, 
though this did not reach statistical significance. How could this expression be 
modulated so rapidly? PMN have a vast selection of functionally important molecules 
that are stored in cytoplasmic granules and vesicles. Upon stimulation, these 
intracellular granules are mobilized to the plasma membrane, increasing the quantity 
of specific receptors, cell adhesion molecules and proteases, that are involved in 
different activities, such as PMN adhesion, diapedesis and killing of bacteria (Hager 
et al., 2010). The swift upregulation of GPR40 by LTB4 and PAF could be related to 
mobilization of GPR40 present in such cytoplasmic features, showing that GPR40 
may have an important role in the inflammatory response. Another way to address 
the importance of GPR40 expression in ongoing inflammatory processes was to 
check the expression of this receptor in exudate neutrophils induced by Tabasco in 
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mouth cavity. In this case, we showed that exudate human neutrophils have higher 
levels of expression of GPR40 when compared to matched blood donor samples. 
Neutrophils are terminally differentiated cells with a short life-span due to constitutive 
apoptosis. Because of these characteristics, genetic manipulation of neutrophils has 
been difficult, although it is highly desired given the importance of neutrophils in the 
immune system (Geering et al., 2011). The effect of LTB4 in increasing the expression 
of GPR40 in human neutrophils, makes the use of this cytokine an useful tool for 
studying the neutrophil biology. I made use of it when I pre-stimulated neutrophils with 
LTB4 followed by GW9508 stimulation during flow chamber assay in vitro. In addition, 
I have choose a in vivo model where LTB4 plays an important role, the K/BnX model 
(Chen et al., 2006). 
To address the roles of GPR40 in neutrophils, the next aim was to identify a 
tool capable to activate this receptor. GW9508 is shown to stimulate intracellular 
Ca2+ mobilization in human embryonic kidney (HEK) 293 cells expressing GPR40 
(pEC50 values of 7.32±0.03) (Briscoe et al., 2006). In our experimental settings, 
GW9508 did induce intracellular calcium mobilization in neutrophils, alongside a 
concentration dependent curve of the agonist. Therefore, after showing that this 
molecule activated neutrophil responses, we decided to address the effects of 
GW9508 stimulation in human immune cells, focusing on specific bioactions that are 
relevant both to the pro-inflammatory and resolving-phase of inflammation. As 
mentioned before, the resolution of inflammation is a tightly orchestrated and 
multifaceted host response, characterized by at least six key steps: 1) clearance of 
the inciting stimuli; 2) decrease of PMN and increase of monocyte recruitment; 3) 
apoptosis of recruited inflammatory cells; 4) efferocytosis of apoptotic cells by tissue 
and monocyte-derived macrophages; 5) switching from pro-inflammatory cell 
phenotypes and mediators to pro-resolution cell phenotypes and mediators; 6) either 
incorporation of myeloid cells into the local population or recirculation via lymph or 
blood (Alessandri et al., 2013, Norling and Perretti, 2013, Buckley et al., 2014). To 
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address if GPR40 was involved in the clearance of the inciting stimuli, I tested if 
GW9508 could modulate the level of E. coli phagocytosis by neutrophils in vitro. 
Indeed, at 10µM, GW9508 increased the phagocytic ability of neutrophils, when 
compared to the control treatment. Following this, another key step of the resolution 
of inflammation was investigated, that is the recruitment of neutrophils. Firstly, we 
addressed if GW9508 could modulate the expression of adhesion molecules in 
neutrophils. A concentration range (10-100µM) of GW9508 did not alter the 
expression of CD11b or L-selectin in neutrophils isolated from healthy volunteers 
indicating that the agonist itself did not cause neutrophil activation. It is known that 
TNF-α activation of neutrophils induces CD11b expression and L-selectin shedding 
(Hafezi-Moghadam et al., 2001), which I also observed, however, pre-stimulation of 
neutrophils with GW9508 was also not able to modulate the effects of TNF-α 
stimulation. There was also a lack of effect of GW9508 on the interactions of human 
neutrophils with endothelial cells under flow. I previously showed that 10 minutes 
LTB4 stimulation could upregulate GPR40 expression, thus another set of 
experiments were performed to check if with higher surface levels of GPR40, 
GW9508 could have an effect on neutrophil-endothelial cells interactions. Indeed, 
fewer cells were observed rolling when compared to vehicle when neutrophils were 
stimulated with 10ng/ml LTB4 for 10 minutes followed by a 10 minute stimulation with 
1µM GW9508. I also assessed the chemotaxis of neutrophils induced by IL-8. IL-8, 
also known as neutrophil chemotactic factor, has two primary functions. It 
induces chemotaxis of neutrophils, causing them to migrate toward the site of 
infection, and also induces phagocytosis once neutrophils have arrived at the site of 
infection (Harada et al., 1994). Treatment with different concentration of GW9508 led 
to an increase of almost 50% of the chemotaxis of neutrophils, despite this it did not 
reach statistical significance. GW9508 stimulation has been shown to induce IL-8 
release from bovine neutrophils. Thus, as IL-8 is known to induce actin conformation 
and redistribution to promote chemotaxis of neutrophils, GW9508 could increase 
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chemotaxis via this mechanism  (Mena et al., 2016).  
Taking in account the phagocytosis and chemotaxis results, is possible to 
hypothesise that GW9508 might have beneficial roles in another inflammatory 
condition. For instance, in an infection, like sepsis, the use of GW9508 could induce 
an increase of neutrophils into the site of the infection (Figure 27) and an increase in 
the phagocytosis rate (Figure 28). Which could result in a faster clearance of the 
bacteria. 
Next, we studied the effects of GW9508-stimulation on release of neutrophil 
microvesicles. Microvesicles are fragments of plasma membrane ranging from 100 
nm to 1000 nm shed from almost all cell types. This readout was chosen because 
vesicles are emerging as a new mechanism of intercellular communication by 
transferring cellular lipid and protein components to target cells (Camussi et al., 
2010). Over a 15 minute incubation period, at 10 µM, GPR40 activation significantly 
increased the release of microvesicles. Interestingly, despite microvesicle release 
being a normal feature of any cell type, the proteomic profile of microvesicles may 
vary depending on the stimulus. Stimulation of human neutrophils, either in 
suspension or adherent to an endothelial monolayer, led to the production of 
microvesicles containing >400 distinct proteins with only 223 being shared by the two 
subsets. For instance, post-adherent microvesicles are enriched in alpha-2 
macroglobulin and ceruloplasmin, whereas microparticles produced by neutrophils in 
suspension are abundant in heat shock 70 kDa protein 1 (Dalli et al., 2013). It would 
be interesting to assess the proteome profile of these microvesicles but due to time 
constraints I was unable to pursue this line of research.  
Finally, I assessed the effects of GW9508 stimulation in the settings of 
neutrophil apoptosis. Apoptosis is a process of programmed cell death in vertebrates, 
essential to prevent release of intracellular contents of neutrophils in the tissue, which 
could lead to further damage and recruitment of more inflammatory cells into the 
damaged tissue (Savill et al., 1989). Here I showed that 10µM GW9508 neutrophil 
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stimulation delayed neutrophil apoptosis, increasing the number of viable cells. In an 
inflammatory process, many pro-inflammatory mediators, such as GM-CSF (Colotta 
et al., 1992), LTB4 (Lee et al., 1999) and C5a (Lee et al., 1993), are associated with 
increasing the life span of neutrophils. On the other hand, usually pro-resolution 
mediators are associated with inducing apoptosis of neutrophils, such as AnxA1 
(Perretti and Solito, 2004), LXA4 (Weinberger et al., 2008) and RvE1 (El Kebir et al., 
2012). Delayed neutrophil apoptosis contributes to the pathology of many 
inflammatory and autoimmune diseases. This is perhaps best exemplified by the 
phenotype of people with chronic granulomatous disease who are at risk of life-
threatening infections because of inherited defects in the phagocyte NADPH oxidase, 
yet also develop granulomas that obstruct the liver, lungs, and gastrointestinal tract 
secondary to defects in PMN turnover and clearance (Fernandez-Boyanapalli et al., 
2009, Kobayashi et al., 2004). Neutrophils from patients with acute arterial occlusions 
also exhibit delayed apoptosis (Garlichs et al., 2004) and the number of circulating 
neutrophils correlates with mortality subsequent to cardiovascular events (Guasti et 
al., 2011). In rheumatoid arthritis, it is hypothesized that an accumulation of 
neutrophils contributes to the presentation and persistence of autoantigens (Harper 
et al., 2001). In agreement with this, disease severity correlates with exceptionally 
high numbers of apoptotic neutrophils in circulation (Courtney et al., 1999). 
Altogether, these data lend further support to the notion that delayed neutrophil 
apoptosis contributes to the pathology of chronic inflammatory disorders (McCracken 
and Allen, 2014). Accordingly, my in vitro results, where I showed that GW9508 
induces delay in neutrophil apoptosis, could be one of the factors in which severity of 
arthritis were increase in mice treated with GW9508. 
After assessing the functions of GPR40 activation in human neutrophils, we 
evaluated the functions of this long-chain free fatty acid receptor in human 
macrophages. First, we showed expression of this receptor in monocyte-derived 
macrophages by real time PCR and flow cytometry. While basally expressed, we 
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were not able to establish any significant modulation of the level for GPR40 
expression by TNF-α stimulation. Phagocytosis, a major effector function of 
macrophages, is of vital importance in the host immune defence. The multi-step 
process encompasses particle recognition by TLR and NOD receptors, followed by 
binding, regulated ingestion, and finally the destruction of internalized particles. The 
ability of macrophages to bind, engulf, and kill bacteria defines the bactericidal activity 
of the immune cells (Adolph et al., 2012). Long-chain free fatty acids DHA and EPA 
and their products (such as RvD- and RvE- resolvins) have been associated with an 
increase of the phagocytic activity of macrophages (Hong et al., 2008, Adolph et al., 
2012, Rogerio et al., 2012, Hjorth et al., 2013). However, we were not able to 
demonstrate a modulation of the phagocytic ability of macrophages after application 
of GW9508. At this point, this set of experiments indicate that the modulation of 
phagocytosis by long-chain fatty acid may be more associated with an active 
remodelling of the plasma membrane structure (fluidity of the lipid bilayer) rather than 
the activation of the long-chain free fatty acid receptor GPR40 itself.  
Another process involving engulfment is efferocytosis, or clearance of 
apoptotic cells. There is little direct evidence that human inflammatory arthritis is 
caused by defects in cell adherence (Kenyon et al., 2011, Hurst et al., 1983), 
however, it is known that extracellular debris, including oxidized lipids and intracellular 
components such as histone H3 and histone H4, can decrease efferocytosis at sites 
of inflammation (Friggeri et al., 2012). In this work, I evaluated if GPR40 activation 
could modulate efferocytosis of macrophages using two approaches. First, 
stimulating human neutrophils with GW9508 and second stimulating mouse 
macrophages with GPR40 agonist. When macrophages were stimulated with 
GW9508 it had no effect on apoptotic neutrophil clearance. This set of data matches 
the finding in the phagocytosis assay and indicates that GPR40 does not modulate 
any aspect of the engulfment process enacted by macrophages. On the other hand, 
when neutrophils were stimulated with GW9508, a decrease in efferocytosis was 
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visualised. This result corresponds with the finding that GW9508 delays neutrophil 
apoptosis. It is interesting to hypothesise that “find me” signals produced by apoptotic 
neutrophils, such as chemokines that recruit phagocytes, along with the accumulation 
of PS on the exofacial leaflet of the cytoplasmic membrane are modulated by 
GW9508. However, the “catch me” phase, which involves expression of specific 
receptors on macrophages that recognizes distinct ligands on the apoptotic cell were 
not modulated by GW9508 stimulation. Together these findings suggest that GW9508 
has a direct effect on neutrophil lifespan and hence clearance rather than modulation 
of macrophage phenotype and function. These findings make me hypnotize that the 
lack of response induced by GW9508 in human macrophages and, most important, 
the decrease of efferocytosis when human neutrophils are stimulated with GW9508 
is one of the factors by which a more severe disease was observed in the arthritic 
mice treated with the agonist of GPR40. As dying neutrophils, will become necrotic, 
losing the architecture of the plasma membrane, with consequence release of 
intracellular contents to the microenvironment in an irreversible mode. The release of 
these intracellular contents of neutrophils in the tissue is associated with further 
damage and recruitment of more inflammatory cells into the damaged tissue (Savill 
et al., 1989).  
Another important step in the resolution of the inflammation is the switching 
from pro-inflammatory to pro-resolution cell phenotypes and mediators. To assess 
whether GPR40 activation in macrophages was associated with the polarization of 
macrophages into pro-inflammatory (M1) or pro-resolutive (M2) profiles, we 
measured the expression of different clusters of differentiation after treatment with 
GW9508 and stimulation with INF-γ/LPS or IL-4. We could conclude that GPR40 does 
not modulate the polarization of macrophages into M1 or M2 phenotype in vitro. In an 
obese model induced by high fat diet (HFD), administration of RvD1 and DHA 
increased the percentage of M2 adipose tissue macrophages, showing that the long-
chain free fatty acid DHA may have a role in the switching from pro-inflammatory to 
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pro-resolution cell phenotypes (Titos et al., 2011). However, the lack of results when 
using macrophages could be due to insufficient expression of GPR40 in this cell type. 
Indeed, if we focus on the MFI and CT values in assays of flow cytometry and real-
time PCR preformed in this work, we can observe that the expression of this receptor 
is very low. 
When I started work on this project, I hypothesized that GPR40 activation by 
GW9508 would result in anti-inflammatory or pro-resolution effects. We know that 
GPR40 is activated by omega-3 fatty acids, and we also know that positive effects 
using DHA supplementation are observed in models of arthritis when very high doses 
are used. For instance, therapeutic oral or intraarticular administration of DHA 
(10 mg/kg daily and 20 μg/knee) reduced pain-related behaviors and knee edema in 
arthritis induced by complete Freund’s adjuvant (CFA) (Torres-Guzman et al., 2014). 
In other work, prophylactic DHA treatment (1g/kg and 2.5g/kg daily for 4 weeks before 
induction of CFA arthritis) was able to significantly decrease clinical score and 
incidence of arthritis. The higher dose of DHA (2.5g/kg) had more marked and 
consistent effects on all arthritic parameters measured: clinical arthritis scores, 
disease incidence, histopathology, anti-collagen antibodies, and ex vivo cytokine 
production (Olson et al., 2013). Olson et al. (2013) suggested that doses of >2 g/day 
of DHA may be required to reduce disease in humans. Which is in agreement with 
doses of fish oils used in human trials (1.6–7.1 g/day and averaged 3.5 g/day) that 
showed improvement in reducing duration of morning stiffness, number of tender or 
swollen joints, decreasing pain and time to fatigue, increasing grip strength, and 
decreasing the use of non-steroidal anti-inflammatory drugs (reviewed in Calder 
(2008) and Miles and Calder (2012)). In this work, we found that activation of GPR40 
by GW9508 results in a more severe disease, characterized by higher clinical score 
and increase of oedema associated with arthritis in K/BxN serum transfer induced 
arthritis when compared to the control group. This was associated with an increased 
number of leukocytes in the arthritic joints. We believe that most of the protective 
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effects induced by omega-3 FAs are indeed due to the effects of their metabolic 
mediators, such as RvD1 as recently shown (Norling et al., 2016). But we also 
speculate that GPR40 activation by GW9508 may set in motion a cascade of events 
that are different from when this receptor is activated by natural omega-3 FAs. Indeed, 
GPCRs are known to produce different types of responses depending on the 
activator, for example FPR2/ALX, which has a variety of different protein/peptide and 
lipid agonists that either induce or protect from inflammation (Cooray et al., 2013). 
 An interesting and surprising result was that despite GW9508 exacerbating 
arthritis it did not cause an increase in cartilage damage. We believe that two factors 
could be involved in this phenomenon, the direct effect of GPR40 activation in 
chondrocytes; and the number of microvesicles released in response to GW9508 
stimulation of neutrophils. First, Monfoulet and colleagues have demonstrated that IL-
1-treated GPR40 deficient chondrocytes secrete more inflammatory mediators 
(such as nitric oxide, IL-6, PGE2) and active catabolic enzymes (such as 
metalloproteinase-1, and metalloproteinase-9), and showed decreased anabolism 
compared to GPR40 positive chondrocytes (Monfoulet et al., 2015). Second, we have 
shown that GW9508-stimulation increases microvesicle release by neutrophils. 
Previously, we have shown that mice lacking the putative phospholipid scramblase 
TMEM16F, a lipid scramblase required for microvesicle release, exhibited 
exacerbated cartilage damage when subjected to inflammatory arthritis, despite no 
differences in the clinical scores when compared to wild-type mice after induction of 
arthritis (Headland et al., 2015). Accordingly, when we gave microvesicles derived 
from neutrophils to arthritic mice, we saw a decrease in cartilage damage when 
compared to vehicle mice (Headland et al., 2015). We therefore hypothesise that 
despite the increased number of leukocytes in the joints and hence an increase in 
inflammatory mediators, cartilage in GW9508 treated mice is protected by the effects 
of activation of GPR40 in chondrocytes and the protective effects of neutrophil-
derived microvesicles in the cartilage.  
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Importantly, G-coupled protein receptors are quite promiscuous both in terms 
of agonist activation as well as interaction with binding partners. In this work, we 
focused on the use of GW9508, a compound that is currently in phase II clinical trials 
for the treatment of diabetes. However, as mentioned before, GPR40 can be activated 
by medium and long chain free fatty acid receptors. Despite the pro-inflammatory 
effects of GPR40 activation evoked in neutrophils by GW9508, it is possible that this 
same receptor can produce another type of response if activated by another agonist 
or compound.  
Despite the interesting results found, some considerations must be taken into 
account. First, here it was chosen GW9058 as an activator for GPR40 (pEC50=7.32 
±0.03) (Briscoe et al., 2006). However, this agonist can also activate GPR120 (see 
Introduction), another long-chain free fatty acid receptor, but in higher concentrations 
(pEC50=5.46 ±0.09) (Briscoe et al., 2006). With this in mind, it might be possible that 
the results obtained herein may not solely be due to activation of GPR40 only, but 
also be secondary to activation of GPR120. However, due to time constraints it 
proved difficult to further dissect the actions of GPR40 by using other techniques or 
genetically deficient mice. Attempts were made to block the actions of GW9508 via 
GPR40 to show specificity. However, this antagonist also seemed to act as a partial 
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Notwithstanding the importance of the results presented here, some questions 
were left answered. One of the limitations with using an agonist is potential off-target 
effects. It is known that GW9508 can also activate GPR120, at higher concentrations 
than I tested (Briscoe et al., 2006). It would however be useful to verify my findings in 
a setting where the target cell does not express GPR120, and also utilise cells 
overexpressing/knocked-down in GPR40 to confirm specific actions. To do this, I 
could use the leukocyte-like cell line HL-60 overexpressing GPR40. In addition, the 
role of GPR40 could be assessed by performing the K/BxN arthritis model in GPR40 
knockout mice. 
Despite showing that GW9508 increases calcium flux in neutrophils, the 
signalling cascade of GPR40 activation in human neutrophils was not addressed. It 
is known that GW9508 induces intracellular calcium mobilization and 
ERK2 phosphorylation in bovine neutrophils (Hidalgo et al., 2011). I would like to 
perform western blot analyses to evaluate if GW9508 also induces phosphorylation 
of ERK1/2 in human neutrophils. 
In this work, I have shown that GW9508-stimulated neutrophils have delayed 
apoptosis. Three main apoptotic pathways have been described: an extrinsic 
pathway, that is activated by ligation of surface death receptors that bind Fas ligand, 
TNF-α or TRAIL; an intrinsic pathway, that is regulated at the level of mitochondria 
and is initiated by disruption of the outer mitochondrial membrane; and the 
phagocytosis induced cell death (PICD) pathway (McCracken and Allen, 2014). The 
extrinsic pathway is mediated by activation of caspase-3, while the intrinsic and PICD 
pathways are mediated by Bcl-2 and Mcl-1. I would therefore like to evaluate if such 
proteins are modulated by GW9508 stimulation. 
Finally, I have shown that activation of GPR40 increased microvesicle release 
by neutrophils. Microvesicle release is a normal feature of any cell type, however, the 
proteomic profile of the microvesicle is crucial for the initiation, exacerbation or 
resolution of the inflammatory process. In RA patients, increased numbers of 
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circulating levels of platelet derived microvesicles are correlated to disease activity 
(Knijff-Dutmer et al., 2002, Umekita et al., 2009). In the synovial fluid, elevation of 
platelet MPs was found at a significantly higher concentration than circulating MPs 
which can act alone by promoting coagulation so contributing to fibrin deposits in the 
joints or by causing activation of synovial fibroblasts partly responsible of 
inflammatory phenomena or by secreting pro-inflammatory mediators (Boilard et al., 
2010, Buzas et al., 2014). However, the proteomic profile of the microvesicle can also 
differ depending of the stimulus in the same cell type. For instance, Dalli and 
colleagues showed that stimulation of human neutrophils, either in suspension or 
adherent to an endothelial monolayer, led to the production of microvesicles 
containing >400 distinct proteins with only 223 being shared by the two subsets (Dalli 
et al., 2013). Recently, we have shown that TNF-α stimulated microvesicles derived 
from neutrophils can actually promote cartilage repair (Headland et al., 2015). With 
this in mind, I would like to evaluate the proteomic profile of GW9508-stimulated 
neutrophils. 
 
In conclusion, we demonstrated expression of GPR40 in human (neutrophils and 
monocyte derived-macrophages) and murine (neutrophils, inflammatory monocytes 
and macrophages) immune cells. We have also demonstrated that GPR40 
expression is up-regulated after stimulation with pro-inflammatory mediators, an 
effect evident also at the site of inflammation. In addition, we have shown that one 
agonist of GPR40 – compound GW9058 – can promote pro-inflammatory features in 
neutrophils (chemotaxis and phagocytosis) as well as delaying apoptosis and 
increasing microvesicle release. These in vitro actions are translated in vivo to an 
exacerbation of inflammatory arthritis with a delay of resolution (Figure 42). Therefore, 
GPR40 should be targeted through antagonists or biased agonists in order to inform 
therapeutic approaches based on this receptor target. 
 




Figure 42: GW9508 induces a pro-inflammatory profile in neutrophils and increases severity of 
inflammatory arthritis. 
Inducers are sensed by effector cells which will initiate the inflammatory response against the inducer. 
Pro-inflammatory mediators, such as LTB4 and PAF, increase the expression of GPR40 in neutrophils, 
which when activated by GW9508, causes a calcium flux in these cells. Activation of GPR40 by its 
selective agonist promotes increased chemotaxis, phagocytosis and microvesicle release. On the other 
hand, GW9508 delays apoptosis of neutrophils and decreases efferocytosis by macrophages. The 
combination of such events results in the delay of the resolution of the inflammation as evidenced in a 
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